Author Index to Volume 39*

A

Adams LA, Feldstein A, Lindor KD, Angulo P. Nonalcoholic fatty liver disease among patients with hypothalamic and pituitary dysfunction. 2004;39:909–914

Adams PC, Arthur MJ, Boyer TD, DeLeve LD, Di Bisceglie AM, Hall M, Levin TR, Provenzale D, Seeff L. Screening in liver disease: Report of an AASLD clinical workshop. 2004;39:1205–1213 (Special Article)

Agrati C (*see* Bordoni V et al). 2004;39:1508–1516

Aithal GP, Ramsay L, Daly AK, Sonchit N, Leathart JBS, Alexander G, Kenna JG, Caldwell J, Day CP. Hepatic adducts, circulating antibodies, and cytokine polymorphisms in patients with diclofenac hepatotoxicity. 2004;39:1437–1447

Akano AO (*see* Kirk GD et al). 2004;39:211–219

Akita H (*see* Shoda J et al). 2004;39:167–178

Alayrach ME (*see* Restuccia T et al). 2004;39:1613–1622

Albano E (*see* Stewart SF et al). 2004;39:197–203

Alberti A (*see* Cammà C et al). 2004;39:333–342

Al-Dhalimy M (*see* Vogel A et al). 2004;39:433–443

Alessandria C (*see* Restuccia T et al). 2004;39:1613–1622

Alexander G (*see* Aithal GP et al). 2004;39:1437–1447

Alonso A (*see* Andrade RJ et al). 2004;39:1603–1612

Alonzi T (*see* Bordoni V et al). 2004;39:1508–1516

Al-Osaimi A (*see* Le TH et al). 2004;39:1430–1436

Alter HJ. Hepatology Highlights. 2004;39:2–4, 877–879

Alvarez F (*see* Lapierre P et al). 2004;39:1066–1074

Alvaro D (*see* Invernizzi P et al). 2004;39:1175–1176 (Correspondence)

Alwayn IPJ, Javid PJ, Gura KM, Nosé V, Ollero M, Puder M. Do polyunsaturated fatty acids ameliorate hepatic steatosis in obese mice by SREPB-1 suppression or by correcting essential fatty acid deficiency. 2004;39:1176–1177 (Correspondence)

amfAR DCRI 010 Study Group (*see* Bräu N et al). 2004;39:989–998

Amoroso P, Buonocore S, Lettieri G, Pierri P, Mele A. The clinical profile of acute hepatitis A infection: Is it really so severe? 2004;39:572 (Correspondence)

An JK (*see* Rudnick DA et al). 2004;39:1048–1055

Anania FA (*see* Jadaho SB et al). 2004;39:1302–1307

Anderson GJ (*see* Stuart KA et al). 2004;39:492–499

Andrade RJ, Lucena MI, Alonso A, García-Cortés M, García-Ruiz E, Benitez R, Fernández MC, Pelaez G, Romero M, Corpas R, Durán JA, Jiménez M, Rodrigo L, Nogueras F, Martín-Vivaldi R, Navarro JM, Salmerón J, Sánchez de la Cuesta F, Hidalgo R. HLA class II genotype influences the type of liver injury in drug-induced idiosyncratic liver disease. 2004;39:1603–1612

André N, Roquelaure B, Thuret I, Ziol M, Rieux-Laucat F, Le Deist F. Expression of granzyme B in viral hepatitis in patients with ALPS. 2004;39:864–865 (Correspondence)

Andreola F, Calvisi DF, Elizondo G, Jakowlew SB, Mariano J, Gonzalez FJ, De Luca LM. Reversal of liver fibrosis in aryl hydrocarbon receptor *null* mice by dietary vitamin A depletion. 2004;39:157–166

Angulo P (*see* Adams LA et al). 2004;39:909–914

— (*see* Lindor KD et al). 2004;39:770–778

— (*see* Zein CO et al). 2004;39:204–210

Angus PW (*see* Crawford DHG et al). 2004;39:1655–1662

Ansari AA (*see* Matsumura S et al). 2004;39:1422–1429

Antonelli E (*see* Fiorucci S et al). 2004;39:365–375

Anwald B (*see* Pauli-Magnus C et al). 2004;39:779–791

Anwer MS. Cellular regeneration of hepatic bile acid transport in health and cholestasis. 2004;39:581–590 (Concise Review in Mechanisms of Disease)

Araújo W (*see* França A et al). 2004;39:1461 (Correspondence)

Arii S (*see* Kudo A et al). 2004;39:1099–1109

Arjunan V (*see* Thevananther S et al). 2004;39:393–402

Armonis A (*see* Avgerinos A et al). 2004;39:1623–1630

Aronow B (*see* Zhang DY et al). 2004;39:954–962

Arroyo AG (*see* Medina J et al). 2004;39:1185–1195 (Concise Review in Mechanisms of Disease)

Arroyo V (*see* Del Árbol L and Arroyo V). 2004;39:866–867 (Reply)

— (*see* Restuccia T et al). 2004;39:1613–1622

Arseneau KO (*see* Le TH et al). 2004;39:1430–1436

Arthur MJ (*see* Adams PC et al). 2004;39:1205–1213 (Special Article)

Asahara T (*see* Ochi M et al). 2004;39:1326–1336

Ascher NL (*see* Yao FY et al). 2004;39:230–238

Assi A (*see* Casiraghi MA). 2004;39:90–96

Association Française pour l'Etude du Foie (AFEF) (*see* Naveau S et al). 2004;39:1396–1403

Astemborski J (*see* Torbenson M et al). 2004;39:51–57

Auzinger G (*see* Murphy N et al). 2004;39:464–470

Avgerinos A, Armonis A, Stefanidis G, Mathou N, Vlachogiannakos J, Kougioumtzian A, Triantos C, Papaxoinis C, Manolakopoulos S, Panani A, Raptis SA. Sustained rise of portal pressure after sclerotherapy, but not band ligation, in acute variceal bleeding in cirrhosis. 2004;39:1623–1630

Avila MA (*see* Hevia H et al). 2004;39:1088–1098

Aw TY (*see* Taniai H et al). 2004;39:1544–1552

Awad SS (*see* Thevananther S et al). 2004;39:393–402

Azuma H (*see* Hoppo T et al). 2004;39:1367–1375

B

Baba S (*see* Hoppo T et al). 2004;39:1367–1375

Bacchetti P (*see* Yao FY et al). 2004;39:230–238

Baffy G (*see* Horimoto M et al). 2004;39:386–392

Balabaud C (*see* Roskams TA et al). 2004;39:1739–1745 (Special Article)

Balart L (*see* Cammà C et al). 2004;39:333–342

Baldoni M (*see* Fiorucci S et al). 2004;39:365–375

Bandara P (*see* Sud A et al). 2004;39:1242–1250

*January, 1–270; February, 271–578; March, 579–876; April, 877–1182; May, 1183–1466; June, 1467–1798.

Author Index to Volume 39*

A

Adams LA, Feldstein A, Lindor KD, Angulo P. Nonalcoholic fatty liver disease among patients with hypothalamic and pituitary dysfunction. 2004;39:909–914

Adams PC, Arthur MJ, Boyer TD, DeLeve LD, Di Bisceglie AM, Hall M, Levin TR, Provenzale D, Seeff L. Screening in liver disease: Report of an AASLD clinical workshop. 2004;39:1205–1213 (Special Article)

Agrati C (*see* Bordoni V et al). 2004;39:1508–1516

Aithal GP, Ramsay L, Daly AK, Sonchit N, Leathart JBS, Alexander G, Kenna JG, Caldwell J, Day CP. Hepatic adducts, circulating antibodies, and cytokine polymorphisms in patients with diclofenac hepatotoxicity. 2004;39:1437–1447

Akano AO (*see* Kirk GD et al). 2004;39:211–219

Akita H (*see* Shoda J et al). 2004;39:167–178

Alayrach ME (*see* Restuccia T et al). 2004;39:1613–1622

Albano E (*see* Stewart SF et al). 2004;39:197–203

Alberti A (*see* Cammà C et al). 2004;39:333–342

Al-Dhalimy M (*see* Vogel A et al). 2004;39:433–443

Alessandria C (*see* Restuccia T et al). 2004;39:1613–1622

Alexander G (*see* Aithal GP et al). 2004;39:1437–1447

Alonso A (*see* Andrade RJ et al). 2004;39:1603–1612

Alonzi T (*see* Bordoni V et al). 2004;39:1508–1516

Al-Osaimi A (*see* Le TH et al). 2004;39:1430–1436

Alter HJ. Hepatology Highlights. 2004;39:2–4, 877–879

Alvarez F (*see* Lapierre P et al). 2004;39:1066–1074

Alvaro D (*see* Invernizzi P et al). 2004;39:1175–1176 (Correspondence)

Alwayn IPJ, Javid PJ, Gura KM, Nosé V, Ollero M, Puder M. Do polyunsaturated fatty acids ameliorate hepatic steatosis in obese mice by SREPB-1 suppression or by correcting essential fatty acid deficiency. 2004;39:1176–1177 (Correspondence)

amfAR DCRI 010 Study Group (*see* Bräu N et al). 2004;39:989–998

Amoroso P, Buonocore S, Lettieri G, Pierri P, Mele A. The clinical profile of acute hepatitis A infection: Is it really so severe? 2004;39:572 (Correspondence)

An JK (*see* Rudnick DA et al). 2004;39:1048–1055

Anania FA (*see* Jadaho SB et al). 2004;39:1302–1307

Anderson GJ (*see* Stuart KA et al). 2004;39:492–499

Andrade RJ, Lucena MI, Alonso A, García-Cortés M, García-Ruiz E, Benitez R, Fernández MC, Pelaez G, Romero M, Corpas R, Durán JA, Jiménez M, Rodrigo L, Nogueras F, Martín-Vivaldi R, Navarro JM, Salmerón J, Sánchez de la Cuesta F, Hidalgo R. HLA class II genotype influences the type of liver injury in drug-induced idiosyncratic liver disease. 2004;39:1603–1612

André N, Roquelaure B, Thuret I, Ziol M, Rieux-Laucat F, Le Deist F. Expression of granzyme B in viral hepatitis in patients with ALPS. 2004;39:864–865 (Correspondence)

Andreola F, Calvisi DF, Elizondo G, Jakowlew SB, Mariano J, Gonzalez FJ, De Luca LM. Reversal of liver fibrosis in aryl hydrocarbon receptor *null* mice by dietary vitamin A depletion. 2004;39:157–166

Angulo P (*see* Adams LA et al). 2004;39:909–914

— (*see* Lindor KD et al). 2004;39:770–778

— (*see* Zein CO et al). 2004;39:204–210

Angus PW (*see* Crawford DHG et al). 2004;39:1655–1662

Ansari AA (*see* Matsumura S et al). 2004;39:1422–1429

Antonelli E (*see* Fiorucci S et al). 2004;39:365–375

Anwald B (*see* Pauli-Magnus C et al). 2004;39:779–791

Anwer MS. Cellular regeneration of hepatic bile acid transport in health and cholestasis. 2004;39:581–590 (Concise Review in Mechanisms of Disease)

Araújo W (*see* França A et al). 2004;39:1461 (Correspondence)

Arii S (*see* Kudo A et al). 2004;39:1099–1109

Arjunan V (*see* Thevananther S et al). 2004;39:393–402

Armonis A (*see* Avgerinos A et al). 2004;39:1623–1630

Aronow B (*see* Zhang DY et al). 2004;39:954–962

Arroyo AG (*see* Medina J et al). 2004;39:1185–1195 (Concise Review in Mechanisms of Disease)

Arroyo V (*see* Del Árbol L and Arroyo V). 2004;39:866–867 (Reply)

— (*see* Restuccia T et al). 2004;39:1613–1622

Arseneau KO (*see* Le TH et al). 2004;39:1430–1436

Arthur MJ (*see* Adams PC et al). 2004;39:1205–1213 (Special Article)

Asahara T (*see* Ochi M et al). 2004;39:1326–1336

Ascher NL (*see* Yao FY et al). 2004;39:230–238

Assi A (*see* Casiraghi MA). 2004;39:90–96

Association Française pour l'Etude du Foie (AFEF) (*see* Naveau S et al). 2004;39:1396–1403

Astemborski J (*see* Torbenson M et al). 2004;39:51–57

Auzinger G (*see* Murphy N et al). 2004;39:464–470

Avgerinos A, Armonis A, Stefanidis G, Mathou N, Vlachogiannakos J, Kougioumtzian A, Triantos C, Papaxoinis C, Manolakopoulos S, Panani A, Raptis SA. Sustained rise of portal pressure after sclerotherapy, but not band ligation, in acute variceal bleeding in cirrhosis. 2004;39:1623–1630

Avila MA (*see* Hevia H et al). 2004;39:1088–1098

Aw TY (*see* Taniai H et al). 2004;39:1544–1552

Awad SS (*see* Thevananther S et al). 2004;39:393–402

Azuma H (*see* Hoppo T et al). 2004;39:1367–1375

B

Baba S (*see* Hoppo T et al). 2004;39:1367–1375

Bacchetti P (*see* Yao FY et al). 2004;39:230–238

Baffy G (*see* Horimoto M et al). 2004;39:386–392

Balabaud C (*see* Roskams TA et al). 2004;39:1739–1745 (Special Article)

Balart L (*see* Cammà C et al). 2004;39:333–342

Baldoni M (*see* Fiorucci S et al). 2004;39:365–375

Bandara P (*see* Sud A et al). 2004;39:1242–1250

*January, 1–270; February, 271–578; March, 579–876; April, 877–1182; May, 1183–1466; June, 1467–1798.

Barbera C (*see* Iorio R et al). 2004;39:1173–1174 (Correspondence)
Barnett MJ (*see* Zickmund S et al). 2004; 39:999–1007
Barre SS (*see* McClain CJ et al). 2004;39: 1488–1490 (Editorial)
Bartenschlager R. Hepatology *Elsewhere.* 2004;39:835–837
Bass NM (*see* Yao FY et al). 2004;39:230–238
Batra SK (*see* Shibahara H et al). 2004;39: 220–229
Batteux F (*see* Laurent A et al). 2004;39: 1282–1290
Bäuerle J (*see* Walker UA et al). 2004;39: 311–317
Bavdekar AR (*see* Müller T et al). 2004;39: 963–969
Beard MR (*see* Helbig KJ et al). 2004;39: 1221–1231
Bell AW (*see* Köhler C et al). 2004;39:1056–1065
Bell BP (*see* Vong S and Bell BP). 2004;39: 476–483
Bendavid C (*see* Lainé F et al). 2004;39: 1639–1646
Benferhat S (*see* Roulot D et al). 2004;39: 239–347
Bengmark S (*see* Liu Q et al). 2004;39: 1448–1456
Benitez R (*see* Andrade RJ et al). 2004;39: 1603–1612
Benlloch S (*see* Francés R et al). 2004;39: 484–491, 1470 (Correction)
Bennett JJ (*see* Delman KA et al). 2004;39: 1525–1532
Benson JT (*see* Kim WR et al). 2004;39: 811–816
Berasain C (*see* Hevia H et al). 2004;39: 1088–1098
Berg T, Sarrazin C, Hinrichsen H, Buggisch P, Gerlach T, Zachoval R, Zeuzem S. Does noninvasive staging of fibrosis challenge liver biopsy as a gold standard in chronic hepatitis C? 2004;39:1462–1464 (Correspondence)
Bergasa NV. Hepatology *Elsewhere.* 2004; 39:1457–1460
Bernel W (*see* Murphy N et al). 2004;39: 464–470
Béroud C (*see* Vona G et al). 2004;39:792–797
Berson A (*see* Tinel M et al). 2004;39:655–666
Beuers U (*see* Denk GU et al). 2004;39: 1388–1395
— (*see* Pauli-Magnus C et al). 2004;39: 779–791
Beug H (*see* Mikula M et al). 2004;39: 628–634
Bezerra JA (*see* Zhang DY et al). 2004;39: 954–962
Bhagat G (*see* Roskams TA et al). 2004;39: 1739–1745 (Special Article)
Bhargava A (*see* Delman KA et al). 2004; 39:1525–1532
Bharwani S (*see* Taniai H et al). 2004;39: 1544–1552
Bhathal PS (*see* Dixon JB et al). 2004;39: 1647–1654
Bhathal PS (*see* Roskams TA et al). 2004; 39:1739–1745 (Special Article)
Biffi R (*see* Casiraghi MA). 2004;39:90–96
Bihl F (*see* Grattagliano I et al). 2004;39: 1251–1258
Bilodeau M (*see* Huet PM et al). 2004;39: 1110–1119
Bin Inayat I (*see* Kuniyasu Y et al). 2004; 39:1017–1027
Binelli G (*see* Casiraghi MA). 2004;39:90–96
Bioulac-Sage P (*see* Roskams TA et al). 2004;39:1739–1745 (Special Article)
Blei AT. The impact of *Hepatology.* 2004; 39:1 (Editorial)
Blum HE (*see* Huber R et al). 2004;39: 1732–1733 (Concise Communication)
— (*see* Spangenberg HC et al). 2004;39: 1736–1738
Boëlle PY (*see* Poujol-Robert A et al). 2004; 39:1174–1175 (Correspondence)
Bonacini M (*see* Bräu N et al). 2004;39: 989–998
Bonis PAL (*see* Kaplan MM et al). 2004; 39:915–923
Borderie D (*see* Laurent A et al). 2004;39: 1282–1290
Bordoni V, Alonzi T, Agrati C, Poccia F, Borsellino G, Mancino G, Fimia GM, Piacentini M, Fantoni A, Tripodi M. Murine hepatocyte cell lines promote expansion and differentiation of NK cells from stem cell precursors. 2004; 39:1508–1516
Borras C (*see* Serviddio G et al). 2004;39: 711–720
Borsellino G (*see* Bordoni V et al). 2004; 39:1508–1516
Bortolotti F, Guido M, Zancan L, Gussetti N. Long-term outcome of hepatitis C in children. 2004;39:1462 (Correspondence)
Bosch J (*see* Garcia-Pagán JC and Bosch J). 2004;39:1746–1747 (Correspondence)
Bostrom A (*see* Monto A et al). 2004;39: 826–834
Bottinger EP (*see* Petkov PM et al). 2004; 39:617–627
Bourne EJ (*see* Yuen MF et al). 2004;39: 1694–1701
Bouwens L (*see* Lardon J et al). 2004;39: 1499–1507
Bowen WC (*see* Köhler C et al). 2004;39: 1056–1065
Boyer JL (*see* Denk GU et al). 2004;39: 1388–1395
— (*see* Wang L and Boyer JL). 2004;39: 892–899 (Science Frontier)
Boyer TD. Changing clinical practice with measurements of portal pressure. 2004;39:283–285 (Perspectives in Clinical Hepatology)
— (*see* Adams PC et al). 2004;39:1205–1213 (Special Article)
Bralet MP (*see* Huet PM et al). 2004;39: 1110–1119
Brancati FL (*see* Clark JM and Brancati FL). 2004;39:602–603 (Editorial)
Bräu N, Rodriguez-Torres M, Prokupek D, Bonacini M, Giffen CA, Smith JJ, Frost KR, Kostman JR, amfAR DCRI 010 Study Group. Treatment of chronic hepatitis C in HIV/HCV-coinfection with interferon α-2b+ full-course vs. 16-week delayed ribavirin. 2004;39:989–998
Brault A (*see* Huet PM et al). 2004;39: 1110–1119
Bréchot C (*see* Vona G et al). 2004;39: 792–797
Brenner D, Krueger A, Suess D, Fas SC, Frey CR, Dax A, Zink D, Büchler P, Müller M, Krammer PH (*see* Schulze-Bergkamen H et al). 2004;39:645–654
Bresson-Hadni S (*see* Roulot D et al). 2004;39:239–347
Breuning MH (*see* Drenth JPH et al). 2004;39:924–931
Brissot P (*see* Lainé F et al). 2004;39:1639–1646
Broët P (*see* Naveau S et al). 2004;39:1396–1403
Bruce MG (*see* McMahon BJ et al). 2004; 39:325–332
Bruden D (*see* McMahon BJ et al). 2004; 39:325–332
Bruix J and Llovet JM. Prognostic prediction in HCC: Did anybody expect it to be easy?. 2004;39:551–552 (Hepatology *Elsewhere*)
Brunt EM (*see* Roskams TA et al). 2004; 39:1739–1745 (Special Article)
Büchler P (*see* Schulze-Bergkamen H et al). 2004;39:645–654
Buck A (*see* Reuter S et al). 2004;39:509–517
Buder R (*see* Lenz K et al). 2004;39:865–866 (Correspondence)
Budhu A (*see* Kim JW et al). 2004;39:518–527
Buendia MA (*see* Jacob JR et al). 2004;39: 1008–1016
Buggisch P (*see* Berg T et al). 2004;39: 1462–1464 (Correspondence)
Bugianesi E, Manzini P, D'Antico S, Vanni E, Longo F, Leone N, Massarenti P, Piga A, Marchesini G, Rizzetto M. Relative contribution of iron burden, HFE mutations, and insulin resistance to fibrosis in nonalcoholic fatty liver. 2004;39:179–187
—, Marchesini G. Uric acid levels and liver fibrosis in nonalcoholic fatty liver disease. 2004;39:1749 (Reply)
Buist-Homan M (*see* Schoemaker MH et al). 2004;39:1563–1573

Bukh J. A critical role for the chimpanzee model in the study of hepatitis C. 2004;39:1469–1475 (Concise Review in Mechanisms of Disease)
Buonocore S (*see* Amoroso P et al). 2004;39:572 (Correspondence)
Burgart L (*see* Lindor KD et al). 2004;39:770–778
Burroughs AK, Thalheimer U, Mela M, Patch D. Monitoring of HVPG during pharmacological therapy: Evidence in favor of the prognostic value of a 20% reduction. 2004;39:1747 (Reply)
— (*see* Thalheimer U et al). 2004;39:286–290 (Perspectives in Clinical Hepatology)
Burt AD (*see* Palmer JM et al). 2004;39:1583–1592

C

Caldwell J (*see* Aithal GP et al). 2004;39:1437–1447
Caldwell JG (*see* Aithal GP et al). 2004;39:1437–1447
Caldwell SH, Chang C, Macik BG. Recombinant activated factor VII (rFVIIa) as a hemostatic agent in liver disease: A break from convention in need of controlled trials. 2004;39:592–598
— (*see* Le TH et al). 2004;39:1430–1436
Calès P (*see* Roulot D et al). 2004;39:239–347
Caliendo G (*see* Fiorucci S et al). 2004;39:365–375
Calmus Y (*see* Laurent A et al). 2004;39:1282–1290
Calon E (*see* Lainé F et al). 2004;39:1639–1646
Calvisi DF (*see* Andreola F et al). 2004;39:157–166
Camacho I (*see* Romero-Gómez M et al). 2004;39:939–943
Cammà C, Di Bona D, Schepis F, Heathcote EJ, Zeuzem S, Pockros PJ, Marcellin P, Balart L, Alberti A, Craxì A. Effect of peginterferon alfa-2a on liver histology in chronic hepatitis C: A meta-analysis of individual patient data. 2004;39:333–342
Canbay A, Friedman S, Gores GJ. Apoptosis: The nexus of liver injury and fibrosis. 2004;39:273–278 (Science Frontier)
Canbay AE (*see* Yoon JH et al). 2004;39:732–738
Capron F (*see* Vona G et al). 2004;39:792–797
Carbonell N (*see* Roulot D et al). 2004;39:239–347
Carey MC (*see* Lammert F et al). 2004;39:117–128
Carnicer F (*see* Francés R et al). 2004;39:484–491, 1470 (Correction)
Carpenter HA (*see* Czaja AJ and Carpenter HA). 2004;39:1631–1638
Carretero J (*see* Estrela JM et al). 2004;39:570–571 (Correspondence)
— (*see* Serviddio G et al). 2004;39:711–720
Carulli N (*see* Loria P et al). 2004;39:1748 (Correspondence)
Carver R (*see* Petkov PM et al). 2004;39:617–627
Casellas JA (*see* Francés R et al). 2004;39:484–491, 1470 (Correction)
Caselmann WH (*see* Jüngst C et al). 2004;39:1663–1672
Casiraghi MA, De Paschale M, Romanò L, Biffi R, Assi A, Binelli G, Zanetti AR. Long-term outcome (35 years) of hepatitis C after acquisition of infection through mini transfusion of blood given at birth. 2004;39:90–96
Cassidy W (*see* Jeffers LJ et al). 2004;39:1702–1708
Castellví M (*see* Restuccia T et al). 2004;39:1613–1622
Cellier D (*see* Coulouarn C et al). 2004;39:353–364
Cha MY, Kim CM, Park YM, Ryu WS. Hepatitis B virus X protein is essential for the activation of Wnt/β-catenin signaling in hepatoma cells. 2004;39:1683–1693
Chandraratna RAS (*see* Hellemans K et al). 2004;39:97–108
Chang C (*see* Caldwell SH et al). 2004;39:592–598
Chang CJ (*see* Chen HL et al). 2004;39:58–63
Chang FY (*see* Hou MC et al). 2004;39:746–753
Chang MH (*see* Chen HL et al). 2004;39:58–63
Chau TN, Lee KC, Yao H, Tsang TY, Chow TC, Yeung YC, Choi KW, Tso YK, Lau T, Lai ST, Lai CL. SARS-associated viral hepatitis caused by a novel coronavirus: Report of three cases. 2004;39:302–310
Chazouillères O (*see* Roulot D et al). 2004;39:239–347
Cheever AW (*see* Wynn TA et al). 2004;39:676–687
Chen CJ, Wang LY, Chien YC. News from Taiwan. 2004;39:1196–1197
Chen DS (*see* Chen HL et al). 2004;39:58–63
Chen HL, Chang CJ, Kong MS, Huang FC, Lee HC, Lin CC, Liu CC, Lee IH, Wu TC, Wu SF, Ni YH, Hsu HY, Chen DS, Chang MH. Pediatric fulminant hepatic failure in endemic areas of hepatitis B infection: 15 years after universal hepatitis B vaccination. 2004;39:58–63
Chen Y (*see* Kim JW et al). 2004;39:518–527
Chen YC, Ginès P, Yang J, Summer SN, Falk S, Russell NS, Schrier RW. Increased vascular heme oxygenase-1 expression contributes to arterial vasodilation in experimental cirrhosis in rats. 2004;39:1075–1087
Cheng B (*see* Jüngst C et al). 2004;39:1663–1672
Cheng S (*see* Kaplan MM et al). 2004;39:915–923
Chéreau C (*see* Laurent A et al). 2004;39:1282–1290
Cheremnova OA (*see* Lazarevich NL et al). 2004;39:1038–1047
Chiaramonte MG (*see* Wynn TA et al). 2004;39:676–687
Chida Y, Sudo N, Sonoda J, Sogawa H, Kubo C. Electric foot shock stress-induced exacerbation of α-galactosylceramide–triggered apoptosis in mouse liver. 2004;39:1131–1140
Chien YC (*see* Chen CJ et al). 2004;39:1196–1197
Cho BH (*see* Kim JH et al). 2004;39:129–138
Choi J, Lee KJ, Zheng Y, Yamaga AK, Lai MMC, Ou J. Reactive oxygen species suppress hepatitis C virus RNA replication in human hepatoma cells. 2004;39:81–89
Choi KW (*see* Chau TN et al). 2004;39:302–310
Chollet-Martin S (*see* Naveau S et al). 2004;39:1396–1403
Chow TC (*see* Chau TN et al). 2004;39:302–310
Christensen C (*see* McMahon BJ et al). 2004;39:325–332
Chu L (*see* Pei Z et al). 2004;39:1376–1387
Chu T (*see* Petkov PM et al). 2004;39:617–627
Chung S (*see* Zeindl-Eberhart E et al). 2004;39:540–549
Cianco A, Smedile A, Rizzetto M, Lagget M, Gerin J, Korba B. Identification of HBV DNA sequences that are predictive of responses to lamivudine therapy. 2004;39:64–73
Cirino G (*see* Fiorucci S et al). 2004;39:365–375
Clark JM and Brancati FL. Negative trials in nonalcoholic steatohepatitis: Why they happen and what they teach us. 2004;39:602–603 (Editorial)
Clement YN (*see* Goldring CEP et al). 2004;39:1271–1281
Clore JN (*see* Levy JR et al). 2004;39:608–616
Clouston AD (*see* Walsh MJ et al). 2004;39:1232–1241
Colin P (*see* Lindor KD et al). 2004;39:770–778
Colombo M and Sangiovanni A. The strategic role of staging in the treatment of HCC: Comments. 2004;39:552–553 (Hepatology *Elsewhere*)

Conde de la Rosa L (*see* Schoemaker MH et al). 2004;39:1563–1573
Condreay LD (*see* Yuen MF et al). 2004; 39:1694–1701
Conti F (*see* Laurent A et al). 2004;39:1282–1290
Conzelmann LO (*see* Isayama F et al). 2004;39:721–731
Coppel RL (*see* Matsumura S et al). 2004; 39:1422–1429
Córdoba J and Lucke R. Driving under the influence of minimal hepatic encephalopathy. 2004;39:599–601 (Editorial)
Corpas R (*see* Andrade RJ et al). 2004;39: 1603–1612
Corrales FJ (*see* Hevia H et al). 2004;39: 1088–1098
Cote PJ (*see* Jacob JR et al). 2004;39:1008–1016
Coulouarn C, Lefebvre G, Derambure C, Lequerre T, Scotte M, Francois A, Cellier D, Daveau M, Salier JP. Altered gene expression in acute systemic inflammation detected by complete coverage of the human liver transcriptome. 2004;39:353–364
Crawford DH (*see* Stuart KA et al). 2004; 39:492–499
Crawford DHG, Fletcher LM, Hubscher SG, Stuart KA, Gane E, Angus PW, Jeffrey GP, McCaughan GW, Kerlin P, Powell LW, Elias EE. Patient and graft survival after liver transplantation for hereditary hemochromatosis: Implications for pathogenesis. 2004;39:1655–1662
Crawford JM (*see* Roskams TA et al). 2004;39:1739–1745 (Special Article)
Crawford SE. Vascular interference: A blockade to tumor epithelial growth. 2004;39:1491–1494 (Editorial)
Craxì A (*see* Cammà C et al). 2004;39: 333–342
Crosby HA (*see* Roskams TA et al). 2004; 39:1739–1745 (Special Article)
Crosignani A (*see* Invernizzi P et al). 2004; 39:1175–1176 (Correspondence)
Cui F (*see* Wang Y et al). 2004;39:318–324
Cutrin J (*see* Serviddio G et al). 2004;39: 711–720
Czaja AJ and Carpenter HA. Progressive fibrosis during corticosteroid therapy of autoimmune hepatitis. 2004;39: 1631–1638
Czaja MJ (*see* Schattenberg JM et al). 2004; 39:444–455

D

Dabeva MD (*see* Petkov PM et al). 2004; 39:617–627
Dahari H (*see* Major ME et al). 2004;39: 1709–1720
Dalgard O, Egeland A, Skaug K, Vilimas K, Steen T. Health-related quality of life in active injecting drug users with and without chronic hepatitis C virus infection. 2004;39:74–80
Daly AK (*see* Aithal GP et al). 2004;39: 1437–1447
D'Ambrosi M (*see* Iorio R et al). 2004;39: 1173–1174 (Correspondence)
Damdinsuren B (*see* Ogawa M et al). 2004; 39:528–539
D'Amico G and Morabito A. Noninvasive markers of esophageal varices: Another round, not the last. 2004;39: 30–34 (Editorial)
Damotte D (*see* Vona G et al). 2004;39: 792–797
D'Antico S (*see* Bugianesi E et al). 2004;39: 179–187
Darge K (*see* Reuter S et al). 2004;39:509–517
Daveau M (*see* Coulouarn C et al). 2004; 39:353–364
Davies NA (*see* Shawcross DL et al). 2004; 39:471–475
Davila JA (*see* El-Serag HB and Davila JA). 2004;39:798–803
Davion T (*see* Naveau S et al). 2004;39: 1396–1403
Davis CA (*see* Le TH et al). 2004;39:1430–1436
Dawson V (*see* Yang S et al). 2004;39:403–411
Dax A (*see* Schulze-Bergkamen H et al). 2004;39:645–654
Day CP (*see* Aithal GP et al). 2004;39: 1437–1447
— (*see* Stewart SF et al). 2004;39:197–203
De Breuck S (*see* Lardon J et al). 2004;39: 1499–1507
de Groen PC (*see* Murad SD et al). 2004; 39:500–508
De Las Heras et al. Increased carbon monoxide production in patients with cirrhosis with and without spontaneous bacterial peritonitis. 2004;39:265 (Correction)
De Luca LM (*see* Andreola F et al). 2004; 39:157–166
de Man RA (*see* van Zonneveld M et al). 2004;39:804–810
De Paschale M (*see* Casiraghi MA). 2004; 39:90–96
Degott C (*see* Roulot D et al). 2004;39: 239–347
Del Árbol L and Arroyo V. Systemic, renal, and hepatic hemodynamic derangement in cirrhotic patients with spontaneous bacterial peritonitis. 2004;39:866–867 (Reply)
DeLeve LD (*see* Adams PC et al). 2004;39: 1205–1213 (Special Article)
Delman KA, Zager JS, Bhargava A, Petrowsky H, Malhotra S, Ebright MI, Bennett JJ, Gusani NJ, Kooby DA, Roberts GD, Fong Y. Effect of murine liver cell proliferation on herpes viral behavior: Implications for oncolytic viral therapy. 2004;39:1525–1532
Deng C (*see* Wang Y et al). 2004;39:318–324
Denk GU, Soroka CJ, Mennone A, Koepsell H, Beuers U, Boyer JL. Down-regulation of the organic cation transporter 1 of rat liver in obstructive cholestasis. 2004;39:1388–1395
Denk H (*see* Müller T et al). 2004;39:963–969
Dent P (*see* Han SI et al). 2004;39:456–463
Derambure C (*see* Coulouarn C et al). 2004;39:353–364
Derdák Z (*see* Horimoto M et al). 2004;39: 386–392
Desbiens G (*see* Huet PM et al). 2004;39: 1110–1119
Descatoire V (*see* Tinel M et al). 2004;39: 655–666
Deschênes M and Laneuville P. Pre-emptive use of lamivudine in bone marrow transplantation with chronic hepatitis B virus infection. 2004;39: 867 (Correspondence)
Desmet V (*see* Roskams TA et al). 2004;39: 1739–1745 (Special Article)
Deubner H (*see* McMahon BJ et al). 2004; 39:325–332
Deugnier Y (*see* Lainé F et al). 2004;39: 1639–1646
Dhakshinamoorthy S (*see* Hentze H et al). 2004;39:1316–1325
Dharancy S (*see* Naveau S et al). 2004;39: 1396–1403
Di Bisceglie AM and Strasberg S. Hepatology *Elsewhere*. 2004;39:550–551
— (*see* Adams PC et al). 2004;39:1205–1213 (Special Article)
Di Bona D (*see* Cammà C et al). 2004;39: 333–342
Di Liberto G (*see* Ducoulombier D et al). 2004;39:817–825
Diehl AM (*see* Solga SF and Diehl AM). 2004;39:1198–1201 (Editorial)
— (*see* Yang S et al). 2004;39:403–411
Dikopoulos N, Wegenka U, Kröger A, Hauser H, Schirmbeck R, Reimann J. Recently primed CD8+ T cells entering the liver induce hepatocytes to interact with naïve CD8+ T cells in the mouse. 2004;39:1259–1270
Distrutti E (*see* Fiorucci S et al). 2004;39: 365–375
Dixon JB, Bhathal PS, Hughes NR, O'Brien PE. Nonalcoholic fatty liver disease: Improvement in liver histological analysis with weight loss. 2004;39:1647–1654
Djilali-Saiah I (*see* Lapierre P et al). 2004; 39:1066–1074
Doo E (*see* Promrat K et al). 2004;39:188–196
Dorn JM (*see* Stranges S et al). 2004;39: 754–763
Drenth JPH, Tahvanainen E, te Morsche

RHM, Tahvanainen P, Kääriäinen H, Höckerstedt K, van de Kamp JM, Breuning MH, Jansen JBMJ. Abnormal hepatocystin caused by truncating *PRKCSH* mutations leads to autosomal dominant polycystic liver disease. 2004;39:924–931
Duan ZP (*see* Liu Q et al). 2004;39:1448–1456
Dubuisson J (*see* Penin F et al). 2004;39:5–19 (Scientific Frontier)
Ducoulombier D, Roque-Afonso AM, Di Liberto G, Penin F, Kara R, Richard Y, Dussaix E, Féray C. Frequent compartmentalization of hepatitis C virus variants in circulating B cells and monocytes. 2004;39:817–825
Dufour JF (*see* Martin J and Dufour JF). 2004;39:248–249
Dun H (*see* Zeng S et al). 2004;39:422–432
Duncan SA (*see* Lazarevich NL et al). 2004;39:1038–1047
Durán JA (*see* Andrade RJ et al). 2004;39:1603–1612
Dussaix E (*see* Ducoulombier D et al). 2004;39:817–825

E

Ebright MI (*see* Delman KA et al). 2004;39:1525–1532
Egeland A (*see* Dalgard et al). 2004;39:74–80
Ehmer U, Vogel A, Schütte JK, Krone B, Manns MP, Strassburg CP. Variation of hepatic glucuronidation: Novel functional polymorphisms of the UDP–glucuronosyltransferase UGT1A4. 2004;39:970–977
Ekong U (*see* Zeng S et al). 2004;39:422–432
El-Gibaly AM, Scheuer C, Menger MD, Vollmar B. Improvement of rat liver graft quality by pifithrin-α-mediated inhibition of hepatocyte necrapoptosis. 2004;39:1553–1562
Elias E. Hepatology Highlights. 2004;39:579–580, 1467–1468
Elias EE (*see* Crawford DHG et al). 2004;39:1655–1662
Elizondo G (*see* Andreola F et al). 2004;39:157–166
Ellemunter H (*see* Müller T et al). 2004;39:963–969
Elsby R (*see* Goldring CEP et al). 2004;39:1271–1281
El-Serag HB and Davila JA. Is fibrolamellar carcinoma different from hepatocellular carcinoma? A US population-based study. 2004;39:798–803
Emilie D (*see* Naveau S et al). 2004;39:1396–1403
Emond JC (*see* Zeng S et al). 2004;39:422–432
Endo F (*see* Hisatomi Y et al). 2004;39:667–675
Engelhardt NV (*see* Lazarevich NL et al). 2004;39:1038–1047
Estepa L (*see* Vona G et al). 2004;39:792–797
Estrela JM, Ortega AL, Carretero J. A role for the 2-oxoglutarate carrier in glutathione transport into hepatocyte mitochondria? 2004;39:570–571 (Correspondence)

F

Factor VM (*see* Sánchez A et al). 2004;39:376–385
Falk S (*see* Chen YC et al). 2004;39:1075–1087
Fallon MB (*see* Ling Y et al). 2004;39:1593–1602
Fang Y (*see* Han SI et al). 2004;39:456–463
Fantoni A (*see* Bordoni V et al). 2004;39:1508–1516
Farinaro E (*see* Stranges S et al). 2004;39:754–763
Farrell G (*see* Ip E et al). 2004;39:1291–1301
— (*see* Teoh N et al). 2004;39:412–421
Farrell GC (*see* Hui JM et al). 2004;39:1464 (Correspondence)
— (*see* Sud A et al). 2004;39:1242–1250
Fas SC, Frey CR, Dax A, Zink D, Büchler P, Müller M, Krammer PH (*see* Schulze-Bergkamen H et al). 2004;39:645–654
Fattinger K (*see* Pauli-Magnus C et al). 2004;39:779–791
Fausto N. Liver regeneration and repair: Hepatocytes, progenitor cells, and stem cells. 2004;39:1477–1487 (Science Frontier)
Fehr JJ (*see* Kamal SM et al). 2004;39:1721–1731
Feinstone SM (*see* Major ME et al). 2004;39:1709–1720
Feirt N (*see* Zeng S et al). 2004;39:422–432
Feldmann G (*see* Tinel M et al). 2004;39:655–666
Feldstein A (*see* Adams LA et al). 2004;39:909–914
Feng S (*see* McTaggart RA and Feng S). 2004;39:1143–1146
Féray C (*see* Ducoulombier D et al). 2004;39:817–825
Fernández JC and Garcia-Ruiz C. A role for the 2-oxoglutarate carrier in glutathione transport into hepatocyte mitochondria? 2004;39:571–572 (Reply)
Fernández MC (*see* Andrade RJ et al). 2004;39:1603–1612
Feucht HH (*see* Zöllner B et al). 2004;39:42–50
Fickert P (*see* Lammert F et al). 2004;39:117–128
Field J (*see* Teoh N et al). 2004;39:412–421
Filho AP (*see* França A et al). 2004;39:1461 (Correspondence)
Filho JT (*see* França A et al). 2004;39:1461 (Correspondence)
Fimia GM (*see* Bordoni V et al). 2004;39:1508–1516
Finegold M (*see* Vogel A et al). 2004;39:433–443
Finegold MJ (*see* Roskams TA et al). 2004;39:1739–1745 (Special Article)
Fiorentina R (*see* Fiorucci S et al). 2004;39:365–375
Fiorucci S, Antonelli E, Distrutti E, Severino B, Fiorentina R, Baldoni M, Caliendo G, Santagada V, Morelli A, Cirino G. PAR_1 antagonism protects against experimental liver fibrosis. Role of proteinase receptors in stellate cell activation. 2004;39:365–375
Fischer L (*see* Zöllner B et al). 2004;39:42–50
Fleig W (*see* Köhler C et al). 2004;39:1056–1065
Fleishman DI (*see* Lazarevich NL et al). 2004;39:1038–1047
Fletcher LM (*see* Crawford DHG et al). 2004;39:1655–1662
— (*see* Stuart KA et al). 2004;39:492–499
Flores SC (*see* Taniai H et al). 2004;39:1544–1552
Foie-Alcool group of the Association Française pour l'Etude du Foie (AFEF) (*see* Naveau S et al). 2004;39:1396–1403
Fong Y (*see* Delman KA et al). 2004;39:1525–1532
Fontana RJ and Kronfol Z. The patient's perspective in hepatitis C. 2004;39:903–905 (Editorial)
Forgues M (*see* Kim JW et al). 2004;39:518–527
França A, Lima B, Filho AP, Araújo W, Martinez J, Maciel B, Simões M, Filho JT, Martinelli A. Evolution of intrapulmonary vascular dilatations in cirrhosis. 2004;39:1461 (Correspondence)
Francavilla R (*see* Iorio R et al). 2004;39:1173–1174 (Correspondence)
Francés R, Benlloch S, Zapater P, González JM, Lozano B, Muñoz C, Pascual S, Casellas JA, Uceda F, Palazón JM, Carnicer F, Pérez-Mateo M, Such J. A sequential study of serum bacterial DNA in patients with advanced cirrhosis and ascites. 2004;39:484–491, 1470 (Correction)
Franco D (*see* Vona G et al). 2004;39:792–797
Francois A (*see* Coulouarn C et al). 2004;39:353–364
Franzese A (*see* Vajro P et al). 2004;39:569 (Correspondence)
Frazer DM (*see* Stuart KA et al). 2004;39:492–499

Frediani T (*see* Iorio R et al). 2004;39:1173–1174 (Correspondence)
Freedman RJ (*see* Promrat K et al). 2004; 39:188–196
Freeman RB (*see* Kremers WK et al). 2004; 39:764–769
Freudenheim JL (*see* Stranges S et al). 2004;39:754–763
Frey CR (*see* Schulze-Bergkamen H et al). 2004;39:645–654
Friedman S (*see* Canbay A et al). 2004;39: 273–278 (Science Frontier)
Froh M (*see* Isayama F et al). 2004;39:721–731
Frost KR (*see* Bräu N et al). 2004;39:989–998
Fuchs E (*see* Mikula M et al). 2004;39: 628–634
Fuchsbichler A (*see* Müller T et al). 2004; 39:963–969
Fujii H (*see* Hoppo T et al). 2004;39:1367–1375
Fukui H (*see* Yoshiji H et al). 2004;39: 1517–1524
Fülöp P (*see* Horimoto M et al). 2004;39: 386–392
Fung C (*see* Sud A et al). 2004;39:1242–1250

G

Gane E (*see* Crawford DHG et al). 2004; 39:1655–1662
Gao B, Hong F, Radaeva S. Host factors and failure of interferon-α treatment in hepatitis C virus. 2004;39:880–890 (Concise Review in Mechanisms of Disease)
— (*see* Radaeva S et al). 2004;39:1337–1347
— (*see* Taniai H et al). 2004;39:1544–1552
García-Cortés M (*see* Andrade RJ et al). 2004;39:1603–1612
Garcia-Pagán JC and Bosch J. Monitoring of HVPG during pharmacological therapy: Evidence in favor of the prognostic value of a 20% reduction. 2004;39:1746–1747 (Correspondence)
Garcia-Ruiz C (*see* Fernández JC and Garcia-Ruiz C). 2004;39:571–572 (Reply)
García-Ruiz E (*see* Andrade RJ et al). 2004; 39:1603–1612
García-Trevijano ER (*see* Hevia H et al). 2004;39:1088–1098
Gatell JM (*see* Walker UA et al). 2004;39: 311-317
Gaudio E (*see* Invernizzi P et al). 2004;39: 1175–1176 (Correspondence)
Geerts A (*see* Hellemans K et al). 2004;39: 97-108
Gegenhuber A (*see* Lenz K et al). 2004;39: 865–866 (Correspondence)
Gehrke R (*see* Jüngst C et al). 2004;39: 1663-1672
Geier A (*see* Lammert F et al). 2004;39: 117–128
Geller SA (*see* Roskams TA et al). 2004;39: 1739–1745 (Special Article)
Gelpí E (*see* Serafín A et al). 2004;39:688–698
George J (*see* Hui JM et al). 2004;39:1464 (Correspondence)
— (*see* Sud A et al). 2004;39:1242–1250
Gerin J (*see* Cianco A et al). 2004;39:64–73
Gerin JL (*see* Jacob JR et al). 2004;39:1008–1016
Gerken G (*see* Hilgard P et al). 2004;39: 1404–1414
Gerlach JC (*see* Sauer IM et al). 2004;39: 1415–1421
Gerlach T (*see* Berg T et al). 2004;39:1462–1464 (Correspondence)
Gershwin ME (*see* Matsumura S et al). 2004;39:1422–1429
Ghany M (*see* Promrat K et al). 2004;39: 188–196
Giacchino R (*see* Iorio R et al). 2004;39: 1173–1174 (Correspondence)
Gieling RG (*see* Ruijter JM et al). 2004;39: 343–352
Giffen CA (*see* Bräu N et al). 2004;39:989–998
Ginès P (*see* Chen YC et al). 2004;39:1075–1087
— (*see* Restuccia T et al). 2004;39:1613–1622
Glenn JS. Hepatology *Elsewhere*. 2004;39: 1734–1735
Godbole MM (*see* Upadhyay G et al). 2004;39:1120–1130
Goedert JJ (*see* Kirk GD et al). 2004;39: 211–219
Goetz D (*see* Petkov PM et al). 2004;39: 617–627
Goetz M (*see* Sauer IM et al). 2004;39: 1415–1421
Goldring CEP, Kitteringham NR, Elsby R, Randle LE, Clement YN, Williams DP, McMahon M, Hayes JD, Itoh K, Yamamoto M, Park BK. Activation of hepatic Nrf2 *in vivo* by acetaminophen in CD-1 mice. 2004; 39:1271–1281
Goldstein M (*see* Zeng S et al). 2004;39: 422–432
Gómez-Ansón B (*see* Restuccia T et al). 2004;39:1613–1622
Gong DW (*see* Jadaho SB et al). 2004;39: 1302–1307
Gonzalez FJ (*see* Andreola F et al). 2004; 39:157–166
González JM (*see* Francés R et al). 2004;39: 484–491, 1470 (Correction)
Gores GJ (*see* Canbay A et al). 2004;39: 273–278 (Science Frontier)
— (*see* Matsumura S et al). 2004;39:1422–1429
— (*see* Yoon JH et al). 2004;39:732–738
Goss JA (*see* Thevananther S et al). 2004; 39:393–402
Goto M (*see* Shibahara H et al). 2004;39: 220–229
Gouw ASH (*see* Roskams TA et al). 2004; 39:1739–1745 (Special Article)
Graham CS (*see* Kamal SM et al). 2004;39: 1721–1731
Grande L (*see* Romero-Gómez M et al). 2004;39:939–943
Grant S (*see* Han SI et al). 2004;39:456–463
Grattagliano I, Russmann S, Palmieri VO, Jüni P, Bihl F, Portincasa P, Palasciano G, Lauterburg BH. Low membrane protein sulfhydrils but not glucose-6-phosphate dehydrogenase deficiency predict ribavirin-induced hemolysis in hepatitis C. 2004;39: 1251–1258
Gretch DR (*see* McMahon BJ et al). 2004; 39:325–332
Grisham MB (*see* Taniai H et al). 2004;39: 1544–1552
Grizzle WE (*see* Ling Y et al). 2004;39: 1593–1602
Grodet A (*see* Tinel M et al). 2004;39:655–666
Grompe M. The importance of knowing your identity: Sources of confusion in stem cell biology. 2004;39:35–37 (Editorial)
— (*see* Vogel A et al). 2004;39:433–443
Groopman J (*see* Vogel A et al). 2004;39: 433–443
Groszmann RJ and Wongcharatrawee S. The hepatic venous pressure gradient: Anything worth doing should be done right. 2004;39:280–282 (Perspectives in Clinical Hepatology)
Gu J (*see* Pei Z et al). 2004;39:1376–1387
Guarrera J (*see* Zeng S et al). 2004;39:422–432
Guevara M (*see* Restuccia T et al). 2004;39: 1613–1622
Guido M (*see* Bortolotti F et al). 2004;39: 1462 (Correspondence)
Guillygomarc'h A (*see* Lainé F et al). 2004; 39:1639–1646
Gupta S (*see* Han SI et al). 2004;39:456–463
Gura KM (*see* Alwayn IPJ et al). 2004;39: 1176–1177 (Correspondence)
Gusani NJ (*see* Delman KA et al). 2004;39: 1525–1532
Gussetti N (*see* Bortolotti F et al). 2004;39: 1462 (Correspondence)
Guyader D (*see* Lainé F et al). 2004;39: 1639–1646

H

Ha DK (*see* Liu Q et al). 2004;39:1448–1456
Haagsma EB (*see* Murad SD et al). 2004; 39:500–508

Hagoort J (*see* Ruijter JM et al). 2004;39:343–352
Hainaut P (*see* Kirk GD et al). 2004;39:211–219
Haisma HJ (*see* Schoemaker MH et al). 2004;39:1563–1573
Hall AJ (*see* Kirk GD et al). 2004;39:211–219
Hall JG (*see* Yuen MF et al). 2004;39:1694–1701
Hall M (*see* Adams PC et al). 2004;39:1205–1213 (Special Article)
Hall P (*see* Ip E et al). 2004;39:1291–1301
Halsted CH (*see* Villanueva JA and Halsted CH). 2004;39:1308–1315
Han SI, Studer E, Gupta S, Fang Y, Qiao L, Li W, Grant S, Hylemon PB, Dent P. Bile acids enhance the activity of the insulin receptor and glycogen synthase in primary rodent hepatocytes. 2004;39:456–463
Hansen BE (*see* Murad SD et al). 2004;39:500–508
— (*see* van Zonneveld M et al). 2004;39:804–810
Hara H (*see* Ochi M et al). 2004;39:1326–1336
Haraida S (*see* Zeindl-Eberhart E et al). 2004;39:540–549
Harbrecht BG (*see* Zhang B et al). 2004;39:1348–1357
Harley HAJ (*see* Helbig KJ et al). 2004;39:1221–1231
Harper AM (*see* Kremers WK et al). 2004;39:764–769
Harrison ME (*see* Lindor KD et al). 2004;39:770–778
Hasegawa T (*see* Yoneda M et al). 2004;39:568 (Correspondence)
Hata T (*see* Ogawa M et al). 2004;39:528–539
Hauser H (*see* Dikopoulos N et al). 2004;39:1259–1270
Havinga R (*see* Schoemaker MH et al). 2004;39:1563–1573
Hayashi I (*see* Katagiri H et al). 2004;39:139–150
Hayashi J (*see* Nomura H et al). 2004;39:1214–1220
Hayes JD (*see* Goldring CEP et al). 2004;39:1271–1281
Hayes PC (*see* Shawcross DL et al). 2004;39:471–475
He Q (*see* Kamal SM et al). 2004;39:1721–1731
Heathcote EJ (*see* Cammà C et al). 2004;39:333–342
— (*see* Lindor KD et al). 2004;39:770–778
Heathcote J. Federally funded research in hepatology. 2004;39:20 (News from Canada)
Heinz-Erian P (*see* Müller T et al). 2004;39:963–969
Helbig KJ, Ruszkiewicz A, Semendric L, Harley HAJ, McColl SR, Beard MR. Expression of the CXCR3 ligand I-TAC by hepatocytes in chronic hepatitis C and its correlation with hepatic inflammation. 2004;39:1221–1231
Hellemans K, Verbuyst P, Quartier E, Schuit F, Rombouts K, Chandraratna RAS, Schuppan D, Geerts A. Differential modulation of rat hepatic stellate phenotype by natural and synthetic retinoids. 2004;39:97–108
Heller T (*see* Promrat K et al). 2004;39:188–196
Hennessy TW (*see* McMahon BJ et al). 2004;39:325–332
Hentze H, Latta M, Künstle G, Dhakshinamoorthy S, Ng PY, Porter AG, Wendel A. Topoisomerase inhibitor camptothecin sensitizes mouse hepatocytes *in vitro* and *in vivo* to TNF-mediated apoptosis. 2004;39:1316–1325
Hespenheide EE (*see* Le TH et al). 2004;39:1430–1436
Hesse M (*see* Wynn TA et al). 2004;39:676–687
Hevia H, Varela-Rey M, Corrales FJ, Berasain C, Martínez-Chantar ML, Latasa MU, Lu SC, Mato JM, García-Trevijano ER, Avila MA. 5'-Methylthioadenosine modulates the inflammatory response to endotoxin in mice and in rat hepatocytes. 2004;39:1088–1098
Hicklin DJ (*see* Yoshiji H et al). 2004;39:1517–1524
Hidalgo R (*see* Andrade RJ et al). 2004;39:1603–1612
Higashi M (*see* Shibahara H et al). 2004;39:220–229
Hilgard P, Schreiter T, Stockert RJ, Gerken G, Treichel U. Asialoglycoprotein receptor facilitates hemolysis in patients with alcoholic liver cirrhosis. 2004;39:1404–1414
Hill D (*see* McClain C et al). 2004;39:569–570 (Reply)
Hill DB (*see* McClain CJ et al). 2004;39:1488–1490 (Editorial)
Hillebrandt S (*see* Lammert F et al). 2004;39:117–128
Hillis SL (*see* Zickmund S et al). 2004;39:999–1007
Hines IN (*see* Taniai H et al). 2004;39:1544–1552
Hinrichsen H (*see* Berg T et al). 2004;39:1462–1464 (Correspondence)
Hirose R (*see* Yao FY et al). 2004;39:230–238
Hirose T (*see* Hoppo T et al). 2004;39:1367–1375
Hisaeda K, Inokuchi A, Nakamura T, Iwamoto Y, Kohno K, Kuwano M, Uchiumi T. Interleukin-1β represses MRP2 gene expression through inactivation of interferon regulatory factor 3 in HepG2 cells. 2004;39:1574–1582
Hisatomi Y, Okumura K, Nakamura K, Matsumoto S, Satoh A, Nagano K, Yamamoto T, Endo F. Flow cytometric isolation of endodermal progenitors from mouse salivary gland differentiate into hepatic and pancreatic lineages. 2004;39:667–675
Ho SSM (*see* Yu SCH et al). 2004;39:932–938
Hockenjos B (*see* Huber R et al). 2004;39:1732–1733 (Concise Communication)
Höckerstedt K (*see* Drenth JPH et al). 2004;39:924–931
Hoffmann KF (*see* Wynn TA et al). 2004;39:676–687
Hofseth LJ (*see* Kim JW et al). 2004;39:518–527
Hollingsworth MA (*see* Shibahara H et al). 2004;39:220–229
Homan C (*see* McMahon BJ et al). 2004;39:325–332
Hong F (*see* Gao B et al). 2004;39:880–890 (Concise Review in Mechanisms of Disease)
— (*see* Radaeva S et al). 2004;39:1337–1347
Honkoop P (*see* van Zonneveld M et al). 2004;39:804–810
Hoofnagle JH. Biliary Atresia Research Consortium (BARC). 2004;39:891 (This Month From the NIH)
—. Hepatobiliary Pathophysiology study section. 2004;39:1476 (This Month From the NIH)
—. Liver disease research funding. 2004;39:279 (This Month From the NIH)
— (*see* Promrat K et al). 2004;39:188–196
Hopmans JAM (*see* Murad SD et al). 2004;39:500–508
Hoppo T, Fujii H, Hirose T, Yasuchika K, Azuma H, Baba S, Naito M, Machimoto T, Ikai I. Thy1-positive mesenchymal cells promote the maturation of CD49f-positive hepatic progenitor cells in the mouse fetal liver. 2004;39:1367–1375
Horimoto M, Fülöp P, Derdák Z, Wands JR, Baffy G. Uncoupling protein-2 deficiency promotes oxidant stress and delays liver regeneration in mice. 2004;39:386–392
Hoskins AC (*see* Smith JL et al). 2004;39:1673–1682
Hou MC, Lin HC, Liu TT, Kuo BIT, Lee FY, Chang FY, Lee SD. Antibiotic prophylaxis after endoscopic therapy prevents rebleeding in acute variceal hemorrhage: A randomized trial. 2004;39:746–753
Howell CD (*see* Jeffers LJ et al). 2004;39:1702–1708
Hsu HY (*see* Chen HL et al). 2004;39:58–63
Hu G (*see* Wang Y et al). 2004;39:318–324

Hu H (*see* Jadaho SB et al). 2004;39:1302–1307
Hu S (*see* Jeffers LJ et al). 2004;39:1702–1708
Huang C (*see* Wang Y et al). 2004;39:318–324
Huang FC (*see* Chen HL et al). 2004;39:58–63
Huang J (*see* Yang S et al). 2004;39:403–411
Huber H (*see* Mikula M et al). 2004;39:628–634
Huber R, Hockenjos B, Blum HE. DDB treatment of patients with chronic hepatitis. 2004;39:1732–1733 (Concise Communication)
Hubscher SG (*see* Crawford DHG et al). 2004;39:1655–1662
Huet PM, Nagaoka MR, Desbiens G, Tarrab E, Brault A, Bralet MP, Bilodeau M. Sinusoidal endothelial cell and hepatocyte death following cold ischemia-warm reperfusion of the rat liver. 2004;39:1110–1119
—, Pomier-Layrargues G. The hepatic venous pressure gradient: "Remixed and revisited." 2004;39:295–298 (Editorial)
Hughes NR (*see* Dixon JB et al). 2004;39:1647–1654
Hui JM, Farrell GC, George J, Kench JG. High sensitivity C-reactive protein values do not reliably predict the severity of histological change in NAFLD. 2004;39:1464 (Correspondence)
— (*see* Sud A et al). 2004;39:1242–1250
Humar A, McGilvray I, Phillips MJ, Levy GA. Severe acute respiratory syndrome and the liver. 2004;39:291–294 (Editorial)
Hwang YJ (*see* Sauer IM et al). 2004;39:1415–1421
Hylemon PB (*see* Han SI et al). 2004;39:456–463
Hytiroglou P (*see* Roskams TA et al). 2004;39:1739–1745 (Special Article)

I

Iezzoni JC (*see* Le TH et al). 2004;39:1430–1436
Ikai I (*see* Hoppo T et al). 2004;39:1367–1375
Ikeda M (*see* Ogawa M et al). 2004;39:528–539
Ikegami T (*see* Shoda J et al). 2004;39:167–178
Ikenaga M (*see* Ogawa M et al). 2004;39:528–539
Ikenaka Y (*see* Yoshiji H et al). 2004;39:1517–1524
Imai K (*see* Shibahara H et al). 2004;39:220–229
Imbert-Bismut F (*see* Le Calvez S et al). 2004;39:862–863 (Correspondence)
— (*see* Ratziu V et al). 2004;39:1172 (Correspondence)
Inokuchi A (*see* Hisaeda K et al). 2004;39:1574–1582
Invernizzi P, Alvaro D, Crosignani A, Gaudio E, Podda M. Tamoxifen in treatment of primary biliary cirrhosis. 2004;39:1175–1176 (Correspondence)
Iordanov MS (*see* Vogel A et al). 2004;39:433–443
Iorio R, D'Ambrosi M, Marcellini M, Barbera C, Maggiore G, Zancan L, Giacchino R, Vajro P, Marazzi MG, Francavilla R, Michielutti F, Resti M, Frediani T, Pastore M, Vegnente A. Persistence of elevated aminotransferases in Wilson's disease despite adequate therapy. 2004;39:1173–1174 (Correspondence)
Ip E, Farrell G, Hall P, Robertson G, Leclercq I. Administration of the potent PPARα agonist, Wy-14,643, reverses nutritional fibrosis and steatohepatitis in mice. 2004;39:1291–1301
Ippagunta N (*see* Zeng S et al). 2004;39:422–432
Ippolito L (*see* Zickmund S et al). 2004;39:999–1007
Isayama F, Froh M, Yin M, Conzelmann LO, Milton RJ, McKim SE, Wheeler MD. TNF α-induced Ras activation due to ethanol promotes hepatocyte proliferation independently of liver injury in the mouse. 2004;39:721–731
Ishibashi H (*see* Nomura H et al). 2004;39:1214–1220
Ishii Ki (*see* Katagiri H et al). 2004;39:139–150
Ishiyama K (*see* Ochi M et al). 2004;39:1326–1336
Islam AFM (*see* Neo SN et al). 2004;39:944–953
Ismail A (*see* Kamal SM et al). 2004;39:1721–1731
Ito H (*see* Takeuchi D et al). 2004;39:699–710
Ito K (*see* Shoda J et al). 2004;39:167–178
Ito Y (*see* Katagiri H et al). 2004;39:139–150
Itoh K (*see* Goldring CEP et al). 2004;39:1271–1281
Iwamoto Y (*see* Hisaeda K et al). 2004;39:1574–1582

J

Jäckel E (*see* Wedemeyer H et al). 2004;39:1202–1204 (Editorial)
Jacob JR, Sterczer A, Toshkov IA, Yeager AE, Korba BE, Cote PJ, Buendia MA, Gerin JL, Tennant BC. Integration of woodchuck hepatitis and N-myc rearrangement determine size and histologic grade of hepatic tumors. 2004;39:1008–1016
Jadhao SB, Yang RZ, Lin Q, Hu H, Anania FA, Shuldiner AR, Gong DW. Murine alanine aminotransferase: cDNA cloning, functional expression, and differential gene regulation in mouse fatty liver. 2004;39:1302–1307
Jaeschke H, Mullen K, Moradpour D. Hepatology *Elsewhere*. 2004;39:248–249, 550–553, 835–840, 1141–1146
Jaffray P (*see* Laurent A et al). 2004;39:1282–1290
Jäger G (*see* Zeindl-Eberhart E et al). 2004;39:540–549
Jakowlew SB (*see* Andreola F et al). 2004;39:157–166
Jalan R (*see* Shawcross DL et al). 2004;39:471–475
Jansen JBMJ (*see* Drenth JPH et al). 2004;39:924–931
Jansen PLM (*see* Schoemaker MH et al). 2004;39:1563–1573
Janssen HLA (*see* Murad SD et al). 2004;39:500–508
— (*see* van Zonneveld M et al). 2004;39:804–810
Javid PJ (*see* Alwayn IPJ et al). 2004;39:1176–1177 (Correspondence)
Jeffers LJ, Cassidy W, Howell CD, Hu S, Reddy KR. Peginterferon alfa-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1. 2004;39:1702–1708
Jeffrey GP (*see* Crawford DHG et al). 2004;39:1655–1662
Jiménez M (*see* Andrade RJ et al). 2004;39:1603–1612
Jones DEJ (*see* Palmer JM et al). 2004;39:1583–1592
— (*see* Stewart SF et al). 2004;39:197–203
Jonsson JR (*see* Walsh MJ et al). 2004;39:1232–1241
Jorgensen R (*see* Lindor KD et al). 2004;39:770–778
Jouet P (*see* Naveau S et al). 2004;39:1396–1403
Jungblut PR (*see* Zeindl-Eberhart E et al). 2004;39:540–549
Jüngst C, Cheng B, Gehrke R, Schmitz V, Nischalke HD, Ramakers J, Schramel P, Schirmacher P, Sauerbruch T, Caselmann WH. Oxidative damage is increased in human liver tissue adjacent to hepatocellular carcinoma. 2004;39:1663–1672
Jüni P (*see* Grattagliano I et al). 2004;39:1251–1258

K

Kääriäinen H (*see* Drenth JPH et al). 2004;39:924–931
Kajimura M (*see* Kudo A et al). 2004;39:1099–1109

Kakita A (*see* Katagiri H et al). 2004;39:139–150
Kamal SM, Ismail A, Graham CS, He Q, Rasenack JW, Peters T, Tawil AA, Fehr JJ, Khalifa KES, Massoud MM, Koziel MJ. Pegylated interferon α therapy in acute hepatitis C: Relation to hepatitis C virus–specific T cell response kinetics. 2004;39:1721–1731
Kamath PS (*see* Kremers WK et al). 2004;39:764–769
Kann M. Hepatology *Elsewhere*. 2004;39:838–840
Kannangai R (*see* Torbenson M et al). 2004;39:51–57
Kano M (*see* Shoda J et al). 2004;39:167–178
Kaplan MM, Cheng S, Price LL, Bonis PAL. A randomized controlled trial of colchicine plus ursodiol versus methotrexate plus ursodiol in primary biliary cirrhosis: Ten-year results. 2004;39:915–923
Kaplowitz N. Hepatology Highlights. 2004;39:271–272, 1183–1184
Kapoor A (*see* Upadhyay G et al). 2004;39:1120–1130
Kapral C (*see* Lenz K et al). 2004;39:865–866 (Correspondence)
Kara R (*see* Ducoulombier D et al). 2004;39:817–825
Karpen SJ (*see* Thevananther S et al). 2004;39:393–402
Kashiwagi S (*see* Kudo A et al). 2004;39:1099–1109
— (*see* Nomura H et al). 2004;39:1214–1220
Kaslow RA (*see* Wang C et al). 2004;39:978–988
Katagiri H, Ito Y, Ishii Ki, Hayashi I, Suematsu M, Yamashina S, Murata T, Narumiya S, Kakita A, Majima M. Role of thromboxane derived from COX-1 and -2 in hepatic microcirculatory dysfunction during endotoxemia in mice. 2004;39:139–150
Kato A, Ito H, Kimura F, Shimizu H, Ohtsuka M, Morita Y, Miyazaki M (*see* Takeuchi D et al). 2004;39:699–710
Kaul R (*see* Kim JW et al). 2004;39:518–527
Kaviratne M (*see* Wynn TA et al). 2004;39:676–687
Kehr DC (*see* Sauer IM et al). 2004;39:1415–1421
Kench JG (*see* Hui JM et al). 2004;39:1464 (Correspondence)
— (*see* Sud A et al). 2004;39:1242–1250
Kenna JG (*see* Aithal GP et al). 2004;39:1437–1447
Kerb R (*see* Pauli-Magnus C et al). 2004;39:779–791
Kerlin P (*see* Crawford DHG et al). 2004;39:1655–1662
Kern P (*see* Reuter S et al). 2004;39:509–517
Khalifa KES (*see* Kamal SM et al). 2004;39:1721–1731
Kikuta H (*see* Müller T et al). 2004;39:963–969
Kim B (*see* Ogawa M et al). 2004;39:528–539
Kim CM (*see* Cha MY et al). 2004;39:1683–1693
Kim CY (*see* Kim JH et al). 2004;39:129–138
Kim DG (*see* Kim JH et al). 2004;39:129–138
Kim IH (*see* Kim JH et al). 2004;39:129–138
Kim JH, You KR, Kim IH, Cho BH, Kim CY, Kim DG. Over-expression of the ribosomal protein L36a gene Is associated with cellular proliferation in hepatocellular carcinoma. 2004;39:129–138
Kim JS, Ohshima S, Pediaditakis P, Lemasters JJ. Nitric oxide protects rat hepatocytes against reperfusion injury mediated by the mitochondrial permeability transition. 2004;39:1533–1543
Kim JW, Ye Q, Forgues M, Chen Y, Budhu A, Sime J, Hofseth LJ, Kaul R, Wang XW. Cancer-associated molecular signature in the tissue samples of patients with cirrhosis. 2004;39:518–527
Kim WR, Benson JT, Therneau TM, Torgerson HA, Yawn BP, Melton LJ III. Changing epidemiology of hepatitis B in a U.S. community. 2004;39:811–816
— (*see* Kremers WK et al). 2004;39:764–769
Kimura F (*see* Takeuchi D et al). 2004;39:699–710
Kimura Y (*see* Nomura H et al). 2004;39:1214–1220
Kirby JA (*see* Palmer JM et al). 2004;39:1583–1592
Kirk GD, Lesi OA, Mendy M, Akano AO, Sam O, Goedert JJ, Hainaut P, Hall AJ, Whittle H, Montesano R. The Gambia liver cancer study: Infection with hepatitis B and C and the risk of hepatocellular carcinoma in West Africa. 2004;39:211–219
Kitade M (*see* Yoshiji H et al). 2004;39:1517–1524
Kitteringham NR (*see* Goldring CEP et al). 2004;39:1271–1281
Kleiner DE (*see* Promrat K et al). 2004;39:188–196
Kletzmayr J (*see* Zöllner B et al). 2004;39:42–50
Knisely AS (*see* Roskams TA et al). 2004;39:1739–1745 (Special Article)
Kobayashi K (*see* Müller T et al). 2004;39:963–969
Koch H (*see* Wein C et al). 2004;39:739–745
Koepsell H (*see* Denk GU et al). 2004;39:1388–1395
Köhler C, Bell AW, Bowen WC, Monga SP, Fleig W, Michalopoulos GK. Expression of Notch-1 and its ligand Jagged-1 in rat liver during liver regeneration. 2004;39:1056–1065
Kohno K (*see* Hisaeda K et al). 2004;39:1574–1582
Kojiro M (*see* Roskams TA et al). 2004;39:1739–1745 (Special Article)
Kong MS (*see* Chen HL et al). 2004;39:58–63
Kono T (*see* Yoneda M et al). 2004;39:568 (Correspondence)
Kooby DA (*see* Delman KA et al). 2004;39:1525–1532
Koop DR (*see* Schattenberg JM et al). 2004;39:444–455
Kopper L (*see* Paku S et al). 2004;39:1358–1366
Korba B (*see* Cianco A et al). 2004;39:64–73
Korba BE (*see* Jacob JR et al). 2004;39:1008–1016
Kostman JR (*see* Bräu N et al). 2004;39:989–998
Koteish A (*see* Yang S et al). 2004;39:403–411
Kougioumtzian A (*see* Avgerinos A et al). 2004;39:1623–1630
Kowdley KV. Liver transplantation: An "in vivo" model for the pathophysiology of hemochromatosis? 2004;39:1495–1498 (Editorial)
— (*see* Lindor KD et al). 2004;39:770–778
Koziel MJ (*see* Kamal SM et al). 2004;39:1721–1731
Krammer PH (*see* Schulze-Bergkamen H et al). 2004;39:645–654
Kratzer W (*see* Reuter S et al). 2004;39:509–517
Kremers WK, van IJperen M, Kim WR, Freeman RB, Harper AM, Kamath PS, Wiesner RH. MELD score as a predictor of pretransplant and posttransplant survival in OPTN/UNOS Status 1 patients. 2004;39:764–769
Kröger A (*see* Dikopoulos N et al). 2004;39:1259–1270
Krone B (*see* Ehmer U et al). 2004;39:970–977
Kronfol Z (*see* Fontana RJ and Kronfol Z). 2004;39:903–905 (Editorial)
Krueger A, Suess D, Fas SC, Frey CR, Dax A, Zink D, Büchler P, Müller M, Krammer PH (*see* Schulze-Bergkamen H et al). 2004;39:645–654
Kruhøffer M (*see* Lardon J et al). 2004;39:1499–1507
Ku DD (*see* Ling Y et al). 2004;39:1593–1602

Kubo C (*see* Chida Y et al). 2004;39:1131–1140
Kudo A, Kashiwagi S, Kajimura M, Yoshimura Y, Uchida K, Arii S, Suematsu M. Kupffer cells alter organic anion transport through multidrug resistance protein 2 in the post-cold ischemic rat liver. 2004;39:1099–1109
Kudrjavtseva EI (*see* Lazarevich NL et al). 2004;39:1038–1047
Kugelmas M (*see* McClain C et al). 2004;39:569–570 (Reply)
Kullak-Ublick GA (*see* Pauli-Magnus C et al). 2004;39:779–791
Kumar A (*see* Upadhyay G et al). 2004;39:1120–1130
Kumar S (*see* Upadhyay G et al). 2004;39:1120–1130
Kuniyasu Y, Marfani SM, Bin Inayat I, Sheikh SZ, Mehal WZ. Kupffer cells required for high affinity peptide-induced deletion, not retention, of activated CD8+ T cells by mouse liver. 2004;39:1017–1027
Künstle G (*see* Hentze H et al). 2004;39:1316–1325
Kuo BIT (*see* Hou MC et al). 2004;39:746–753
Kuriyama S (*see* Yoshiji H et al). 2004;39:1517–1524
Kurtovic J (*see* Liu Q et al). 2004;39:1448–1456
Kuwano M (*see* Hisaeda K et al). 2004;39:1574–1582

L

LaBrecque DR (*see* Zickmund S et al). 2004;39:999–1007
Lacour B (*see* Vona G et al). 2004;39:792–797
Lagget M (*see* Cianco A et al). 2004;39:64–73
Laguno M (*see* Walker UA et al). 2004;39:311–317
Lai CL (*see* Chau TN et al). 2004;39:302–310
— (*see* Yuen MF et al). 2004;39:1694–1701
Lai GH (*see* Zhang Z et al). 2004;39:1028–1037
Lai MMC (*see* Choi J et al). 2004;39:81–89
Lai PBS (*see* Neo SN et al). 2004;39:944–953
Lai ST (*see* Chau TN et al). 2004;39:302–310
Lainé F, Bendavid C, Moirand R, Tessier S, Perrin M, Guillygomarc'h A, Guyader D, Calon E, Renault A, Brissot P, Turlin B, Deugnier Y. Prediction of liver fibrosis in patients with features of the metabolic syndrome regardless of alcohol consumption. 2004;39:1639–1646
Lamer S (*see* Zeindl-Eberhart E et al). 2004;39:540–549
Lamers WH (*see* Ruijter JM et al). 2004;39:343–352
Lammert F, Wang DQH, Hillebrandt S, Geier A, Fickert P, Trauner M, Matern S, Paigen B, Carey MC. Spontaneous cholecysto- and hepatolithiasis in *Mdr2*$^{-/-}$ mice: A model for low phospholipid-associated cholelithiasis. 2004;39:117–128
— (*see* Wasmuth HE). 2004;39:604–607 (Editorial)
Laneuville P (*see* Deschênes M and Laneuville P). 2004;39:867 (Correspondence)
Lang T (*see* Pauli-Magnus C et al). 2004;39:779–791
Lang Z (*see* Wang Y et al). 2004;39:318–324
Langner C (*see* Müller T et al). 2004;39:963–969
Lapierre P, Djilali-Saiah I, Vitozzi S, Alvarez F. A murine model of type 2 autoimmune hepatitis: Xenoimmunization with human antigens. 2004;39:1066–1074
Lardon J, De Breuck S, Rooman I, Van Lommel L, Kruhøffer M, Orntoft T, Schuit F, Bouwens L. Plasticity in the adult rat pancreas: Transdifferentiation of exocrine to hepatocytelike cells in primary culture. 2004;39:1499–1507
Larsen FS. Optimal management of patients with fulminant hepatic failure: Targeting the brain. 2004;39:299–301 (Editorial)
LaRusso NF (*see* Splinter PL et al). 2004;39:109–116
Latasa MU (*see* Hevia H et al). 2004;39:1088–1098
Latta M (*see* Hentze H et al). 2004;39:1316–1325
Lau GKK, Zhang HY, Luk JM, Locarnini S, Liang R. Pre-emptive use of lamivudine in bone marrow transplantation with chronic hepatitis B virus infection. 2004;39:867–868 (Reply)
Lau T (*see* Chau TN et al). 2004;39:302–310
Lau WY (*see* Yu SCH et al). 2004;39:932–938
Laufs R (*see* Zöllner B et al). 2004;39:42–50
Laurent A, Nicco C, Van Nhieu JT, Borderie D, Chéreau C, Conti F, Jaffray P, Soubrane O, Calmus Y, Weill B, Batteux F. Pivotal role of superoxide anion and beneficial effect of antioxidant molecules in murine steatohepatitis. 2004;39:1282–1290
Lauterburg BH (*see* Grattagliano I et al). 2004;39:1251–1258
Lazar AA (*see* Yao FY et al). 2004;39:230–238
Lazarevich NL, Cheremnova OA, Varga EV, Ovchinnikov DA, Kudrjavtseva EI, Morozova OV, Fleishman DI, Engelhardt NV, Duncan SA. Progression of HCC in mice is associated with a downregulation in the expression of hepatocyte nuclear factors. 2004;39:1038–1047
Le Calvez S, Thabut D, Messous D, Munteanu M, Ratziu V, Imbert-Bismut F, Poynard T. The predictive value of Fibrotest vs. APRI for the diagnosis of fibrosis in chronic hepatitis C. 2004;39:862–863 (Correspondence)
Le Deist F (*see* André N et al). 2004;39:864–865 (Correspondence)
Le TH, Caldwell SH, Redick JA, Sheppard BL, Davis CA, Arseneau KO, Iezzoni JC, Hespenheide EE, Al-Osaimi A, Peterson TC. The zonal distribution of megamitochondria with crystalline inclusions in nonalcoholic steatohepatitis. 2004;39:1430–1436
Leathart JBS (*see* Aithal GP et al). 2004;39:1437–1447
Lebensztejn DM, Kaczmarski M, Sobaniec-Lotowska M, Bauer M, Voelker M, Schuppan D. Serum laminin-2 and hyaluronan predict severe liver fibrosis in children with chronic hepatitis B. 2004;39:868–869 (Correspondence)
Leclercq I (*see* Ip E et al). 2004;39:1291–1301
Lee A (*see* Shawcross DL et al). 2004;39:471–475
Lee FY (*see* Hou MC et al). 2004;39:746–753
Lee HC (*see* Chen HL et al). 2004;39:58–63
Lee IH (*see* Chen HL et al). 2004;39:58–63
Lee KC (*see* Chau TN et al). 2004;39:302–310
Lee KJ (*see* Choi J et al). 2004;39:81–89
Lee PSF (*see* Yu SCH et al). 2004;39:932–938
Lee SD (*see* Hou MC et al). 2004;39:746–753
Lee SP (*see* Yoon JH et al). 2004;39:732–738
Lefebvre G (*see* Coulouarn C et al). 2004;39:353–364
Leffert HL and Sell S. Unexpected artifacts raise new caution in stem cell culture research. 2004;39:258 (Correspondence)
Lefkowitch JH (*see* Roskams TA et al). 2004;39:1739–1745 (Special Article)
Lemasters JJ (*see* Kim JS et al). 2004;39:1533–1543
Lenz K, Kapral C, Gegenhuber A, Buder R, Wewalka F. Systemic, renal, and hepatic hemodynamic derangement in cirrhotic patients with spontaneous

bacterial peritonitis. 2004;39:865–866 (Correspondence)
Leone N (*see* Bugianesi E et al). 2004;39:179–187
Leow CK (*see* Neo SN et al). 2004;39:944–953
Lequerre T (*see* Coulouarn C et al). 2004;39:353–364
Lesi OA (*see* Kirk GD et al). 2004;39:211–219
Lettieri G (*see* Amoroso P et al). 2004;39:572 (Correspondence)
Leung P (*see* Matsumura S et al). 2004;39:1422–1429
Levin TR (*see* Adams PC et al). 2004;39:1205–1213 (Special Article)
Levy GA (*see* Humar A et al). 2004;39:291–294 (Editorial)
Levy JR, Clore JN, Stevens W. Dietary n-3 polyunsaturated fatty acids decrease hepatic triglycerides in Fischer 344 rats. 2004;39:608–616
Lewindon PJ (*see* Smith JL et al). 2004;39:1673–1682
Li C (*see* Wang Y et al). 2004;39:318–324
Li D (*see* Thevananther S et al). 2004;39:393–402
Li W (*see* Han SI et al). 2004;39:456–463
Liang R (*see* Lau GKK et al). 2004;39:867–868 (Reply)
Liang TJ (*see* Promrat K et al). 2004;39:188–196
Liao Y (*see* Rudnick DA et al). 2004;39:1048–1055
Liddle C (*see* Sud A et al). 2004;39:1242–1250
Liebmann S (*see* Zeindl-Eberhart E et al). 2004;39:540–549
Lima B (*see* França A et al). 2004;39:1461 (Correspondence)
Lin CC (*see* Chen HL et al). 2004;39:58–63
Lin H (*see* Yang S et al). 2004;39:403–411
Lin HC (*see* Hou MC et al). 2004;39:746–753
Lin Q (*see* Jadaho SB et al). 2004;39:1302–1307
Lin R (*see* Sud A et al). 2004;39:1242–1250
Lindor KD, Kowdley KV, Heathcote EJ, Harrison ME, Jorgensen R, Angulo P, Lymp JF, Burgart L, Colin P. Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: Results of a randomized trial. 2004;39:770–778
— (*see* Adams LA et al). 2004;39:909–914
— (*see* Zein CO et al). 2004;39:204–210
Ling Y, Zhang J, Luo B, Song D, Liu L, Tang L, Stockard CR, Grizzle WE, Ku DD, Fallon MB. The role of endothelin-1 and the endothelin B receptor in the pathogenesis of experimental hepatopulmonary syndrome. 2004;39:1593–1602
Liu CC (*see* Chen HL et al). 2004;39:58–63
Liu ET (*see* Neo SN et al). 2004;39:944–953
Liu L (*see* Ling Y et al). 2004;39:1593–1602
Liu Q, Duan ZP, Ha DK, Bengmark S, Kurtovic J, Riordan SM. Synbiotic modulation of gut flora: Effect on minimal hepatic encephalopathy in patients with cirrhosis. 2004;39:1448–1456
Liu S (*see* Zhang B et al). 2004;39:1348–1357
Liu TT (*see* Hou MC et al). 2004;39:746–753
Liu X (*see* Pei Z et al). 2004;39:1376–1387
Livingston S (*see* McMahon BJ et al). 2004;39:325–332
Llovet JM (*see* Bruix J and Llovet JM). 2004;39:551–552
Lobashevsky E (*see* Wang C et al). 2004;39:978–988
Locarnini S (*see* Lau GKK et al). 2004;39:867–868 (Reply)
Lok AS and Wai CT. The predictive value of Fibrotest vs. APRI for the diagnosis of fibrosis in chronic hepatitis C. 2004;39:863 (Reply)
Lok ASF and McMahon BJ. Chronic hepatitis B: Update of recommendations. 2004;39:857–861 (AASLD Practice Guideline)
— (*see* Wai CT and Lok ASF). 2004;39:1464–1465 (Reply)
Lonardo A (*see* Loria P et al). 2004;39:1748 (Correspondence)
Long PM (*see* Neo SN et al). 2004;39:944–953
Longo F (*see* Bugianesi E et al). 2004;39:179–187
Loria P, Lonardo A, Carulli N. Relative contribution of iron burden, HFE mutations, and insulin resistance to fibrosis in nonalcoholic fatty liver. 2004;39:1748 (Correspondence)
Loss G (*see* Xu L et al). 2004;39:151–156
Lozano B (*see* Francés R et al). 2004;39:484–491, 1470 (Correction)
Lu SC (*see* Hevia H et al). 2004;39:1088–1098
Lu Y (*see* Zeng S et al). 2004;39:422–432
Lucariello S (*see* Vajro P et al). 2004;39:569 (Correspondence)
Lucena MI (*see* Andrade RJ et al). 2004;39:1603–1612
Lucke R (*see* Córdoba J and Lucke R). 2004;39:599–601 (Editorial)
Luk JM (*see* Lau GKK et al). 2004;39:867–868 (Reply)
Luo B (*see* Ling Y et al). 2004;39:1593–1602
Lutchman G (*see* Promrat K et al). 2004;39:188–196
Lv Y (*see* Wang Y et al). 2004;39:318–324
Ly D (*see* Yao FY et al). 2004;39:230–238
Lymp JF (*see* Lindor KD et al). 2004;39:770–778

M

Machimoto T (*see* Hoppo T et al). 2004;39:1367–1375
Maciel B (*see* França A et al). 2004;39:1461 (Correspondence)
Macik BG (*see* Caldwell SH et al). 2004;39:592–598
Mack C (*see* Zhang DY et al). 2004;39:954–962
Madwar MM (*see* Kamal SM et al). 2004;39:1721–1731
Maggiore G (*see* Iorio R et al). 2004;39:1173–1174 (Correspondence)
Maher JJ. Hepatology *Elsewhere*. 2004;39:1141–1143
Majima M (*see* Katagiri H et al). 2004;39:139–150
Major ME, Dahari H, Mihalik K, Puig M, Rice CM, Neumann AU, Feinstone SM. Hepatitis C virus kinetics and host responses associated with disease and outcomes of infection in chimpanzees. 2004;39:1709–1720
Malhotra S (*see* Delman KA et al). 2004;39:1525–1532
Mallolas J (*see* Walker UA et al). 2004;39:311–317
Maloney RE (*see* Taniai H et al). 2004;39:1544–1552
Mancino G (*see* Bordoni V et al). 2004;39:1508–1516
Mandato C (*see* Vajro P et al). 2004;39:569 (Correspondence)
Manfras B (*see* Reuter S et al). 2004;39:509–517
Manns MP (*see* Ehmer U et al). 2004;39:970–977
— (*see* Wedemeyer H et al). 2004;39:1202–1204 (Editorial)
Manolakopoulos S (*see* Avgerinos A et al). 2004;39:1623–1630
Manzini P (*see* Bugianesi E et al). 2004;39:179–187
Marazzi MG (*see* Iorio R et al). 2004;39:1173–1174 (Correspondence)
Marcellin P (*see* Cammà C et al). 2004;39:333–342
Marcellini M (*see* Iorio R et al). 2004;39:1173–1174 (Correspondence)
Marchesini G (*see* Bugianesi E and Marchesini G). 2004;39:1749 (Correspondence)
— (*see* Bugianesi E et al). 2004;39:179–187
Marfani SM (*see* Kuniyasu Y et al). 2004;39:1017–1027
Mariano J (*see* Andreola F et al). 2004;39:157–166
Marinelli RA (*see* Splinter PL et al). 2004;39:109–116
Markman MM (*see* Ruijter JM et al). 2004;39:343–352
Martin J and Dufour JF. Hepatology *Elsewhere*. 2004;39:248–249
Martín M (*see* Restuccia T et al). 2004;39:1613–1622

Martinelli A (*see* França A et al). 2004;39: 1461 (Correspondence)
Martinez J (*see* França A et al). 2004;39: 1461 (Correspondence)
Martínez-Chantar ML (*see* Hevia H et al). 2004;39:1088–1098
Martín-Vivaldi R (*see* Andrade RJ et al). 2004;39:1603–1612
Masaki T (*see* Yoshiji H et al). 2004;39: 1517–1524
Mason A (*see* Xu L et al). 2004;39:151–156
Massarenti P (*see* Bugianesi E et al). 2004; 39:179–187
Masyuk AI (*see* Splinter PL et al). 2004;39: 109–116
Matern S (*see* Lammert F et al). 2004;39: 117–128
— (*see* Wasmuth HE). 2004;39:604–607 (Editorial)
Mathou N (*see* Avgerinos A et al). 2004;39: 1623–1630
Mathurin P (*see* Naveau S et al). 2004;39: 1396–1403
Mato JM (*see* Hevia H et al). 2004;39:1088–1098
Matsumoto S (*see* Hisatomi Y et al). 2004; 39:667–675
Matsumura S, Van de Water J, Leung P, Odin JA, Yamamoto K, Gores GJ, Mostov K, Ansari AA, Coppel RL, Shiratori Y, Gershwin ME. Caspase induction by IgA antimitochondrial antibody: IgA-mediated biliary injury in primary biliary cirrhosis. 2004;39: 1422–1429
Matsuura N (*see* Ogawa M et al). 2004;39: 528–539
Mauss S (*see* Walker UA et al). 2004;39: 311–317
Mayer D (*see* Zeindl-Eberhart E et al). 2004;39:540–549
McCaughan GW (*see* Crawford DHG et al). 2004;39:1655–1662
— (*see* Sud A et al). 2004;39:1242–1250
McClain C, Hill D, Kugelmas M. More on vitamin E therapy. 2004;39:569–570 (Reply)
McClain CJ, Hill DB, Barre SS. Infliximab and prednisolone: Too much of a good thing? 2004;39:1488–1490 (Editorial)
McColl SR (*see* Helbig KJ et al). 2004;39: 1221–1231
McCord JM (*see* Taniai H et al). 2004;39: 1544–1552
McGilvray I (*see* Humar A et al). 2004;39: 291–294 (Editorial)
McHutchison JG (*see* Monto A et al). 2004;39:826–834
— (*see* Pawlotsky JM and McHutchison JG). 2004;39:554–567 (Special Article)
McKim SE (*see* Isayama F et al). 2004;39: 721–731
McMahon BJ, Hennessy TW, Christensen C, Bruden D, Sullivan DG, Homan C, Deubner H, Bruce MG, Livingston S, Williams J, Gretch DR. Epidemiology and risk factors for hepatitis C in Alaska Natives. 2004; 39:325–332
— (*see* Lok ASF and McMahon BJ). 2004; 39:857–861 (AASLD Practice Guideline)
McMahon M (*see* Goldring CEP et al). 2004;39:1271–1281
McTaggart RA and Feng S. Hepatology *Elsewhere*. 2004;39:1143–1146
Medina J, Arroyo AG, Sánchez-Madrid F, Moreno-Otero R. Angiogenesis in chronic inflammatory liver disease. 2004;39:1185–1195 (Concise Review in Mechanisms of Disease)
Mehal WZ (*see* Kuniyasu Y et al). 2004;39: 1017–1027
Meier PJ (*see* Pauli-Magnus C et al). 2004; 39:779–791
Mela M (*see* Burroughs AK et al). 2004;39: 1747 (Reply)
— (*see* Thalheimer U et al). 2004;39:286–290 (Perspectives in Clinical Hepatology)
Mele A (*see* Amoroso P et al). 2004;39:572 (Correspondence)
Melter M (*see* Müller T et al). 2004;39: 963–969
Melton LJ III (*see* Kim WR et al). 2004;39: 811–816
Mendy M (*see* Kirk GD et al). 2004;39: 211–219
Menger MD (*see* El-Gibaly AM et al). 2004;39:1553–1562
Mennone A (*see* Denk GU et al). 2004;39: 1388–1395
Mentink-Kane MM (*see* Wynn TA et al). 2004;39:676–687
Messous D (*see* Le Calvez S et al). 2004;39: 862–863 (Correspondence)
— (*see* Ratziu V et al). 2004;39:1172 (Correspondence)
Metreweli C (*see* Yu SCH et al). 2004;39: 932–938
Michalopoulos GK (*see* Köhler C et al). 2004;39:1056–1065
Michielutti F (*see* Iorio R et al). 2004;39: 1173–1174 (Correspondence)
Mihalik K (*see* Major ME et al). 2004;39: 1709–1720
Mikula M, Fuchs E, Huber H, Beug H, Schulte-Hermann R, Mikulits W. Immortalized p19^{ARF} null hepatocytes restore liver injury and generate hepatic progenitors after transplantation. 2004;39:628–634
Mikulits W (*see* Mikula M et al). 2004;39: 628–634
Milton RJ (*see* Isayama F et al). 2004;39: 721–731
Mineur A (*see* Vona G et al). 2004;39:792–797
Miquel R (*see* Walker UA et al). 2004;39: 311–317
Mitsuta H (*see* Ochi M et al). 2004;39: 1326–1336
Miura T (*see* Shoda J et al). 2004;39:167–178
Miyajima A (*see* Nakamura K et al). 2004; 39:635–644
Miyake Y (*see* Ogawa M et al). 2004;39: 528–539
Miyazaki M (*see* Takeuchi D et al). 2004; 39:699–710
Moirand R (*see* Lainé F et al). 2004;39: 1639–1646
Monden M (*see* Ogawa M et al). 2004;39: 528–539
Monga SP (*see* Köhler C et al). 2004;39: 1056–1065
Montesano R (*see* Kirk GD et al). 2004;39: 211–219
Monto A, Patel K, Bostrom A, Pianko S, Pockros P, McHutchison JG, Wright TL. Risks of a range of alcohol intake on hepatitis C-related fibrosis. 2004; 39:826–834
Mookerjee RP (*see* Shawcross DL et al). 2004;39:471–475
Morabito A (*see* D'Amico G and Morabito A). 2004;39:30–34 (Editorial)
Moradpour D (*see* Jaeschke H et al). 2004; 39:248–249, 550–553, 835–840, 1141–1146
— (*see* Penin F et al). 2004;39:5–19 (Scientific Frontier)
Morelli A (*see* Fiorucci S et al). 2004;39: 365–375
Moreno-Otero R (*see* Medina J et al). 2004;39:1185–1195 (Concise Review in Mechanisms of Disease)
Morita Y (*see* Takeuchi D et al). 2004;39: 699–710
Morozova OV (*see* Lazarevich NL et al). 2004;39:1038–1047
Moshage H (*see* Schoemaker MH et al). 2004;39:1563–1573
Mostov K (*see* Matsumura S et al). 2004; 39:1422–1429
Muglia LJ (*see* Rudnick DA et al). 2004;39: 1048–1055
Mullen K (*see* Jaeschke H et al). 2004;39: 248–249, 550–553, 835–840, 1141–1146
Müller M (*see* Schulze-Bergkamen H et al). 2004;39:645–654
Müller T, Langner C, Fuchsbichler A, Heinz-Erian P, Ellemunter H, Schlenck B, Bavdekar AR, Pradhan AM, Pandit A, Müller-Höcker J, Melter M, Kobayashi K, Nagasaka H, Kikuta H, Müller W, Tanner MS, Sternlieb I, Zatloukal K, Denk H. Immunohistochemical analysis of Mallory bodies in Wilsonian and non-Wilsonian hepatic copper toxicosis. 2004;39:963–969
Müller W (*see* Müller T et al). 2004;39: 963–969
Müller-Höcker J (*see* Müller T et al). 2004; 39:963–969

Muñoz C (*see* Francés R et al). 2004;39:484–491, 1470 (Correction)
Munteanu M (*see* Le Calvez S et al). 2004;39:862–863 (Correspondence)
Murad SD, Valla DC, de Groen PC, Zeitoun G, Hopmans JAM, Haagsma EB, van Hoek B, Hansen BE, Rosendaal FR, Janssen HLA. Determinants of survival and the effect of portosystemic shunting in patients with Budd-Chiari syndrome. 2004;39:500–508
— (*see* van Zonneveld M et al). 2004;39:804–810
Murata T (*see* Katagiri H et al). 2004;39:139-150
Murillas J (*see* Walker UA et al). 2004;39:311–317
Murphy N, Auzinger G, Bernel W, Wendon J. The effect of hypertonic sodium chloride on intracranial pressure in patients with acute liver failure. 2004;39:464–470
Murphy TL (*see* Stuart KA et al). 2004;39:492–499
Muti P (*see* Stranges S et al). 2004;39:754–763

N

Nagahama T (*see* Nomura H et al). 2004;39:1214–1220
Nagano H (*see* Ogawa M et al). 2004;39:528–539
Nagano K (*see* Hisatomi Y et al). 2004;39:667–675
Nagaoka MR (*see* Huet PM et al). 2004;39:1110–1119
Nagasaka H (*see* Müller T et al). 2004;39:963–969
Nagy P (*see* Paku S et al). 2004;39:1358–1366
— (*see* Sánchez A et al). 2004;39:376–385
Naito M (*see* Hoppo T et al). 2004;39:1367–1375
Nakamori S (*see* Ogawa M et al). 2004;39:528–539
Nakamura K, Nonaka H, Saito H, Tanaka M, Miyajima A. Hepatocyte proliferation and tissue remodeling is impaired after liver injury in oncostatin M receptor knockout mice. 2004;39:635–644
— (*see* Hisatomi Y et al). 2004;39:667–675
— (*see* Yoneda M et al). 2004;39:568 (Correspondence)
Nakamura T (*see* Hisaeda K et al). 2004;39:1574–1582
Nakanuma Y (*see* Roskams TA et al). 2004;39:1739–1745 (Special Article)
Nalpas B (*see* Vona G et al). 2004;39:792–797
Namisaki T (*see* Yoshiji H et al). 2004;39:1517–1524
Narumiya S (*see* Katagiri H et al). 2004;39:139–150
Navarro JM (*see* Andrade RJ et al). 2004;39:1603–1612
Naveau S, Chollet-Martin S, Dharancy S, Mathurin P, Jouet P, Piquet MA, Davion T, Oberti F, Broët P, Emilie D, Foie-Alcool group of the Association Française pour l'Etude du Foie (AFEF). A double-blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis. 2004;39:1396–1403
Neo SN, Leow CK, Vega VB, Long PM, Islam AFM, Lai PBS, Liu ET, Ren EC. Identification of discriminators of hepatoma by gene expression profiling using a minimal dataset approach. 2004;39:944–953
Neuberger J (*see* Xu L et al). 2004;39:151–156
Neuhaus P (*see* Sauer IM et al). 2004;39:1415–1421
Neumann AU (*see* Major ME et al). 2004;39:1709–1720
Ng IOI (*see* Yuen MF et al). 2004;39:1694–1701
Ng PY (*see* Hentze H et al). 2004;39:1316–1325
Ngan CY (*see* Ogawa M et al). 2004;39:528–539
Ni YH (*see* Chen HL et al). 2004;39:58–63
Nicco C (*see* Laurent A et al). 2004;39:1282–1290
Niesters HGM (*see* van Zonneveld M et al). 2004;39:804–810
Nimura Y (*see* Taniai H et al). 2004;39:1544–1552
Nischalke HD (*see* Jüngst C et al). 2004;39:1663–1672
Nochajski TH (*see* Stranges S et al). 2004;39:754–763
Noguchi R (*see* Yoshiji H et al). 2004;39:1517–1524
Nogueras F (*see* Andrade RJ et al). 2004;39:1603–1612
Nomura H, Sou S, Tanimoto H, Nagahama T, Kimura Y, Hayashi J, Ishibashi H, Kashiwagi S. Short-term interferon-alfa therapy for acute hepatitis C: A randomized controlled trial. 2004;39:1214–1220
Nonaka H (*see* Nakamura K et al). 2004;39:635–644
Nosé V (*see* Alwayn IPJ et al). 2004;39:1176–1177 (Correspondence)

O

Oberti F (*see* Naveau S et al). 2004;39:1396–1403
— (*see* Roulot D et al). 2004;39:239–347
O'Brien PE (*see* Dixon JB et al). 2004;39:1647–1654
Ochi M, Ohdan H, Mitsuta H, Onoe T, Tokita D, Hara H, Ishiyama K, Zhou W, Tanaka Y, Asahara T. Liver NK cells expressing TRAIL are toxic against self hepatocytes in mice. 2004;39:1326–1336
O'Connell NC (*see* Smith JL et al). 2004;39:1673–1682
Oda K (*see* Shoda J et al). 2004;39:167–178
Odin JA (*see* Matsumura S et al). 2004;39:1422–1429
Oehler G (*see* Wein C et al). 2004;39:739–745
Ogawa M , Yamamoto H, Nagano H, Miyake Y, Sugita Y, Hata T, Kim B, Ngan CY, Damdinsuren B, Ikenaga M, Ikeda M, Ohue M, Nakamori S, Sekimoto M, Sakon M, Matsuura N, Monden M. Hepatic expression of *ANG2* RNA in metastatic colorectal cancer. 2004;39:528–539
Ohdan H (*see* Ochi M et al). 2004;39:1326–1336
Ohshima S (*see* Kim JS et al). 2004;39:1533–1543
Ohtsuka M (*see* Takeuchi D et al). 2004;39:699–710
Ohue M (*see* Ogawa M et al). 2004;39:528–539
Okumura K (*see* Hisatomi Y et al). 2004;39:667–675
Ollero M (*see* Alwayn IPJ et al). 2004;39:1176–1177 (Correspondence)
Olynyk JK (*see* Roskams TA et al). 2004;39:1739–1745 (Special Article)
Onoe T (*see* Ochi M et al). 2004;39:1326–1336
Orntoft T (*see* Lardon J et al). 2004;39:1499–1507
Ortega AL , (*see* Estrela JM et al). 2004;39:570–571 (Correspondence)
Ou CN (*see* Vogel A et al). 2004;39:433–443
Ou J (*see* Choi J et al). 2004;39:81–89
Ovchinnikov DA (*see* Lazarevich NL et al). 2004;39:1038–1047

P

Paigen B (*see* Lammert F et al). 2004;39:117–128
Paku S, Nagy P, Kopper L, Thorgeirsson SS. 2-Acetylaminofluorene dose-dependent differentiation of oval cells into hepatocytes: Confocal and electron microscopic studies. 2004;39:1358–1366
Palasciano G (*see* Grattagliano I et al). 2004;39:1251–1258
Palazón JM (*see* Francés R et al). 2004;39:484–491, 1470 (Correction)
Pallardó FV (*see* Serviddio G et al). 2004;39:711–720
Palmer JM, Robe AJ, Burt AD, Kirby JA, Jones DEJ. Covalent modification as a mechanism for the breakdown of immune tolerance to pyruvate dehydrogenase complex in the mouse. 2004;39:1583–1592

Palmieri VO (*see* Grattagliano I et al). 2004;39:1251–1258
Pan H (*see* Radaeva S et al). 2004;39:1337–1347
Panani A (*see* Avgerinos A et al). 2004;39: 1623–1630
Pandit A (*see* Müller T et al). 2004;39:963–969
Papaxoinis C (*see* Avgerinos A et al). 2004; 39:1623–1630
Park BK (*see* Goldring CEP et al). 2004;39: 1271–1281
Park Y (*see* Promrat K et al). 2004;39:188–196
Park YM (*see* Cha MY et al). 2004;39:1683–1693
Park YN (*see* Roskams TA et al). 2004;39: 1739–1745 (Special Article)
Pascher A (*see* Sauer IM et al). 2004;39: 1415–1421
Pascual S (*see* Francés R et al). 2004;39: 484–491, 1470 (Correction)
Pastore M (*see* Iorio R et al). 2004;39:1173–1174 (Correspondence)
Patch D (*see* Burroughs AK et al). 2004;39: 1747 (Reply)
— (*see* Thalheimer U et al). 2004;39:286–290 (Perspectives in Clinical Hepatology)
Patel K (*see* Monto A et al). 2004;39:826–834
Paterlini-Bréchot P (*see* Vona G et al). 2004;39:792–797
Pauli-Magnus C, Kerb R, Fattinger K, Lang T, Anwald B, Kullak-Ublick GA, Beuers U, Meier PJ. *BSEP* and *MDR3* haplotype structure in healthy Caucasians, primary biliary cirrhosis and primary sclerosing cholangitis. 2004;39:779–791
Pawlotsky JM and McHutchison JG. Hepatitis C. Development of new drugs and clinical trials. Promises and pitfalls. 2004;39:554–567 (Special Article)
— (*see* Penin F et al). 2004;39:5–19 (Scientific Frontier)
Pediaditakis P (*see* Kim JS et al). 2004;39: 1533–1543
Pei Z, Chu L, Zou W, Zhang Z, Qiu S, Qi R, Gu J, Qian C, Liu X. An oncolytic adenoviral vector of Smac increases antitumor activity of TRAIL against HCC in human cells and in mice. 2004;39:1376–1387
Pelaez G (*see* Andrade RJ et al). 2004;39: 1603–1612
Penin F, Dubuisson J, Rey FA, Moradpour D, Pawlotsky JM. Structural biology of hepatitis C virus. 2004;39:5–19 (Scientific Frontier)
— (*see* Ducoulombier D et al). 2004;39: 817–825
Peralta C (*see* Serafin A et al). 2004;39: 688–698
Pereda J (*see* Serviddio G et al). 2004;39: 711–720
Pereira TN (*see* Smith JL et al). 2004;39: 1673–1682
Pérez-Mateo M (*see* Francés R et al). 2004; 39:484–491, 1470 (Correction)
Perlmutter DH (*see* Rudnick DA et al). 2004;39:1048–1055
Perpetua MD (*see* Zhang B et al). 2004;39: 1348–1357
Perrin M (*see* Lainé F et al). 2004;39:1639–1646
Pessayre D (*see* Tinel M et al). 2004;39: 655–666
Peters T (*see* Kamal SM et al). 2004;39: 1721–1731
Petersen J (*see* Zöllner B et al). 2004;39: 42–50
Peterson TC (*see* Le TH et al). 2004;39: 1430–1436
Petkov PM, Zavadil J, Goetz D, Chu T, Carver R, Rogler CE, Bottinger EP, Shafritz DA, Dabeva MD. Gene expression pattern in hepatic stem/progenitor cells during rat fetal development using complementary DNA microarrays. 2004;39:617–627
Petrowsky H (*see* Delman KA et al). 2004; 39:1525–1532
Phillips MJ (*see* Humar A et al). 2004;39: 291–294 (Editorial)
Piacentini M (*see* Bordoni V et al). 2004; 39:1508–1516
Pianko S (*see* Monto A et al). 2004;39: 826–834
Pierri P (*see* Amoroso P et al). 2004;39:572 (Correspondence)
Pietrangelo A. Non-*HFE* hemochromatosis. 2004;39:21–29 (Perspectives in Clinical Hepatology)
Piga A (*see* Bugianesi E et al). 2004;39: 179–187
Piquet MA (*see* Naveau S et al). 2004;39: 1396–1403
Poccia F (*see* Bordoni V et al). 2004;39: 1508–1516
Pockros P (*see* Monto A et al). 2004;39: 826–834
Pockros PJ (*see* Cammà C et al). 2004;39: 333–342
Podda M (*see* Invernizzi P et al). 2004;39: 1175–1176 (Correspondence)
Poelstra K (*see* Schoemaker MH et al). 2004;39:1563–1573
Pol S (*see* Vona G et al). 2004;39:792–797
Poli G (*see* Serviddio G et al). 2004;39: 711–720
Pomier-Layrargues G (*see* Huet PM and Pomier-Layrargues G). 2004;39:295–298 (Editorial)
Popp B (*see* Wein C et al). 2004;39:739–745
Porter AG (*see* Hentze H et al). 2004;39: 1316–1325
Portincasa P (*see* Grattagliano I et al). 2004;39:1251–1258
Portmann B (*see* Roskams TA et al). 2004; 39:1739–1745 (Special Article)
Poujol-Robert A, Boëlle PY, Poupon R, Robert A. Factor V Leiden as a risk factor for cirrhosis in chronic hepatitis C. 2004;39:1174–1175 (Correspondence)
Poupon R. Trials in primary biliary cirrhosis: Need for the right drugs at the right time. 2004;39:900–902 (Editorial)
— (*see* Poujol-Robert A et al). 2004;39: 1174–1175 (Correspondence)
Powell EE (*see* Walsh MJ et al). 2004;39: 1232–1241
Powell LW (*see* Crawford DHG et al). 2004;39:1655–1662
— (*see* Stuart KA et al). 2004;39:492–499
Poynard T (*see* Le Calvez S et al). 2004;39: 862–863 (Correspondence)
— (*see* Ratziu V et al). 2004;39:1172 (Correspondence)
Pradhan AM (*see* Müller T et al). 2004;39: 963–969
Prats N (*see* Serafin A et al). 2004;39:688–698
Premkumar A (*see* Promrat K et al). 2004; 39:188–196
Price LL (*see* Kaplan MM et al). 2004;39: 915–923
Prokupek D (*see* Bräu N et al). 2004;39: 989–998
Promrat K, Lutchman G, Uwaifo GI, Freedman RJ, Soza A, Heller T, Doo E, Ghany M, Premkumar A, Park Y, Liang TJ, Yanovski JA, Kleiner DE, Hoofnagle JH. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. 2004;39: 188–196
Provenzale D (*see* Adams PC et al). 2004; 39:1205–1213 (Special Article)
Puchhammer-Stöckl E (*see* Zöllner B et al). 2004;39:42–50
Puder M (*see* Alwayn IPJ et al). 2004;39: 1176–1177 (Correspondence)
Puig M (*see* Major ME et al). 2004;39: 1709–1720
Purdie DM (*see* Walsh MJ et al). 2004;39: 1232–1241

Q

Qi R (*see* Pei Z et al). 2004;39:1376–1387
Qian C (*see* Pei Z et al). 2004;39:1376–1387
Qiao L (*see* Han SI et al). 2004;39:456–463
Qiu S (*see* Pei Z et al). 2004;39:1376–1387
Qu W (*see* Zeng S et al). 2004;39:422–432
Quartier E (*see* Hellemans K et al). 2004; 39:97–108

R

Rabes HM (*see* Zeindl-Eberhart E et al). 2004;39:540–549

Radaeva S, Sun R, Pan H, Hong F, Gao B. Interleukin 22 (IL-22) plays a protective role in T cell-mediated hepatitis: IL-22 is a survival factor for hepatocytes via STAT3 activation. 2004;39:1337–1347
— (*see* Gao B et al). 2004;39:880–890 (Concise Review in Mechanisms of Disease)
Ramakers J (*see* Jüngst C et al). 2004;39: 1663–1672
Rami L (*see* Restuccia T et al). 2004;39: 1613–1622
Ramm GA (*see* Smith JL et al). 2004;39: 1673–1682
Ramsay L (*see* Aithal GP et al). 2004;39: 1437–1447
Randle LE (*see* Goldring CEP et al). 2004; 39:1271–1281
Raptis SA (*see* Avgerinos A et al). 2004;39: 1623–1630
Rasenack JW (*see* Kamal SM et al). 2004; 39:1721–1731
Ratziu V, Imbert-Bismut F, Messous D, Poynard T. The elusiveness of "normal" ALT in fatty liver. 2004;39: 1172 (Correspondence)
— (*see* Le Calvez S et al). 2004;39:862–863 (Correspondence)
Ray FA (*see* Penin F et al). 2004;39:5–19 (Scientific Frontier)
Reddy KR (*see* Jeffers LJ et al). 2004;39: 1702–1708
Redick JA (*see* Le TH et al). 2004;39:1430–1436
Reiman R (*see* Wynn TA et al). 2004;39: 676–687
Reimann J (*see* Dikopoulos N et al). 2004; 39:1259–1270
Ren EC (*see* Neo SN et al). 2004;39:944–953
Renault A (*see* Lainé F et al). 2004;39:1639–1646
Reske SN (*see* Reuter S et al). 2004;39: 509–517
Resti M (*see* Iorio R et al). 2004;39:1173–1174 (Correspondence)
Restuccia T, Gómez-Ansón B, Guevara M, Alessandria C, Torre A, Alayrach ME, Terra C, Martín M, Castellví M, Rami L, Sainz A, Ginès P, Arroyo V. Effects of dilutional hyponatremia on brain organic osmolytes and water content in patients with cirrhosis. 2004;39:1613–1622
Reuben A. The body has a liver. 2004;39: 1179–1181 (Landmarks in Hepatology)
— Hy's Law. 2004;39:574–578 (Landmarks in Hepatology)
— Never say dye. 2004;39:259–264 (Landmarks in Hepatology), 875 (Correction)
— Old scratch. 2004;39:870–874 (Landmarks in Hepatology)
— Prometheus and Pandora—Together again. 2004;39:1466–1469 (Landmarks in Hepatology)
— Try, try, try again . . . and again. 2004; 39:1750–1753 (Landmarks in Hepatology)
Reuter S, Buck A, Manfras B, Kratzer W, Seitz HM, Darge K, Reske SN, Kern P. Structured treatment interruption in patients with alveolar echinococcosis. 2004;39:509–517
Rice CM (*see* Major ME et al). 2004;39: 1709–1720
Richard Y (*see* Ducoulombier D et al). 2004;39:817–825
Richardson MM (*see* Walsh MJ et al). 2004;39:1232–1241
Rieux-Laucat F (*see* André N et al). 2004; 39:864–865 (Correspondence)
Rigoli RM (*see* Schattenberg JM et al). 2004;39:444–455
Riordan SM (*see* Liu Q et al). 2004;39: 1448–1456
Rizzetto M (*see* Bugianesi E et al). 2004;39: 179–187
— (*see* Cianco A et al). 2004;39:64–73
Robe AJ (*see* Palmer JM et al). 2004;39: 1583–1592
Robert A (*see* Poujol-Robert A et al). 2004; 39:1174–1175 (Correspondence)
Roberts GD (*see* Delman KA et al). 2004; 39:1525–1532
Roberts JP (*see* Yao FY et al). 2004;39:230–238
Robertson G (*see* Ip E et al). 2004;39:1291–1301
Rockey DC and Shah V. Nitric oxide biology and the liver: Report of an AASLD research workshop. 2004;39: 250–257 (Special Article)
Rodés J. News from Spain. 2004;39:591
— (*see* Serafin A et al). 2004;39:688–698
Rodrigo L (*see* Andrade RJ et al). 2004;39: 1603–1612
Rodriguez-Torres M (*see* Bräu N et al). 2004;39:989–998
Rogler CE (*see* Petkov PM et al). 2004;39: 617–627
Romanò L (*see* Casiraghi MA). 2004;39: 90–96
Rombouts K (*see* Hellemans K et al). 2004; 39:97–108
Romero M (*see* Andrade RJ et al). 2004;39: 1603–1612
Romero-Gómez M, Grande L, Camacho I. Prognostic value of altered oral glutamine challenge in patients with minimal hepatic encephalopathy. 2004;39:939–943
Rooman I (*see* Lardon J et al). 2004;39: 1499–1507
Roque-Afonso AM (*see* Ducoulombier D et al). 2004;39:817–825
Roquelaure B (*see* André N et al). 2004;39: 864–865 (Correspondence)
Roselló-Catafau J (*see* Serafin A et al). 2004;39:688–698
Rosendaal FR (*see* Murad SD et al). 2004; 39:500–508
Roskams T (*see* Yang S et al). 2004;39: 403–411
Roskams TA, Theise ND, Balabaud C, Bhagat G, Bhathal PS, Bioulac-Sage P, Brunt EM, Crawford JM, Crosby HA, Desmet V, Finegold MJ, Geller SA, Gouw ASH, Hytiroglou P, Knisely AS, Kojiro M, Lefkowitch JH, Nakanuma Y, Olynyk JK, Park YN, Portmann B, Saxena R, Scheuer PJ, Strain AJ, Thung SN, Wanless IR, West AB. Nomenclature of the finer branches of the biliary tree: Canals, ductules, and ductular reactions in human livers. 2004;39:1739–1745 (Special Article)
Roulot D, Degott C, Chazouillères O, Oberti F, Calès P, Carbonell N, Benferhat S, Bresson-Hadni S, Valla D. Vascular involvement of the liver in Turner's syndrome. 2004;39:239–347
Rudnick DA, Liao Y, An JK, Muglia LJ, Perlmutter DH, Teckman JH. Analyses of hepatocellular proliferation in a mouse model of α-1-antitrypsin deficiency. 2004;39: 1048–1055
Ruijter JM, Gieling RG, Markman MM, Hagoort J, Lamers WH. Stereological measurement of porto-central gradients in gene expression in mouse liver. 2004;39:343–352
Runyon BA. Management of adult patients with ascites due to cirrhosis. 2004;39: 841–856 (AASLD Practice Guideline)
Russell M (*see* Stranges S et al). 2004;39: 754–763
Russell NS (*see* Chen YC et al). 2004;39: 1075–1087
Russmann S (*see* Grattagliano I et al). 2004;39:1251–1258
Ruszkiewicz A (*see* Helbig KJ et al). 2004; 39:1221–1231
Ryabinina O (*see* Vogel A et al). 2004;39: 433–443
Ryu WS (*see* Cha MY et al). 2004;39:1683–1693

S

Saab S (*see* Yao FY et al). 2004;39:230–238
Sabla G (*see* Zhang DY et al). 2004;39: 954–962
Sablon E (*see* Yuen MF et al). 2004;39: 1694–1701
Sainz A (*see* Restuccia T et al). 2004;39: 1613–1622
Saito H (*see* Nakamura K et al). 2004;39: 635–644
Sakalian M (*see* Xu L et al). 2004;39:151–156

Sakon M (*see* Ogawa M et al). 2004;39: 528–539
Salier JP (*see* Coulouarn C et al). 2004;39: 353–364
Salmerón J (*see* Andrade RJ et al). 2004;39: 1603–1612
Sam O (*see* Kirk GD et al). 2004;39:211–219
Samarasinghe D (*see* Sud A et al). 2004;39: 1242–1250
Sánchez A, Factor VM, Schroeder IS, Nagy P, Thorgeirsson SS. Activation of NF-κB and STAT3 in rat oval cells during 2-acetylaminofluorene/partial hepatectomy-induced liver regeneration. 2004;39:376–385
Sánchez de la Cuesta F (*see* Andrade RJ et al). 2004;39:1603–1612
Sánchez-Madrid F (*see* Medina J et al). 2004;39:1185–1195 (Concise Review in Mechanisms of Disease)
Sander TJ (*see* Yuen MF et al). 2004;39: 1694–1701
Sandler NG (*see* Wynn TA et al). 2004;39: 676–687
Sangiovanni A (*see* Colombo M and Sangiovanni A). 2004;39:552–553 (Hepatology *Elsewhere*)
Santagada V (*see* Fiorucci S et al). 2004;39: 365–375
Sanyal AJ. The elusiveness of "normal" ALT in fatty liver. 2004;39:1173 (Reply)
Sarrazin C (*see* Berg T et al). 2004;39:1462–1464 (Correspondence)
Sastre J (*see* Serviddio G et al). 2004;39: 711–720
Satoh A (*see* Hisatomi Y et al). 2004;39: 667–675
Sauer IM, Goetz M, Steffen I, Walter G, Kehr DC, Schwartlander R, Hwang YJ, Pascher A, Gerlach JC, Neuhaus P. *In vitro* comparison of the molecular adsorbent recirculation system (MARS) and single-pass albumin dialysis (SPAD). 2004;39: 1415–1421
Sauerbruch T (*see* Jüngst C et al). 2004;39: 1663–1672
Saxena R (*see* Roskams TA et al). 2004;39: 1739–1745 (Special Article)
Schalm SW (*see* van Zonneveld M et al). 2004;39:804–810
Schattenberg JM, Wang Y, Rigoli RM, Koop DR, Czaja MJ. CYP2E1 overexpression alters hepatocyte death from menadione and fatty acids by activation of ERK1/2 signaling. 2004; 39:444–455
Schauder P (*see* Wein C et al). 2004;39: 739–745
Schepis F (*see* Cammà C et al). 2004;39: 333–342
Scheuer C (*see* El-Gibaly AM et al). 2004; 39:1553–1562
Scheuer PJ (*see* Roskams TA et al). 2004; 39:1739–1745 (Special Article)
Schirmacher P (*see* Jüngst C et al). 2004; 39:1663–1672
Schirmbeck R (*see* Dikopoulos N et al). 2004;39:1259–1270
Schlenck B (*see* Müller T et al). 2004;39: 963–969
Schmidt AM (*see* Zeng S et al). 2004;39: 422–432
Schmitz V (*see* Jüngst C et al). 2004;39: 1663–1672
Schmutz G (*see* Walker UA et al). 2004;39: 311–317
Schoemaker MH, Conde de la Rosa L, Buist-Homan M, Vrenken TE, Havinga R, Poelstra K, Haisma HJ, Jansen PLM, Moshage H. Tauroursodeoxycholic acid protects rat hepatocytes from bile acid-induced apoptosis via activation of survival pathways. 2004;39:1563–1573
Schramel P (*see* Jüngst C et al). 2004;39: 1663–1672
Schreiter T (*see* Hilgard P et al). 2004;39: 1404–1414
Schrier RW (*see* Chen YC et al). 2004;39: 1075–1087
Schroeder IS (*see* Sánchez A et al). 2004;39: 376–385
Schröter M (*see* Zöllner B et al). 2004;39: 42–50
Schuit F (*see* Hellemans K et al). 2004;39: 97–108
— (*see* Lardon J et al). 2004;39:1499–1507
Schulte-Hermann R (*see* Mikula M et al). 2004;39:628–634
Schulze-Bergkamen H, Brenner D, Krueger A, Suess D, Fas SC, Frey CR, Dax A, Zink D, Büchler P, Müller M, Krammer PH. Hepatocyte growth factor induces Mcl-1 in primary human hepatocytes and inhibits CD95-mediated apoptosis via Akt. 2004;39:645–654
Schuppan D (*see* Hellemans K et al). 2004; 39:97–108
Schütte JK (*see* Ehmer U et al). 2004;39: 970–977
Schwartlander R (*see* Sauer IM et al). 2004; 39:1415–1421
Scotte M (*see* Coulouarn C et al). 2004;39: 353–364
Seeff L (*see* Adams PC et al). 2004;39:1205–1213 (Special Article)
Seeff LB (*see* Strader DB et al). 2004;39: 1147–1171 (AASLD Practice Guideline)
Seitz HM (*see* Reuter S et al). 2004;39: 509–517
Sekimoto M (*see* Ogawa M et al). 2004;39: 528–539
Sekiya M (*see* Yahagi N et al). 2004;39: 1177–1178 (Reply)
Sell S (*see* Leffert HL and Sell S). 2004;39: 258 (Correspondence)
Semendric L (*see* Helbig KJ et al). 2004;39: 1221–1231
Serafín A, Roselló-Catafau J, Prats N, Gelpí E, Rodés J, Peralta C. Ischemic preconditioning affects interleukin release in fatty livers of rats undergoing ischemia/reperfusion. 2004;39:688–698
Serviddio G, Pereda J, Pallardó FV, Carretero J, Borras C, Cutrin J, Vendemiale G, Poli G, Viña J, Sastre J. Ursodeoxycholic acid protects against secondary biliary cirrhosis in rats by preventing mitochondrial oxidative stress. 2004;39:711–720
Setchell KDR (*see* Smith JL et al). 2004;39: 1673–1682
Setzer B (*see* Walker UA et al). 2004;39: 311–317
Severino B (*see* Fiorucci S et al). 2004;39: 365–375
Shafritz DA (*see* Petkov PM et al). 2004; 39:617–627
Shah V (*see* Rockey DC and Shah V). 2004;39:250–257 (Special Article)
Shawcross DL, Davies NA, Mookerjee RP, Hayes PC, Williams R, Lee A, Jalan R. Worsening of cerebral hyperemia by the administration of terlipressin in acute liver failure with severe encephalopathy. 2004;39:471–475
Sheikh SZ (*see* Kuniyasu Y et al). 2004;39: 1017–1027
Shen Z (*see* Xu L et al). 2004;39:151–156
Shepherd RW (*see* Smith JL et al). 2004; 39:1673–1682
Sheppard BL (*see* Le TH et al). 2004;39: 1430–1436
Shibahara H, Tamada S, Higashi M, Goto M, Batra SK, Hollingsworth MA, Imai K, Yonezawa S. MUC4 is a novel prognostic factor of intrahepatic cholangiocarcinoma-mass forming type. 2004;39:220–229
Shimano H (*see* Yahagi N et al). 2004;39: 1177–1178 (Reply)
Shimizu H (*see* Takeuchi D et al). 2004;39: 699–710
Shiratori Y (*see* Matsumura S et al). 2004; 39:1422–1429
Shivakumar P (*see* Zhang DY et al). 2004; 39:954–962
Shneider BL (*see* Zhang DY et al). 2004; 39:954–962
Shoda J, Miura T, Utsunomiya H, Oda K, Yamamoto M, Kano M, Ikegami T, Tanaka N, Akita H, Ito K, Suzuki H, Sugiyama Y. Genipin enhances Mrp2 (Abcc2)-mediated bile formation and organic anion transport in rat liver. 2004;39:167–178
Shuldiner AR (*see* Jadaho SB et al). 2004; 39:1302–1307
Sime J (*see* Kim JW et al). 2004;39:518–527
Simões M (*see* França A et al). 2004;39: 1461 (Correspondence)

Singh R (*see* Upadhyay G et al). 2004;39:1120–1130
Sirica AE (*see* Zhang Z et al). 2004;39:1028–1037
Siu CW (*see* Yuen MF et al). 2004;39:1694–1701
Sjogren MH. The clinical profile of acute hepatitis A infection: Is it really so severe? 2004;39:572–573 (Reply)
Skaug K (*see* Dalgard et al). 2004;39:74–80
Smedile A (*see* Cianco A et al). 2004;39:64–73
Smith JJ (*see* Bräu N et al). 2004;39:989–998
Smith JL, Lewindon PJ, Hoskins AC, Pereira TN, Setchell KDR, O'Connell NC, Shepherd RW, Ramm GA. Endogenous ursodeoxycholic acid and cholic acid in liver disease due to cystic fibrosis. 2004;39:1673–1682
Sogawa H (*see* Chida Y et al). 2004;39:1131–1140
Sokol RJ (*see* Zhang DY et al). 2004;39:954–962
Solga SF and Diehl AM. Gut flora-based therapy in liver disease? The liver cares about the gut. 2004;39:1198–1201 (Editorial)
Sonchit N (*see* Aithal GP et al). 2004;39:1437–1447
Song D (*see* Ling Y et al). 2004;39:1593–1602
Song W (*see* Wang C et al). 2004;39:978–988
Sonoda J (*see* Chida Y et al). 2004;39:1131–1140
Soroka CJ (*see* Denk GU et al). 2004;39:1388–1395
Sou S (*see* Nomura H et al). 2004;39:1214–1220
Soubrane O (*see* Laurent A et al). 2004;39:1282–1290
Soza A (*see* Promrat K et al). 2004;39:188–196
Spangenberg HC, Thimme R, Blum HE. Hepatology *Elsewhere*. 2004;39:1736–1738
Splinter PL, Masyuk AI, Marinelli RA, LaRusso NF. AQP4 transfected into mouse cholangiocytes promotes water transport in biliary epithelia. 2004;39:109–116
Steen T (*see* Dalgard et al). 2004;39:74–80
Stefanidis G (*see* Avgerinos A et al). 2004;39:1623–1630
Steffen I (*see* Sauer IM et al). 2004;39:1415–1421
Sterczer A (*see* Jacob JR et al). 2004;39:1008–1016
Sterneck M (*see* Zöllner B et al). 2004;39:42–50
Sternlieb I (*see* Müller T et al). 2004;39:963–969
Stevens W (*see* Levy JR et al). 2004;39:608–616
Stewart SF, Vidali M, Day CP, Albano E, Jones DEJ. Oxidative stress as a trigger for cellular immune responses in patients with alcoholic liver disease. 2004;39:197–203
Stockard CR (*see* Ling Y et al). 2004;39:1593–1602
Stockert RJ (*see* Hilgard P et al). 2004;39:1404–1414
Strader DB, Wright T, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C. 2004;39:1147–1171 (AASLD Practice Guideline)
Strain AJ (*see* Roskams TA et al). 2004;39:1739–1745 (Special Article)
Stranges S, Dorn JM, Muti P, Freudenheim JL, Farinaro E, Russell M, Nochajski TH, Trevisan M. Body fat distribution, relative weight, and liver enzyme levels: A population-based study. 2004;39:754–763
Strasberg S (*see* Di Bisceglie AM and Strasberg S). 2004;39:550–551
Strassburg CP (*see* Ehmer U et al). 2004;39:970–977
Strathdee SA (*see* Torbenson M et al). 2004;39:51–57
Stuart KA, Anderson GJ, Frazer DM, Murphy TL, Powell LW, Fletcher LM, Crawford DH. Increased duodenal expression of divalent metal transporter 1 and iron-regulated gene 1 in cirrhosis. 2004;39:492–499
— (*see* Crawford DHG et al). 2004;39:1655–1662
Studer E (*see* Han SI et al). 2004;39:456–463
Such J (*see* Francés R et al). 2004;39:484–491, 1470 (Correction)
Sud A, Hui JM, Farrell GC, Bandara P, Kench JG, Fung C, Lin R, Samarasinghe D, Liddle C, McCaughan GW, George J. Improved prediction of fibrosis in chronic hepatitis C using measures of insulin resistance in a probability index. 2004;39:1242–1250
Sudo N (*see* Chida Y et al). 2004;39:1131–1140
Suematsu M (*see* Katagiri H et al). 2004;39:139–150
— (*see* Kudo A et al). 2004;39:1099–1109
Suess D, Fas SC, Frey CR, Dax A, Zink D, Büchler P, Müller M, Krammer PH (*see* Schulze-Bergkamen H et al). 2004;39:645–654
Sugita Y (*see* Ogawa M et al). 2004;39:528–539
Sugiyama Y (*see* Shoda J et al). 2004;39:167–178
Sulkowski MS. Defining the standard of care: Randomized controlled trials for the treatment of hepatitis C in the HIV-infected person. 2004;39:906–908 (Editorial)
Sullivan DG (*see* McMahon BJ et al). 2004;39:325–332
Summer SN (*see* Chen YC et al). 2004;39:1075–1087
Sun H (*see* Thevananther S et al). 2004;39:393–402
Sun R (*see* Radaeva S et al). 2004;39:1337–1347
Sun Y (*see* Wang Y et al). 2004;39:318–324
Sutton J (*see* Teoh N et al). 2004;39:412–421
Suzuki H (*see* Shoda J et al). 2004;39:167–178
Sypek JP (*see* Wynn TA et al). 2004;39:676–687

T

Tahvanainen E (*see* Drenth JPH et al). 2004;39:924–931
Tahvanainen P (*see* Drenth JPH et al). 2004;39:924–931
Takeuchi D, Yoshidome H, Kato A, Ito H, Kimura F, Shimizu H, Ohtsuka M, Morita Y, Miyazaki M. Interleukin 18 causes hepatic ischemia/reperfusion injury by suppressing anti-inflammatory cytokine expression in mice. 2004;39:699–710
Tamada S (*see* Shibahara H et al). 2004;39:220–229
Tamano M (*see* Yoneda M et al). 2004;39:568 (Correspondence)
Tanaka M (*see* Nakamura K et al). 2004;39:635–644
Tanaka N (*see* Shoda J et al). 2004;39:167–178
Tanaka Y (*see* Ochi M et al). 2004;39:1326–1336
Tang J (*see* Wang C et al). 2004;39:978–988
Tang L (*see* Ling Y et al). 2004;39:1593–1602
Taniai H, Hines IN, Bharwani S, Maloney RE, Nimura Y, Gao B, Flores SC, McCord JM, Grisham MB, Aw TY. Susceptibility of murine periportal hepatocytes to hypoxia-reoxygenation: Role for NO and Kupffer cell-derived oxidants. 2004;39:1544–1552
Tanimoto H (*see* Nomura H et al). 2004;39:1214–1220
Tanner MS (*see* Müller T et al). 2004;39:963–969
Tarrab E (*see* Huet PM et al). 2004;39:1110–1119
Tawil AA (*see* Kamal SM et al). 2004;39:1721–1731
te Morsche RHM (*see* Drenth JPH et al). 2004;39:924–931
Teckman JH (*see* Rudnick DA et al). 2004;39:1048–1055
Tennant BC (*see* Jacob JR et al). 2004;39:1008–1016
Teoh N, Field J, Sutton J, Farrell G. Dual role of tumor necrosis factor-α in hepatic ischemia-reperfusion injury: Studies in tumor necrosis factor-α

gene knockout mice. 2004;39:412–421
Terano A (*see* Yoneda M et al). 2004;39:568 (Correspondence)
Terra C (*see* Restuccia T et al). 2004;39:1613–1622
Terrault N (*see* Yao FY et al). 2004;39:230–238
Tessier S (*see* Lainé F et al). 2004;39:1639–1646
Thabut D (*see* Le Calvez S et al). 2004;39:862–863 (Correspondence)
Thalheimer U, Mela M, Patch D, Burroughs AK. Targeting portal pressure measurements: A critical reappraisal. 2004;39:286–290 (Perspectives in Clinical Hepatology)
— (*see* Burroughs AK et al). 2004;39:1747 (Reply)
Theise ND (*see* Roskams TA et al). 2004;39:1739–1745 (Special Article)
Thénot JP (*see* Tinel M et al). 2004;39:655–666
Therneau TM (*see* Kim WR et al). 2004;39:811–816
Thevananther S, Sun H, Li D, Arjunan V, Awad SS, Wyllie S, Zimmerman TL, Goss JA, Karpen SJ. Extracellular ATP activates c-jun N-terminal kinase signaling and cell cycle progression in hepatocytes. 2004;39:393–402
Thimme R (*see* Spangenberg HC et al). 2004;39:1736–1738
Thomas DL (*see* Strader DB et al). 2004;39:1147–1171 (AASLD Practice Guideline)
— (*see* Torbenson M et al). 2004;39:51–57
Thorgeirsson SS (*see* Paku S et al). 2004;39:1358–1366
— (*see* Sánchez A et al). 2004;39:376–385
Thung SN (*see* Roskams TA et al). 2004;39:1739–1745 (Special Article)
Thuret I (*see* André N et al). 2004;39:864–865 (Correspondence)
Tiao G (*see* Zhang DY et al). 2004;39:954–962
Tinel M, Berson A, Vadrot N, Descatoire V, Grodet A, Feldmann G, Thénot JP, Pessayre D. Subliminal Fas stimulation increases the hepatotoxicity of acetaminophen and bromobenzene in mice. 2004;39:655–666
Tokita D (*see* Ochi M et al). 2004;39:1326–1336
Torbenson M, Kannangai R, Astemborski J, Strathdee SA, Vlahov D, Thomas DL. High prevalence of occult hepatitis B in Baltimore injection drug users. 2004;39:51–57
Torgerson HA (*see* Kim WR et al). 2004;39:811–816
Torre A (*see* Restuccia T et al). 2004;39:1613–1622
Toshkov IA (*see* Jacob JR et al). 2004;39:1008–1016
Trauner M (*see* Lammert F et al). 2004;39:117–128
Treichel U (*see* Hilgard P et al). 2004;39:1404–1414
Trevisan M (*see* Stranges S et al). 2004;39:754–763
Triantos C (*see* Avgerinos A et al). 2004;39:1623–1630
Tripodi M (*see* Bordoni V et al). 2004;39:1508–1516
Tsang TY (*see* Chau TN et al). 2004;39:302–310
Tse E (*see* Yuen MF et al). 2004;39:1694–1701
Tso YK (*see* Chau TN et al). 2004;39:302–310
Tsujinoue H (*see* Yoshiji H et al). 2004;39:1517–1524
Turlin B (*see* Lainé F et al). 2004;39:1639–1646

U

Uceda F (*see* Francés R et al). 2004;39:484–491, 1470 (Correction)
Uchida K (*see* Kudo A et al). 2004;39:1099–1109
Uchiumi T (*see* Hisaeda K et al). 2004;39:1574–1582
Upadhyay G, Singh R, Kumar A, Kumar S, Kapoor A, Godbole MM. Severe hyperthyroidism induces mitochondria-mediated apoptosis in rat liver. 2004;39:1120–1130
Utsunomiya H (*see* Shoda J et al). 2004;39:167–178
Uwaifo GI (*see* Promrat K et al). 2004;39:188–196

V

Vadrot N (*see* Tinel M et al). 2004;39:655–666
Vajro P, Mandato C, Franzese A, Lucariello S. More on vitamin E therapy. 2004;39:569 (Correspondence)
— (*see* Iorio R et al). 2004;39:1173–1174 (Correspondence)
Valla D (*see* Roulot D et al). 2004;39:239–347
Valla DC (*see* Murad SD et al). 2004;39:500–508
van de Kamp JM (*see* Drenth JPH et al). 2004;39:924–931
Van de Water J (*see* Matsumura S et al). 2004;39:1422–1429
van den Berg IET (*see* Vogel A et al). 2004;39:433–443
van Hoek B (*see* Murad SD et al). 2004;39:500–508
van IJperen M (*see* Kremers WK et al). 2004;39:764–769
Van Lommel L (*see* Lardon J et al). 2004;39:1499–1507
Van Nhieu JT (*see* Laurent A et al). 2004;39:1282–1290
van Zonneveld M, Honkoop P, Hansen BE, Niesters HGM, Murad SD, de Man RA, Schalm SW, Janssen HLA. Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B. 2004;39:804–810
Vanags DM (*see* Walsh MJ et al). 2004;39:1232–1241
Vanni E (*see* Bugianesi E et al). 2004;39:179–187
Varela-Rey M (*see* Hevia H et al). 2004;39:1088–1098
Varga EV (*see* Lazarevich NL et al). 2004;39:1038–1047
Vega VB (*see* Neo SN et al). 2004;39:944–953
Vegnente A (*see* Iorio R et al). 2004;39:1173–1174 (Correspondence)
Vendemiale G (*see* Serviddio G et al). 2004;39:711–720
Verbuyst P (*see* Hellemans K et al). 2004;39:97–108
Vergani D, Bogdanos DP, Baum H. Unusual suspects in primary biliary cirrhosis. 2004;39:38–41 (Editorial)
Vidali M (*see* Stewart SF et al). 2004;39:197–203
Vilimas K (*see* Dalgard et al). 2004;39:74–80
Villanueva JA and Halsted CH. Hepatic transmethylation reactions in micropigs with alcoholic liver disease. 2004;39:1308–1315
Viña J (*see* Serviddio G et al). 2004;39:711–720
Vitozzi S (*see* Lapierre P et al). 2004;39:1066–1074
Vlachogiannakos J (*see* Avgerinos A et al). 2004;39:1623–1630
Vlahov D (*see* Torbenson M et al). 2004;39:51–57
Vogel A, van den Berg IET, Al-Dhalimy M, Groopman J, Ou CN, Ryabinina O, Iordanov MS, Finegold M, Grompe M. Chronic liver disease in murine hereditary tyrosinemia type 1 induces resistance to cell death. 2004;39:433–443
— (*see* Ehmer U et al). 2004;39:970–977
Vollmar B (*see* El-Gibaly AM et al). 2004;39:1553–1562
Vona G, Estepa L, Béroud C, Damotte D, Capron F, Nalpas B, Mineur A, Franco D, Lacour B, Pol S, Bréchot C, Paterlini-Bréchot P. Impact of cytomorphological detection of circulating tumor cells in patients with liver cancer. 2004;39:792–797
Vong S and Bell BP. Chronic liver disease mortality in the United States, 1990–1998. 2004;39:476–483
Vrenken TE (*see* Schoemaker MH et al). 2004;39:1563–1573

W

Wai CT and Lok ASF. High sensitivity C-reactive protein values do not reliably predict the severity of histological change in NAFLD. 2004; 39:1464–1465 (Reply)

— (*see* Lok AS and Wai CT). 2004;39:863 (Reply)

Walker UA, Bäuerle J, Laguno M, Murillas J, Mauss S, Schmutz G, Setzer B, Miquel R, Gatell JM, Mallolas J. Depletion of mitochondrial DNA in liver under antiretroviral therapy with didanosine, stavudine, or zalcitabine. 2004;39:311–317

Walker WH (*see* Zhang B et al). 2004;39: 1348–1357

Walsh MJ, Vanags DM, Clouston AD, Richardson MM, Purdie DM, Jonsson JR, Powell EE. Steatosis and liver cell apoptosis in chronic hepatitis C: A mechamism for increased liver injury. 2004;39:1232–1241

Walter G (*see* Sauer IM et al). 2004;39: 1415–1421

Wands JR (*see* Horimoto M et al). 2004; 39:386–392

Wang C, Tang J, Song W, Lobashevsky E, Wilson CM, Kaslow RA. HLA and cytokine gene polymorphisms are independently associated with responses to hepatitis B vaccination. 2004;39:978–988

Wang D (*see* Wang Y et al). 2004;39:318–324

Wang DQH (*see* Lammert F et al). 2004; 39:117–128

Wang L and Boyer JL. The maintenance and generation of membrane polarity in hepatocytes. 2004;39:892–899 (Science Frontier)

Wang LY (*see* Chen CJ et al). 2004;39: 1196–1197

Wang XW (*see* Kim JW et al). 2004;39: 518–527

Wang Y, Cui F, Lv Y, Li C, Xu X, Deng C, Wang D, Sun Y, Hu G, Lang Z, Huang C, Yang X. *HBsAg* and *HBx* knocked into the *p21* locus causes hepatocellular carcinoma in mice. 2004;39:318–324

— (*see* Schattenberg JM et al). 2004;39: 444–455

Wanless IR (*see* Roskams TA et al). 2004; 39:1739–1745 (Special Article)

Wasmuth HE, Matern S, Lammert F. From genotypes to haplotypes in hepatobiliary diseases: One plus one equals (sometimes) more than two. 2004;39:604–607 (Editorial)

Wedemeyer H, Jäckel E, Wiegand J, Manns MP. Whom to treat? When to treat? How to treat? Another piece of evidence for early treatment of acute hepatitis C. 2004;39:1202–1204 (Editorial)

Wegenka U (*see* Dikopoulos N et al). 2004;39:1259–1270

Weill B (*see* Laurent A et al). 2004;39:1282–1290

Wein C, Koch H, Popp B, Oehler G, Schauder P. Minimal hepatic encephalopathy impairs fitness to drive. 2004;39:739–745

Wendel A (*see* Hentze H et al). 2004:39: 1316–1325

Wendon J (*see* Murphy N et al). 2004;39: 464–470

Werneburg NW (*see* Yoon JH et al). 2004; 39:732–738

West AB (*see* Roskams TA et al). 2004;39: 1739–1745 (Special Article)

Wewalka F (*see* Lenz K et al). 2004;39: 865–866 (Correspondence)

Wheeler MD (*see* Isayama F et al). 2004; 39:721–731

Whittle H (*see* Kirk GD et al). 2004;39: 211–219

Wiegand J (*see* Wedemeyer H et al). 2004; 39:1202–1204 (Editorial)

Wiesner RH (*see* Kremers WK et al). 2004; 39:764–769

Williams DP (*see* Goldring CEP et al). 2004;39:1271–1281

Williams J (*see* McMahon BJ et al). 2004; 39:325–332

Williams R (*see* Shawcross DL et al). 2004; 39:471–475

Wilson CM (*see* Wang C et al). 2004;39: 978–988

Wong DKH (*see* Yuen MF et al). 2004;39: 1694–1701

Wongcharatrawee S (*see* Groszmann RJ and Wongcharatrawee S). 2004;39: 280–282 (Perspectives in Clinical Hepatology)

Wright T (*see* Strader DB et al). 2004;39: 1147–1171 (AASLD Practice Guideline)

Wright TL (*see* Monto A et al). 2004;39: 826–834

Wu SF (*see* Chen HL et al). 2004;39:58–63

Wu TC (*see* Chen HL et al). 2004;39:58–63

Wu Y (*see* Yoshiji H et al). 2004;39:1517–1524

Wyllie S (*see* Thevananther S et al). 2004; 39:393–402

Wynn TA, Hesse M, Sandler NG, Kaviratne M, Hoffmann KF, Chiaramonte MG, Reiman R, Cheever AW, Sypek JP, Mentink-Kane MM. P-selectin suppresses hepatic inflammation and fibrosis in mice by regulating interferon γ and the IL-13 decoy receptor. 2004;39: 676–687

X

Xu L, Sakalian M, Shen Z, Loss G, Neuberger J, Mason A. Cloning the human betaretrovirus proviral genome from patients with primary biliary cirrhosis. 2004;39:151–156

Xu X (*see* Wang Y et al). 2004;39:318–324

Y

Yahagi N, Sekiya M, Shimano H. Do polyunsaturated fatty acids ameliorate hepatic steatosis in obese mice by SREPB-1 suppression or by correcting essential fatty acid deficiency. 2004; 39:1177–1178 (Reply)

Yamaga AK (*see* Choi J et al). 2004;39:81–89

Yamamoto H (*see* Ogawa M et al). 2004; 39:528–539

Yamamoto K (*see* Matsumura S et al). 2004;39:1422–1429

Yamamoto M (*see* Goldring CEP et al). 2004;39:1271–1281

— (*see* Shoda J et al). 2004;39:167–178

Yamamoto T (*see* Hisatomi Y et al). 2004; 39:667–675

Yamashina S (*see* Katagiri H et al). 2004; 39:139–150

Yamazaki M (*see* Yoshiji H et al). 2004;39: 1517–1524

Yanase K (*see* Yoshiji H et al). 2004;39: 1517–1524

Yang J (*see* Chen YC et al). 2004;39:1075–1087

Yang RZ (*see* Jadaho SB et al). 2004;39: 1302–1307

Yang S, Koteish A, Lin H, Huang J, Roskams T, Dawson V, Diehl AM. Oval cells compensate for damage and replicative senescence of mature hepatocytes in mice with fatty liver disease. 2004;39:403–411

Yang X (*see* Wang Y et al). 2004;39:318–324

Yanovski JA (*see* Promrat K et al). 2004;39: 188–196

Yao FY, Saab S, Bass NM, Hirose R, Ly D, Terrault N, Lazar AA, Bacchetti P, Ascher NL, Roberts JP. Prediction of survival after liver retransplantation for late graft failure based on preoperative prognostic scores. 2004; 39:230–238

Yao H (*see* Chau TN et al). 2004;39:302–310

Yasuchika K (*see* Hoppo T et al). 2004;39: 1367–1375

Yawn BP (*see* Kim WR et al). 2004;39: 811–816

Ye Q (*see* Kim JW et al). 2004;39:518–527

Yeager AE (*see* Jacob JR et al). 2004;39: 1008–1016

Yeung DTK (*see* Yu SCH et al). 2004;39: 932–938

Yeung YC (*see* Chau TN et al). 2004;39: 302–310

Yin M (*see* Isayama F et al). 2004;39:721–731

Yoneda M, Hasegawa T, Nakamura K,

Tamano M, Kono T, Terano A. Vitamin E therapy in patients with NASH. 2004;39:568 (Correspondence)
Yonezawa S (*see* Shibahara H et al). 2004; 39:220–229
Yoon JH, Canbay AE, Werneburg NW, Lee SP, Gores GJ. Oxysterols induce cyclooxygenase-2 expression in cholangiocytes: Implications for biliary tract carcinogenesis. 2004;39: 732–738
Yoshidome H, Kato A, Ito H, Kimura F, Shimizu H, Ohtsuka M, Morita Y, Miyazaki M (*see* Takeuchi D et al). 2004;39:699–710
Yoshii J (*see* Yoshiji H et al). 2004;39:1517–1524
Yoshiji H, Kuriyama S, Yoshii J, Ikenaka Y, Noguchi R, Hicklin DJ, Wu Y, Yanase K, Namisaki T, Kitade M, Yamazaki M, Tsujinoue H, Masaki T, Fukui H. Halting the interaction between vascular endothelial growth factor and its receptor attenuates liver carcinogenesis in mice. 2004;39:1517–1524
Yoshimura Y (*see* Kudo A et al). 2004;39: 1099–1109
You KR (*see* Kim JH et al). 2004;39:129–138
Yu SCH, Ho SSM, Lau WY, Yeung DTK, Yuen EHY, Lee PSF, Metreweli C. Treatment of pyogenic liver abscess: Prospective randomized comparison of catheter drainage and needle aspiration. 2004;39:932–938
Yuan HJ (*see* Yuen MF et al). 2004;39: 1694–1701
Yuen EHY (*see* Yu SCH et al). 2004;39: 932–938
Yuen MF, Wong DKH, Sablon E, Tse E, Ng IOI, Yuan HJ, Siu CW, Sander TJ, Bourne EJ, Hall JG, Condreay LD, Lai CL. HBsAg seroclearance in chronic hepatitis B in the Chinese: Virological, histological, and clinical aspects. 2004;39:1694–1701

Z

Zachoval R (*see* Berg T et al). 2004;39: 1462–1464 (Correspondence)
Zager JS (*see* Delman KA et al). 2004;39: 1525–1532
Zancan L (*see* Bortolotti F et al). 2004;39: 1462 (Correspondence)
— (*see* Iorio R et al). 2004;39:1173–1174 (Correspondence)
Zanetti AR (*see* Casiraghi MA). 2004;39: 90–96
Zapater P (*see* Francés R et al). 2004;39: 484–491, 1470 (Correction)
Zatloukal K (*see* Müller T et al). 2004;39: 963–969
Zavadil J (*see* Petkov PM et al). 2004;39: 617–627
Zein CO, Lindor KD, Angulo P. Prevalence and predictors of esophageal varices in patients with primary sclerosing cholangitis. 2004; 39:204–210
Zeindl-Eberhart E, Haraida S, Liebmann S, Jungblut PR, Lamer S, Mayer D, Jäger G, Chung S, Rabes HM. Detection and identification of tumor-associated protein variants in human hepatocellular carcinomas. 2004;39:540–549
Zeitoun G (*see* Murad SD et al). 2004;39: 500–508
Zeng S, Feirt N, Goldstein M, Guarrera J, Ippagunta N, Ekong U, Dun H, Lu Y, Qu W, Schmidt AM, Emond JC. Blockade of receptor for advanced glycation end product (RAGE) attenuates ischemia and reperfusion injury to the liver in mice. 2004;39: 422–432
Zeuzem S (*see* Berg T et al). 2004;39:1462–1464 (Correspondence)
— (*see* Cammà C et al). 2004;39:333–342
Zhang B, Liu S, Perpetua MD, Walker WH, Harbrecht BG. Cytokines increase CRE binding but decrease CRE-mediated reporter activity in hepatocytes by increasing c-Jun. 2004; 39:1348–1357
Zhang DY, Sabla G, Shivakumar P, Tiao G, Sokol RJ, Mack C, Shneider BL, Aronow B, Bezerra JA. Coordinate expression of regulatory genes differentiates embryonic and perinatal forms of biliary atresia. 2004;39:954–962
Zhang HY (*see* Lau GKK et al). 2004;39: 867–868 (Reply)
Zhang J (*see* Ling Y et al). 2004;39:1593–1602
Zhang Z, Lai GH, Sirica AE. Celecoxib-induced apoptosis in rat cholangiocarcinoma cells mediated by Akt inactivation and Bax translocation. 2004;39:1028–1037
— (*see* Pei Z et al). 2004;39:1376–1387
Zheng Y (*see* Choi J et al). 2004;39:81–89
Zhou W (*see* Ochi M et al). 2004;39:1326–1336
Zickmund S, Hillis SL, Barnett MJ, Ippolito L, LaBrecque DR. Hepatitis C virus-infected patients report communication problems with physicians. 2004;39:999–1007
Zimmerman TL (*see* Thevananther S et al). 2004;39:393–402
Zink D (*see* Schulze-Bergkamen H et al). 2004;39:645–654
Ziol M (*see* André N et al). 2004;39:864–865 (Correspondence)
Zöllner B, Petersen J, Puchhammer-Stöckl E, Kletzmayr J, Sterneck M, Fischer L, Schröter, M, Laufs R, Feucht HH. Viral features of lamivudine resistant hepatitis genotypes A and D. 2004; 39:42–50
Zou W (*see* Pei Z et al). 2004;39:1376–1387

Subject Index to Volume 39*

A

AASLD Practice Guideline
Management of adult patients with ascites due to cirrhosis (Runyon). 2004;39:841–856 (Practice Guideline)

Abscess
Treatment of pyogenic liver abscess: Prospective randomized comparison of catheter drainage and needle aspiration (Yu et al). 2004;39:932–938

Acetaminophen
Activation of hepatic Nrf2 *in vivo* by acetaminophen in CD-1 mice (Goldring et al). 2004;39:1271–1281
Hepatology Highlights (Kaplowitz). 2004;39:1183–1184
Subliminal Fas stimulation increases the hepatotoxicity of acetaminophen and bromobenzene in mice (Tinel et al). 2004;39:655–666

2-Acetylaminofluorene
2-Acetylaminofluorene dose-dependent differentiation of oval cells into hepatocytes: Confocal and electron microscopic studies (Paku et al). 2004;39:1358–1366

Acronyms
Never say dye (Reuben). 2004;39:259–264 (Landmarks in Hepatology)

Acute alcoholic hepatitis
A double-blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis (Naveau et al). 2004;39:1396–1403

Acute hepatitis A virus infection
The clinical profile of acute hepatitis A infection: Is it really so severe? (Amoroso et al). 2004;39:572 (Correspondence)
The clinical profile of acute hepatitis A infection: Is it really so severe? (Sjogren MH). 2004;39:572–573 (Reply)

Acute hepatitis C virus infection
Pegylated interferon α therapy in acute hepatitis C: Relation to hepatitis C virus–specific T cell response kinetics (Kamal et al). 2004;39:1721–1731
Short-term interferon-alfa therapy for acute hepatitis C: A randomized controlled trial (Nomura et al). 2004;39:1214–1220
Whom to treat? When to treat? How to treat? Another piece of evidence for early treatment of acute hepatitis C (Wedemeyer et al). 2004;39:1202–1204 (Editorial)

Acute liver failure
Hepatology Highlights (Elias). 2004;39:579–580
The effect of hypertonic sodium chloride on intracranial pressure in patients with acute liver failure (Murphy et al). 2004;39:464–470
Worsening of cerebral hyperemia by the administration of terlipressin in acute liver failure with severe encephalopathy (Shawcross et al). 2004;39:471–475

Acute systemic inflammation
Altered gene expression in acute systemic inflammation detected by complete coverage of the human liver transcriptome (Coulouarn et al). 2004;39:353–364

Acute variceal bleeding
Antibiotic prophylaxis after endoscopic therapy prevents rebleeding in acute variceal hemorrhage: A randomized trial (Hou et al). 2004;39:746–753
Sustained rise of portal pressure after sclerotherapy, but not band ligation, in acute variceal bleeding in cirrhosis (Avgerinos et al). 2004;39:1623–1630

Adenoma
Try, try, try again . . . and again (Reuben). 2004;39:1750–1753 (Landmarks in Hepatology)
Vascular interference: A blockade to tumor epithelial growth (Crawford). 2004;39:1491–1494 (Editorial)

Adenosine triphosphate
Extracellular ATP activates c-jun N-terminal kinase signaling and cell cycle progression in hepatocytes (Thevananther et al). 2004;39:393–402

Adenoviral therapy
An oncolytic adenoviral vector of Smac increases antitumor activity of TRAIL against HCC in human cells and in mice (Pei et al). 2004;39:1376–1387

Africa
The Gambia liver cancer study: Infection with hepatitis B and C and the risk of hepatocellular carcinoma in West Africa (Kirk et al). 2004;39:211–219

Akt
Celecoxib-induced apoptosis in rat cholangiocarcinoma cells mediated by Akt inactivation and Bax translocation (Zhang et al). 2004;39:1028–1037
Hepatocyte growth factor induces Mcl-1 in primary human hepatocytes and inhibits CD95-mediated apoptosis via Akt (Schulze-Bergkamen et al). 2004;39:645–654

Alanine aminotransferase
Hepatology Highlights (Kaplowitz). 2004;39:1183–1184
Murine alanine aminotransferase: cDNA cloning, functional expression, and differential gene regulation in mouse fatty liver (Jadaho et al). 2004;39:1302–1307
The elusiveness of "normal" ALT in fatty liver (Ratziu et al). 2004;39:1172 (Correspondence)
The elusiveness of "normal" ALT in fatty liver (Sanyal). 2004;39:1173 (Reply)

Alaska Natives
Epidemiology and risk factors for hepatitis C in Alaska Natives (McMahon BJ et al). 2004;39:325–332

Alcohol intake
Hepatology Highlights (Alter). 2004;39:877–879
Prediction of liver fibrosis in patients with features of the metabolic syndrome regardless of alcohol consumption (Lainé et al). 2004;39:1639–1646
Risks of a range of alcohol intake on hepatitis C-related fibrosis (Monto et al). 2004;39:826–834

Alcoholic hepatitis
A double-blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis (Naveau et al). 2004;39:1396–1403
Hepatology Highlights (Elias). 2004;39:1467–1468

Alcoholic liver disease
Asialoglycoprotein receptor facilitates hemolysis in patients with alcoholic liver cirrhosis (Hilgard et al). 2004;39:1404–1414
Hepatic transmethylation reactions in micropigs with alcoholic liver disease (Villanueva and Halsted). 2004;39:1308–1315
Oxidative stress as a trigger for cellular immune responses in patients with alcoholic liver disease (Stewart et al). 2004;39:197–203

Aldose reductase-like protein-1, human (hARLP-1)
Detection and identification of tumor-associated protein variants in human hepatocellular carcinomas (Zeindl-Eberhart et al). 2004;39:540–549

*January, 1–270; February, 271–578; March, 579–876; April, 877–1182; May, 1183–1466; June, 1467–1798.

Alveolar echinococcosis
Structured treatment interruption in patients with alveolar echinococcosis (Reuter et al). 2004;39:509–517
American Association for the Study of Liver Diseases Clinical Workshops
Screening in liver disease: Report of an AASLD clinical workshop (Adams et al). 2004;39:1205–1213 (Special Article)
American Association for the Study of Liver Diseases practice guidelines
Chronic hepatitis B: Update of recommendations (Lok and McMahon). 2004;39:857–861
Diagnosis, management, and treatment of hepatitis C (Strader et al). 2004; 39:1147–1171 (AASLD Practice Guideline)
Management of adult patients with ascites due to cirrhosis (Runyon). 2004;39:841–856
American Association for the Study of Liver Diseases Research Workshops
Nitric oxide biology and the liver: Report of an AASLD research workshop (Rockey and Shah). 2004; 39:250–257 (Special Article)
American Association for the Study of Liver Diseases Single Topic Conference
Hepatitis C. Development of new drugs and clinical trials. Promises and pitfalls (Pawlotsky and McHutchison). 2004;39:554–567 (Special Article)
Aminotransferase
Persistence of elevated aminotransferases in Wilson's disease despite adequate therapy (Iorio et al). 2004;39:1173–1174 (Correspondence)
Anatomy
Nomenclature of the finer branches of the biliary tree: Canals, ductules, and ductular reactions in human livers (Roskams et al). 2004;39:1739–1745 (Special Article)
Angiogenesis
Angiogenesis in chronic inflammatory liver disease (Medina et al). 2004; 39:1185–1195 (Concise Review in Mechanisms of Disease)
Angiopoietin-2
Hepatic expression of *ANG2* RNA in metastatic colorectal cancer (Ogawa et al). 2004;39:528–539
Animal models
A critical role for the chimpanzee model in the study of hepatitis C (Bukh). 2004;39:1469–1475 (Concise Review in Mechanisms of Disease)
A murine model of type 2 autoimmune hepatitis: Xenoimmunization with human antigens (Lapierre et al). 2004;39:1066–1074
Analyses of hepatocellular proliferation in a mouse model of α-1-antitrypsin deficiency (Rudnick et al). 2004;39: 1048–1055
Hepatitis C virus kinetics and host responses associated with disease and outcomes of infection in chimpanzees (Major et al). 2004;39: 1709–1720
Spontaneous cholecysto- and hepatolithiasis in *Mdr2*$^{-/-}$ mice: A model for low phospholipid-associated cholelithiasis (Lammert et al). 2004;39:117–128
Antibiotic prophylaxis
Antibiotic prophylaxis after endoscopic therapy prevents rebleeding in acute variceal hemorrhage: A randomized trial (Hou et al). 2004;39:746–753
Antioxidants
Pivotal role of superoxide anion and beneficial effect of antioxidant molecules in murine steatohepatitis (Laurent et al). 2004;39:1282–1290
Antiretroviral therapy
Depletion of mitochondrial DNA in liver under antiretroviral therapy with didanosine, stavudine, or zalcitabine (Walker et al). 2004;39: 311–317
α-1-Antitrypsin deficiency
Analyses of hepatocellular proliferation in a mouse model of α-1-antitrypsin deficiency (Rudnick et al). 2004;39: 1048–1055
Antiviral therapy
Interfering with capsid formation: A practicable antiviral strategy against hepatitis B virus? (Deres et al). 2004;39:838–840 (Hepatology *Elsewhere*)
Apoptosis
Apoptosis: The nexus of liver injury and fibrosis (Canbay et al). 2004;39: 273–278 (Science Frontier)
Celecoxib-induced apoptosis in rat cholangiocarcinoma cells mediated by Akt inactivation and Bax translocation (Zhang et al). 2004; 39:1028–1037
Electric foot shock stress-induced exacerbation of α-galactosylceramide–triggered apoptosis in mouse liver (Chida et al). 2004;39:1131–1140
Hepatocyte growth factor induces Mcl-1 in primary human hepatocytes and inhibits CD95-mediated apoptosis via Akt (Schulze-Bergkamen et al). 2004;39:645–654
Improvement of rat liver graft quality by pifithrin-α-mediated inhibition of hepatocyte necrapoptosis (El-Gibaly et al). 2004;39:1553–1562
Severe hyperthyroidism induces mitochondria-mediated apoptosis in rat liver (Upadhyay et al). 2004;39: 1120–1130
Steatosis and liver cell apoptosis in chronic hepatitis C: A mechamism for increased liver injury (Walsh et al). 2004;39:1232–1241
Tauroursodeoxycholic acid protects rat hepatocytes from bile acid-induced apoptosis via activation of survival pathways (Schoemaker et al). 2004; 39:1563–1573
Topoisomerase inhibitor camptothecin sensitizes mouse hepatocytes *in vitro* and *in vivo* to TNF-mediated apoptosis (Hentze et al). 2004;39: 1316–1325
Aquaporin AQP4
AQP4 transfected into mouse cholangiocytes promotes water transport in biliary epithelia (Splinter et al). 2004;39:109–116
Arterial vasodilation
Increased vascular heme oxygenase-1 expression contributes to arterial vasodilation in experimental cirrhosis in rats (Chen et al). 2004; 39:1075–1087
Aryl hydrocarbon receptor
Reversal of liver fibrosis in aryl hydrocarbon receptor *null* mice by dietary vitamin A depletion (Andreola et al). 2004;39:157–166
Ascites
A sequential study of serum bacterial DNA in patients with advanced cirrhosis and ascites (Francés et al). 2004;39:484–491, 1470 (Correction)
Management of adult patients with ascites due to cirrhosis (Runyon). 2004;39:841–856 (AASLD Practice Guideline)
Asialoglycoprotein receptor
Asialoglycoprotein receptor facilitates hemolysis in patients with alcoholic liver cirrhosis (Hilgard et al). 2004; 39:1404–1414
AST-Platelets Ratio Index
Does noninvasive staging of fibrosis challenge liver biopsy as a gold standard in chronic hepatitis C? (Berg et al). 2004;39:1462–1464 (Correspondence)
The predictive value of Fibrotest vs. APRI for the diagnosis of fibrosis in chronic hepatitis C (Le Calvez et al). 2004;39:862–863 (Correspondence)
The predictive value of Fibrotest vs. APRI for the diagnosis of fibrosis in chronic hepatitis C (Lok and Wai). 2004;39:863 (Reply)
Autoimmune hepatitis
A murine model of type 2 autoimmune hepatitis: Xenoimmunization with human antigens (Lapierre et al). 2004;39:1066–1074
Hepatology Highlights (Elias). 2004;39: 1467–1468

Progressive fibrosis during corticosteroid therapy of autoimmune hepatitis (Czaja and Carpenter). 2004;39: 1631–1638

Autoimmune lymphoproliferative syndrome
Expression of granzyme B in viral hepatitis in patients with ALPS (André et al). 2004;39:864–865 (Correspondence)

B

B cells
Frequent compartmentalization of hepatitis C virus variants in circulating B cells and monocytes (Ducoulombier et al). 2004;39:817–825

Bacterial DNA
A sequential study of serum bacterial DNA in patients with advanced cirrhosis and ascites (Francés et al). 2004;39:484–491, 1470 (Correction)

Bacterial peritonitis
Increased carbon monoxide production in patients with cirrhosis with and without spontaneous bacterial peritonitis (De Las Heras et al). 2004;39:265 (Correction)
Systemic, renal, and hepatic hemodynamic derangement in cirrhotic patients with spontaneous bacterial peritonitis (Del Árbol and Arroyo). 2004;39:866–867 (Reply)
Systemic, renal, and hepatic hemodynamic derangement in cirrhotic patients with spontaneous bacterial peritonitis (Lenz et al). 2004;39:865–866 (Correspondence)

Baltimore, Maryland
High prevalence of occult hepatitis B in Baltimore injection drug users (Torbenson et al). 2004;39:51–57

Band ligation
Sustained rise of portal pressure after sclerotherapy, but not band ligation, in acute variceal bleeding in cirrhosis (Avgerinos et al). 2004;39:1623–1630

Baum, Janet
Try, try, try again . . . and again (Reuben). 2004;39:1750–1753 (Landmarks in Hepatology)

Bax
Celecoxib-induced apoptosis in rat cholangiocarcinoma cells mediated by Akt inactivation and Bax translocation (Zhang et al). 2004; 39:1028–1037

Betaretrovirus
Cloning the human betaretrovirus proviral genome from patients with primary biliary cirrhosis (Xu et al). 2004;39:151–156

Bile acid transport
Cellular regeneration of hepatic bile acid transport in health and cholestasis (Anwer). 2004;39:581–590 (Concise Review in Mechanisms of Disease)
Hepatology Highlights (Kaplowitz). 2004;39:271–272

Bile acids
Bile acids enhance the activity of the insulin receptor and glycogen synthase in primary rodent hepatocytes (Han et al). 2004;39: 456–463
Tauroursodeoxycholic acid protects rat hepatocytes from bile acid-induced apoptosis via activation of survival pathways (Schoemaker et al). 2004; 39:1563–1573

Bile canalicular transporters
Hepatology Highlights (Elias). 2004;39: 579–580

Bile formation
Genipin enhances Mrp2 (Abcc2)-mediated bile formation and organic anion transport in rat liver (Shoda et al). 2004;39:167–178

Bile salt export pump
BSEP and *MDR3* haplotype structure in healthy Caucasians, primary biliary cirrhosis and primary sclerosing cholangitis (Pauli-Magnus et al). 2004;39:779–791
Hepatology Highlights (Kaplowitz). 2004;39:271–272

Biliary atresia
Coordinate expression of regulatory genes differentiates embryonic and perinatal forms of biliary atresia (Zhang et al). 2004;39:954–962

Biliary Atresia Research Consortium (BARC)
Biliary Atresia Research Consortium (BARC) (Hoofnagle). 2004;39:891 (This Month From the NIH)

Biliary epithelia
AQP4 transfected into mouse cholangiocytes promotes water transport in biliary epithelia (Splinter et al). 2004;39:109–116

Biliary injury
Caspase induction by IgA antimitochondrial antibody: IgA-mediated biliary injury in primary biliary cirrhosis (Matsumura et al). 2004;39:1422–1429

Biliary tract carcinogenesis
Oxysterols induce cyclooxygenase-2 expression in cholangiocytes: Implications for biliary tract carcinogenesis (Yoon et al). 2004; 39:732–738

Biliary tree
Nomenclature of the finer branches of the biliary tree: Canals, ductules, and ductular reactions in human livers (Roskams et al). 2004;39:1739–1745 (Special Article)

Biopsy
Does noninvasive staging of fibrosis challenge liver biopsy as a gold standard in chronic hepatitis C? (Berg et al). 2004;39:1462–1464 (Correspondence)

Black Americans
Peginterferon alfa-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1 (Jeffers et al). 2004;39:1702–1708

Blood transfusion
Hepatology Highlights (Alter). 2004;39: 2–4
Long-term outcome (35 years) of hepatitis C after acquisition of infection through mini transfusion of blood given at birth (Casiraghi et al). 2004;39:90–96

Body fat distribution
Body fat distribution, relative weight, and liver enzyme levels: A population-based study (Stranges et al). 2004;39:754–763

Bone marrow cells
An uncomfortable silence . . . while we all search for a better reporter gene in adult stem cell biology (Terai et al). 2004;39:1143–1146 (Hepatology *Elsewhere*)

Bone marrow transplantation
Pre-emptive use of lamivudine in bone marrow transplantation with chronic hepatitis B virus infection (Deschênes and Laneuville). 2004; 39:867 (Correspondence)
Pre-emptive use of lamivudine in bone marrow transplantation with chronic hepatitis B virus infection (Lau et al). 2004;39:867–868 (Reply)

Borgia phenomenon
Hepatology Highlights (Kaplowitz). 2004;39:1183–1184

Brain organic osmolytes
Effects of dilutional hyponatremia on brain organic osmolytes and water content in patients with cirrhosis (Restuccia et al). 2004;39:1613–1622
Hepatology Highlights (Elias). 2004;39: 1467–1468

Brain water content
Effects of dilutional hyponatremia on brain organic osmolytes and water content in patients with cirrhosis (Restuccia et al). 2004;39:1613–1622

Bromobenzene
Subliminal Fas stimulation increases the hepatotoxicity of acetaminophen and bromobenzene in mice (Tinel et al). 2004;39:655–666

Budd-Chiari syndrome
Determinants of survival and the effect

of portosystemic shunting in patients with Budd-Chiari syndrome (Murad et al). 2004;39:500–508
Hepatology Highlights (Elias). 2004;39: 579–580

C

Calcium
Cholestasis shuts down calcium signaling in cholangiocytes (Shibao et al). 2004;39:248–249 (Hepatology *Elsewhere*)
Camptothecin
Topoisomerase inhibitor camptothecin sensitizes mouse hepatocytes *in vitro* and *in vivo* to TNF-mediated apoptosis (Hentze et al). 2004;39: 1316–1325
Canada
Federally funded research in hepatology (Heathcote). 2004;39:20 (News from Canada)
Capsids
Interfering with capsid formation: A practicable antiviral strategy against hepatitis B virus? (Deres et al). 2004;39:838–840 (Hepatology *Elsewhere*)
Carbon monoxide
Increased carbon monoxide production in patients with cirrhosis with and without spontaneous bacterial peritonitis (De Las Heras et al). 2004;39:265 (Correction)
Caspase
Caspase induction by IgA antimitochondrial antibody: IgA-mediated biliary injury in primary biliary cirrhosis (Matsumura et al). 2004;39:1422–1429
β-Catenin
Hepatitis B virus X protein is essential for the activation of Wnt/β-catenin signaling in hepatoma cells (Cha et al). 2004;39:1683–1693
Catheter drainage
Treatment of pyogenic liver abscess: Prospective randomized comparison of catheter drainage and needle aspiration (Yu et al). 2004;39:932-938
Caucasians
BSEP and *MDR3* haplotype structure in healthy Caucasians, primary biliary cirrhosis and primary sclerosing cholangitis (Pauli-Magnus et al). 2004;39:779–791
Caveolin
Hepatology Highlights (Kaplowitz). 2004;39:271-272
CD4 cells
Hepatology Highlights (Alter). 2004;39: 2–4
CD8 cells
Kupffer cells required for high affinity peptide-induced deletion, not retention, of activated CD8+ T cells by mouse liver (Kuniyasu et al). 2004;39:1017–1027
Recently primed CD8+ T cells entering the liver induce hepatocytes to interact with naïve CD8+ T cells in the mouse (Dikopoulos et al). 2004; 39:1259–1270
CD49f cells
Thy1-positive mesenchymal cells promote the maturation of CD49f-positive hepatic progenitor cells in the mouse fetal liver (Hoppo et al). 2004;39:1367–1375
CD95 (APO-1/Fas)
Hepatocyte growth factor induces Mcl-1 in primary human hepatocytes and inhibits CD95-mediated apoptosis via Akt (Schulze-Bergkamen et al). 2004;39:645–654
Celecoxib
Celecoxib-induced apoptosis in rat cholangiocarcinoma cells mediated by Akt inactivation and Bax translocation (Zhang et al). 2004; 39:1028–1037
Cell cycle
Extracellular ATP activates c-jun N-terminal kinase signaling and cell cycle progression in hepatocytes (Thevananther et al). 2004;39:393–402
Cell death
Chronic liver disease in murine hereditary tyrosinemia type 1 induces resistance to cell death (Vogel et al). 2004;39:433–443
CYP2E1 overexpression alters hepatocyte death from menadione and fatty acids by activation of ERK1/2 signaling (Schattenberg et al). 2004; 39:444–455
Sinusoidal endothelial cell and hepatocyte death following cold ischemia-warm reperfusion of the rat liver (Huet et al). 2004;39:1110–1119
Cell differentiation
2-Acetylaminofluorene dose-dependent differentiation of oval cells into hepatocytes: Confocal and electron microscopic studies (Paku et al). 2004;39:1358–1366
An uncomfortable silence . . . while we all search for a better reporter gene in adult stem cell biology (Terai et al). 2004;39:1143–1146 (Hepatology *Elsewhere*)
Flow cytometric isolation of endodermal progenitors from mouse salivary gland differentiate into hepatic and pancreatic lineages (Hisatomi et al). 2004;39:667–675
Murine hepatocyte cell lines promote expansion and differentiation of NK cells from stem cell precursors (Bordoni et al). 2004;39:1508–1516
Plasticity in the adult rat pancreas: Transdifferentiation of exocrine to hepatocytelike cells in primary culture (Lardon et al). 2004;39:1499–1507
Cell proliferation
Analyses of hepatocellular proliferation in a mouse model of α-1-antitrypsin deficiency (Rudnick et al). 2004;39: 1048–1055
Effect of murine liver cell proliferation on herpes viral behavior: Implications for oncolytic viral therapy (Delman et al). 2004;39: 1525–1532
Hepatocyte proliferation and tissue remodeling is impaired after liver injury in oncostatin M receptor knockout mice (Nakamura et al). 2004;39:635–644
Over-expression of the ribosomal protein L36a gene Is associated with cellular proliferation in hepatocellular carcinoma (Kim et al). 2004;39: 129–138
TNF α-induced Ras activation due to ethanol promotes hepatocyte proliferation independently of liver injury in the mouse (Isayama et al). 2004;39:721–731
Cell therapy
An uncomfortable silence . . . while we all search for a better reporter gene in adult stem cell biology (Terai et al). 2004;39:1143–1146 (Hepatology *Elsewhere*)
Cellular immune response
Oxidative stress as a trigger for cellular immune responses in patients with alcoholic liver disease (Stewart et al). 2004;39:197–203
Cerebral edema
Hepatology Highlights (Elias). 2004;39: 579–580
Cerebral hyperemia
Worsening of cerebral hyperemia by the administration of terlipressin in acute liver failure with severe encephalopathy (Shawcross et al). 2004;39:471–475
Children
Long-term outcome of hepatitis C in children (Bortolotti et al). 2004;39: 1462 (Correspondence)
Serum laminin-2 and hyaluronan predict severe liver fibrosis in children with chronic hepatitis B (Lebensztejn et al). 2004;39:868–869 (Correspondence)
Child-Turcotte-Pugh (CTP) score
Prediction of survival after liver retransplantation for late graft failure based on preoperative prognostic scores (Yao et al). 2004; 39:230–238

Chinese patients
HBsAg seroclearance in chronic hepatitis B in the Chinese: Virological, histological, and clinical aspects (Yuen et al). 2004;39:1694–1701
Cholangiocarcinoma
Celecoxib-induced apoptosis in rat cholangiocarcinoma cells mediated by Akt inactivation and Bax translocation (Zhang et al). 2004; 39:1028–1037
MUC4 is a novel prognostic factor of intrahepatic cholangiocarcinoma-mass forming type (Shibahara et al). 2004;39:220–229
Cholangiocytes
AQP4 transfected into mouse cholangiocytes promotes water transport in biliary epithelia (Splinter et al). 2004;39:109–116
Cholestasis shuts down calcium signaling in cholangiocytes (Shibao et al). 2004;39:248–249 (Hepatology *Elsewhere*)
Oxysterols induce cyclooxygenase-2 expression in cholangiocytes: Implications for biliary tract carcinogenesis (Yoon et al). 2004; 39:732–738
Cholecystolithiasis
Spontaneous cholecysto- and hepatolithiasis in *Mdr2*$^{-/-}$ mice: A model for low phospholipid-associated cholelithiasis (Lammert et al). 2004;39:117–128
Cholelithiasis
Spontaneous cholecysto- and hepatolithiasis in *Mdr2*$^{-/-}$ mice: A model for low phospholipid-associated cholelithiasis (Lammert et al). 2004;39:117–128
Cholestasis
Cellular regeneration of hepatic bile acid transport in health and cholestasis (Anwer). 2004;39:581–590 (Concise Review in Mechanisms of Disease)
Cholestasis shuts down calcium signaling in cholangiocytes (Shibao et al). 2004;39:248–249 (Hepatology *Elsewhere*)
Down-regulation of the organic cation transporter 1 of rat liver in obstructive cholestasis (Denk et al). 2004;39:1388–1395
Treatment of the pruritus of cholestasis: From unbearable lightness to substance (Terg et al). 2004;39:1457–1460 (Hepatology *Elsewhere*)
What doesn't kill you makes you stronger: How hepatocytes survive prolonged cholestasis (Schoemaker et al). 2004;39:1141–1143 (Hepatology *Elsewhere*)
Cholic acid
Endogenous ursodeoxycholic acid and cholic acid in liver disease due to cystic fibrosis (Smith et al). 2004;39: 1673–1682
Chronic hepatitis B virus infection
Chronic hepatitis B: Update of recommendations (Lok and McMahon). 2004;39:857–861 (AASLD Practice Guideline)
DDB treatment of patients with chronic hepatitis (Huber et al). 2004;39: 1732–1733 (Concise Communication)
HBsAg seroclearance in chronic hepatitis B in the Chinese: Virological, histological, and clinical aspects (Yuen et al). 2004;39:1694–1701
Hepatology Highlights (Alter). 2004;39: 877–879
Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B (van Zonneveld et al). 2004;39:804–810
Pre-emptive use of lamivudine in bone marrow transplantation with chronic hepatitis B virus infection (Deschênes and Laneuville). 2004; 39:867 (Correspondence)
Pre-emptive use of lamivudine in bone marrow transplantation with chronic hepatitis B virus infection (Lau et al). 2004;39:867–868 (Reply)
Serum laminin-2 and hyaluronan predict severe liver fibrosis in children with chronic hepatitis B (Lebensztejn et al). 2004;39:868–869 (Correspondence)
Tracking cccDNA in chronic HBV infection (Zhang et al). 2004;39: 1736–1738 (Hepatology *Elsewhere*)
Chronic hepatitis C virus infection
DDB treatment of patients with chronic hepatitis (Huber et al). 2004;39: 1732–1733 (Concise Communication)
Does noninvasive staging of fibrosis challenge liver biopsy as a gold standard in chronic hepatitis C? (Berg et al). 2004;39:1462–1464 (Correspondence)
Effect of peginterferon alfa-2a on liver histology in chronic hepatitis C: A meta-analysis of individual patient data (Cammà et al). 2004;39:333–342
Expression of the CXCR3 ligand I-TAC by hepatocytes in chronic hepatitis C and its correlation with hepatic inflammation (Helbig et al). 2004; 39:1221–1231
Factor V Leiden as a risk factor for cirrhosis in chronic hepatitis C (Poujol-Robert et al). 2004;39:1174–1175 (Correspondence)
Health-related quality of life in active injecting drug users with and without chronic hepatitis C virus infection (Dalgard et al). 2004;39: 74–80
Improved prediction of fibrosis in chronic hepatitis C using measures of insulin resistance in a probability index (Sud et al). 2004;39:1242–1250
Peginterferon alfa-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1 (Jeffers et al). 2004;39:1702–1708
Steatosis and liver cell apoptosis in chronic hepatitis C: A mechamism for increased liver injury (Walsh et al). 2004;39:1232–1241
The patient's perspective in hepatitis C (Fontana and Kronfol). 2004;39: 903–905 (Editorial)
The predictive value of Fibrotest vs. APRI for the diagnosis of fibrosis in chronic hepatitis C (Le Calvez et al). 2004;39:862–863 (Correspondence)
The predictive value of Fibrotest vs. APRI for the diagnosis of fibrosis in chronic hepatitis C (Lok and Wai). 2004;39:863 (Reply)
Treatment of chronic hepatitis C in HIV/HCV-coinfection with interferon α-2b+ full-course vs. 16-week delayed ribavirin (Bräu et al). 2004;39:989–998
Chronic inflammatory liver disease
Angiogenesis in chronic inflammatory liver disease (Medina et al). 2004; 39:1185–1195 (Concise Review in Mechanisms of Disease)
Chronic liver disease
Chronic liver disease in murine hereditary tyrosinemia type 1 induces resistance to cell death (Vogel et al). 2004;39:433–443
Chronic liver disease mortality in the United States, 1990–1998 (Vong and Bell). 2004;39:476–483
Circulating tumor cells
Impact of cytomorphological detection of circulating tumor cells in patients with liver cancer (Vona et al). 2004; 39:792–797
Cirrhosis. *See also* Indian childhood cirrhosis; Primary biliary cirrhosis; Secondary biliary cirrhosis
A sequential study of serum bacterial DNA in patients with advanced cirrhosis and ascites (Francés et al). 2004;39:484–491, 1470 (Correction)
Cancer-associated molecular signature in the tissue samples of patients with cirrhosis (Kim et al). 2004;39:518–527

Efects of dilutional hyponatremia on brain organic osmolytes and water content in patients with cirrhosis (Restuccia et al). 2004;39:1613–1622
Evolution of intrapulmonary vascular dilatations in cirrhosis (França et al). 2004;39:1461 (Correspondence)
Factor V Leiden as a risk factor for cirrhosis in chronic hepatitis C (Poujol-Robert et al). 2004;39:1174–1175 (Correspondence)
Hepatology Highlights (Elias). 2004;39:1467–1468
Increased carbon monoxide production in patients with cirrhosis with and without spontaneous bacterial peritonitis (De Las Heras et al). 2004;39:265 (Correction)
Increased duodenal expression of divalent metal transporter 1 and iron-regulated gene 1 in cirrhosis (Stuart et al). 2004;39:492–499
Increased vascular heme oxygenase-1 expression contributes to arterial vasodilation in experimental cirrhosis in rats (Chen et al). 2004;39:1075–1087
Sustained rise of portal pressure after sclerotherapy, but not band ligation, in acute variceal bleeding in cirrhosis (Avgerinos et al). 2004;39:1623–1630
Synbiotic modulation of gut flora: Effect on minimal hepatic encephalopathy in patients with cirrhosis (Liu et al). 2004;39:1448–1456
Systemic, renal, and hepatic hemodynamic derangement in cirrhotic patients with spontaneous bacterial peritonitis (Del Árbol and Arroyo). 2004;39:866–867 (Reply)
Systemic, renal, and hepatic hemodynamic derangement in cirrhotic patients with spontaneous bacterial peritonitis (Lenz et al). 2004;39:865–866 (Correspondence)

c-Jun N-terminal kinase
Extracellular ATP activates c-jun N-terminal kinase signaling and cell cycle progression in hepatocytes (Thevananther et al). 2004;39:393–402

Cloning
Cloning the human betaretrovirus proviral genome from patients with primary biliary cirrhosis (Xu et al). 2004;39:151–156

Colchicine
A randomized controlled trial of colchicine plus ursodiol versus methotrexate plus ursodiol in primary biliary cirrhosis: Ten-year results (Kaplan et al). 2004;39:915–923

Cold ischemia
Kupffer cells alter organic anion transport through multidrug resistance protein 2 in the post-cold ischemic rat liver (Kudo et al). 2004;39:1099–1109

Cold ischemia-warm reperfusion injury
Sinusoidal endothelial cell and hepatocyte death following cold ischemia-warm reperfusion of the rat liver (Huet et al). 2004;39:1110–1119

Colorectal cancer
Hepatic expression of *ANG2* RNA in metastatic colorectal cancer (Ogawa et al). 2004;39:528–539

Communication problems
Hepatitis C virus-infected patients report communication problems with physicians (Zickmund et al). 2004;39:999–1007

Complementary DNA
Altered gene expression in acute systemic inflammation detected by complete coverage of the human liver transcriptome (Coulouarn et al). 2004;39:353–364

Complementary DNA microarrays
Gene expression pattern in hepatic stem/progenitor cells during rat fetal development using complementary DNA microarrays (Petkov et al). 2004;39:617–627

Concanavalin A
Hepatology Highlights (Kaplowitz). 2004;39:1183–1184

Continuous veno-venous hemodiafiltration
In vitro comparison of the molecular adsorbent recirculation system (MARS) and single-pass albumin dialysis (SPAD) (Sauer et al). 2004;39:1415–1421

Copper toxicosis
Immunohistochemical analysis of Mallory bodies in Wilsonian and non-Wilsonian hepatic copper toxicosis (Müller et al). 2004;39:963–969

Coronavirus infection
SARS-associated viral hepatitis caused by a novel coronavirus: Report of three cases (Chau et al). 2004;39:302–310

Corticosteroid therapy
Hepatology Highlights (Elias). 2004;39:1467–1468
Progressive fibrosis during corticosteroid therapy of autoimmune hepatitis (Czaja and Carpenter). 2004;39:1631–1638

Covalently closed circular DNA
Tracking cccDNA in chronic HBV infection (Zhang et al). 2004;39:1736–1738 (Hepatology *Elsewhere*)

C-reactive protein
High sensitivity C-reactive protein values do not reliably predict the severity of histological change in NAFLD (Hui et al). 2004;39:1464 (Correspondence)
High sensitivity C-reactive protein values do not reliably predict the severity of histological change in NAFLD (Wai and Lok). 2004;39:1464–1465 (Reply)

CXC receptor 3
Expression of the CXCR3 ligand I-TAC by hepatocytes in chronic hepatitis C and its correlation with hepatic inflammation (Helbig et al). 2004;39:1221–1231

Cyclic AMP response element
Cytokines increase CRE binding but decrease CRE-mediated reporter activity in hepatocytes by increasing c-Jun (Zhang et al). 2004;39:1348–1357

Cyclooxygenase-1
Role of thromboxane derived from COX-1 and -2 in hepatic microcirculatory dysfunction during endotoxemia in mice (Katagiri et al). 2004;39:139–150

Cyclooxygenase-2
Oxysterols induce cyclooxygenase-2 expression in cholangiocytes: Implications for biliary tract carcinogenesis (Yoon et al). 2004;39:732–738
Role of thromboxane derived from COX-1 and -2 in hepatic microcirculatory dysfunction during endotoxemia in mice (Katagiri et al). 2004;39:139–150

Cyclosporin
Hepatology Highlights (Alter). 2004;39:2–4

Cystic fibrosis
Endogenous ursodeoxycholic acid and cholic acid in liver disease due to cystic fibrosis (Smith et al). 2004;39:1673–1682

Cytochrome P450 2E1
CYP2E1 overexpression alters hepatocyte death from menadione and fatty acids by activation of ERK1/2 signaling (Schattenberg et al). 2004;39:444–455

Cytokines
Cytokines increase CRE binding but decrease CRE-mediated reporter activity in hepatocytes by increasing c-Jun (Zhang et al). 2004;39:1348–1357
Hepatic adducts, circulating antibodies, and cytokine polymorphisms in patients with diclofenac hepatotoxicity (Aithal et al). 2004;39:1437–1447
HLA and cytokine gene polymorphisms are independently associated with responses to hepatitis B vaccination (Wang et al). 2004;39:978–988
Interleukin 18 causes hepatic ischemia/reperfusion injury by suppressing

anti-inflammatory cytokine expression in mice (Takeuchi et al). 2004;39:699–710

D

Dialysis
In vitro comparison of the molecular adsorbent recirculation system (MARS) and single-pass albumin dialysis (SPAD) (Sauer et al). 2004; 39:1415–1421

Diclofenac hepatotoxicity
Hepatic adducts, circulating antibodies, and cytokine polymorphisms in patients with diclofenac hepatotoxicity (Aithal et al). 2004; 39:1437–1447

Didanosine
Depletion of mitochondrial DNA in liver under antiretroviral therapy with didanosine, stavudine, or zalcitabine (Walker et al). 2004;39: 311–317

Dietary polyunsaturated fatty acids
Dietary n-3 polyunsaturated fatty acids decrease hepatic triglycerides in Fischer 344 rats (Levy et al). 2004; 39:608–616

Dietary vitamin A
Reversal of liver fibrosis in aryl hydrocarbon receptor *null* mice by dietary vitamin A depletion (Andreola et al). 2004;39:157–166

Diethylmaleate
Low membrane protein sulfhydrils but not glucose-6-phosphate dehydrogenase deficiency predict ribavirin-induced hemolysis in hepatitis C (Grattagliano et al). 2004;39:1251–1258

Dilutional hyponatremia
Effects of dilutional hyponatremia on brain organic osmolytes and water content in patients with cirrhosis (Restuccia et al). 2004;39:1613–1622

Dimethyl-4,4'-dimethoxy-5,6,5,'6-dimethylene-dioxybiphenyl-2,2'dicarboxylate
DDB treatment of patients with chronic hepatitis (Huber et al). 2004;39: 1732–1733 (Concise Communication)

Dipyridamole
Low membrane protein sulfhydrils but not glucose-6-phosphate dehydrogenase deficiency predict ribavirin-induced hemolysis in hepatitis C (Grattagliano et al). 2004;39:1251–1258

Divalent metal transporter 1
Increased duodenal expression of divalent metal transporter 1 and iron-regulated gene 1 in cirrhosis (Stuart et al). 2004;39:492–499

DNA, complementary (cDNA)
Altered gene expression in acute systemic inflammation detected by complete coverage of the human liver transcriptome (Coulouarn et al). 2004;39:353–364
Gene expression pattern in hepatic stem/progenitor cells during rat fetal development using complementary DNA microarrays (Petkov et al). 2004;39:617–627

DNA, covalently closed circular (cccDNA)
Tracking cccDNA in chronic HBV infection (Zhang et al). 2004;39: 1736–1738 (Hepatology *Elsewhere*)

DNA, mitochondrial (mtDNA)
Depletion of mitochondrial DNA in liver under antiretroviral therapy with didanosine, stavudine, or zalcitabine (Walker et al). 2004;39: 311–317

DNA damage
Oxidative damage is increased in human liver tissue adjacent to hepatocellular carcinoma (Jüngst et al). 2004;39: 1663–1672

Driving
Driving under the influence of minimal hepatic encephalopathy (Córdoba and Lucke). 2004;39:599–601 (Editorial)
Minimal hepatic encephalopathy impairs fitness to drive (Wein et al). 2004; 39:739–745

Drug hepatotoxicity
Hepatic adducts, circulating antibodies, and cytokine polymorphisms in patients with diclofenac hepatotoxicity (Aithal et al). 2004; 39:1437–1447
Hepatology Highlights (Kaplowitz). 2004;39:1183-1184
Hy's Law (Reuben A). 2004;39:574–578 (Landmarks in Hepatology)
Subliminal Fas stimulation increases the hepatotoxicity of acetaminophen and bromobenzene in mice (Tinel et al). 2004;39:655–666

Drug trials
Trials in primary biliary cirrhosis: Need for the right drugs at the right time (Poupon). 2004;39:900–902 (Editorial)

Drug-induced idiosyncratic liver disease
HLA class II genotype influences the type of liver injury in drug-induced idiosyncratic liver disease (Andrade et al). 2004;39:1603–1612

Duodenum
Increased duodenal expression of divalent metal transporter 1 and iron-regulated gene 1 in cirrhosis (Stuart et al). 2004;39:492–499

Dyes
Never say dye (Reuben). 2004;39:259–264 (Landmarks in Hepatology)

E

Echinococcosis, alveolar
Structured treatment interruption in patients with alveolar echinococcosis (Reuter et al). 2004;39:509–517

Electric foot shock
Electric foot shock stress-induced exacerbation of α-galactosylceramide–triggered apoptosis in mouse liver (Chida et al). 2004;39:1131–1140

Encephalopathy
Driving under the influence of minimal hepatic encephalopathy (Córdoba and Lucke). 2004;39:599–601 (Editorial)
Minimal hepatic encephalopathy impairs fitness to drive (Wein et al). 2004; 39:739–745
Prognostic value of altered oral glutamine challenge in patients with minimal hepatic encephalopathy (Romero-Gómez et al). 2004;39: 939–943
Synbiotic modulation of gut flora: Effect on minimal hepatic encephalopathy in patients with cirrhosis (Liu et al). 2004;39:1448–1456
Worsening of cerebral hyperemia by the administration of terlipressin in acute liver failure with severe encephalopathy (Shawcross et al). 2004;39:471–475

Endoscopic band ligation
Sustained rise of portal pressure after sclerotherapy, but not band ligation, in acute variceal bleeding in cirrhosis (Avgerinos et al). 2004;39:1623–1630

Endoscopic injection sclerotherapy
Sustained rise of portal pressure after sclerotherapy, but not band ligation, in acute variceal bleeding in cirrhosis (Avgerinos et al). 2004;39:1623–1630

Endoscopic therapy
Antibiotic prophylaxis after endoscopic therapy prevents rebleeding in acute variceal hemorrhage: A randomized trial (Hou et al). 2004;39:746–753

Endothelin-1
The role of endothelin-1 and the endothelin B receptor in the pathogenesis of experimental hepatopulmonary syndrome (Ling et al). 2004;39:1593–1602

Endothelin B receptor
The role of endothelin-1 and the endothelin B receptor in the pathogenesis of experimental hepatopulmonary syndrome (Ling et al). 2004;39:1593–1602

Endotoxemia
Role of thromboxane derived from COX-1 and -2 in hepatic microcirculatory dysfunction during

endotoxemia in mice (Katagiri et al). 2004;39:139–150

Endotoxin
5'-Methylthioadenosine modulates the inflammatory response to endotoxin in mice and in rat hepatocytes (Hevia et al). 2004;39:1088–1098

Epidemiology
Changing epidemiology of hepatitis B in a U.S. community (Kim et al). 2004;39:811–816
Epidemiology and risk factors for hepatitis C in Alaska Natives (McMahon BJ et al). 2004;39:325–332

Esophageal varices
Noninvasive markers of esophageal varices: Another round, not the last (D'Amico and Morabito). 2004;39:30–34 (Editorial)
Prevalence and predictors of esophageal varices in patients with primary sclerosing cholangitis (Zein et al). 2004;39:204–210

Essential fatty acid deficiency
Do polyunsaturated fatty acids ameliorate hepatic steatosis in obese mice by SREPB-1 suppression or by correcting essential fatty acid deficiency (Alwayn et al). 2004;39:1176–1177 (Correspondence)
Do polyunsaturated fatty acids ameliorate hepatic steatosis in obese mice by SREPB-1 suppression or by correcting essential fatty acid deficiency (Yahagi et al). 2004;39:1177–1178 (Reply)

Ethanolinduced liver injury
TNF α-induced Ras activation due to ethanol promotes hepatocyte proliferation independently of liver injury in the mouse (Isayama et al). 2004;39:721–731

Extracellular signal-regulated kinase 1/2
CYP2E1 overexpression alters hepatocyte death from menadione and fatty acids by activation of ERK1/2 signaling (Schattenberg et al). 2004;39:444–455

F

Factor V Leiden
Factor V Leiden as a risk factor for cirrhosis in chronic hepatitis C (Poujol-Robert et al). 2004;39:1174–1175 (Correspondence)

Factor VII, recombinant activated (rFVIIa)
Recombinant activated factor VII (rFVIIa) as a hemostatic agent in liver disease: A break from convention in need of controlled trials (Caldwell et al). 2004;39:592–598

Fas
Subliminal Fas stimulation increases the hepatotoxicity of acetaminophen and bromobenzene in mice (Tinel et al). 2004;39:655–666

Fatty acid deficiency
Do polyunsaturated fatty acids ameliorate hepatic steatosis in obese mice by SREPB-1 suppression or by correcting essential fatty acid deficiency (Alwayn et al). 2004;39:1176–1177 (Correspondence)
Do polyunsaturated fatty acids ameliorate hepatic steatosis in obese mice by SREPB-1 suppression or by correcting essential fatty acid deficiency (Yahagi et al). 2004;39:1177–1178 (Reply)

Fatty liver
Ischemic preconditioning affects interleukin release in fatty livers of rats undergoing ischemia/reperfusion (Serafin et al). 2004;39:688–698
Murine alanine aminotransferase: cDNA cloning, functional expression, and differential gene regulation in mouse fatty liver (Jadaho et al). 2004;39:1302–1307
The elusiveness of "normal" ALT in fatty liver (Ratziu et al). 2004;39:1172 (Correspondence)
The elusiveness of "normal" ALT in fatty liver (Sanyal). 2004;39:1173 (Reply)

Fatty liver disease
Oval cells compensate for damage and replicative senescence of mature hepatocytes in mice with fatty liver disease (Yang et al). 2004;39:403–411

Fatty liver disease, nonalcoholic
High sensitivity C-reactive protein values do not reliably predict the severity of histological change in NAFLD (Hui et al). 2004;39:1464 (Correspondence)
High sensitivity C-reactive protein values do not reliably predict the severity of histological change in NAFLD (Wai and Lok). 2004;39:1464–1465 (Reply)
Nonalcoholic fatty liver disease: Improvement in liver histological analysis with weight loss (Dixon et al). 2004;39:1647–1654
Nonalcoholic fatty liver disease among patients with hypothalamic and pituitary dysfunction (Adams et al). 2004;39:909–914
Relative contribution of iron burden, HFE mutations, and insulin resistance to fibrosis in nonalcoholic fatty liver (Bugianesi et al). 2004;39:179–187
Relative contribution of iron burden, HFE mutations, and insulin resistance to fibrosis in nonalcoholic fatty liver (Loria et al). 2004;39:1748 (Correspondence)
Uric acid levels and liver fibrosis in nonalcoholic fatty liver disease (Bugianesi and Marchesini). 2004;39:1749 (Correspondence)

Federal funding
Federally funded research in hepatology (Heathcote). 2004;39:20 (News from Canada)
Liver disease research funding (Hoofnagle JH). 2004;39:279 (This Month From the NIH)

Fetal development
Gene expression pattern in hepatic stem/progenitor cells during rat fetal development using complementary DNA microarrays (Petkov et al). 2004;39:617–627
Thy1-positive mesenchymal cells promote the maturation of CD49f-positive hepatic progenitor cells in the mouse fetal liver (Hoppo et al). 2004;39:1367–1375

Fibrolamellar carcinoma
Is fibrolamellar carcinoma different from hepatocellular carcinoma? A US population-based study (El-Serag and Davila). 2004;39:798–803

Fibrosis
Administration of the potent PPARα agonist, Wy-14,643, reverses nutritional fibrosis and steatohepatitis in mice (Ip et al). 2004;39:1291–1301
Does noninvasive staging of fibrosis challenge liver biopsy as a gold standard in chronic hepatitis C? (Berg et al). 2004;39:1462–1464 (Correspondence)
Endogenous ursodeoxycholic acid and cholic acid in liver disease due to cystic fibrosis (Smith et al). 2004;39:1673–1682
Hepatology Highlights (Alter). 2004;39:877–879
Hepatology Highlights (Elias). 2004;39:1467–1468
Improved prediction of fibrosis in chronic hepatitis C using measures of insulin resistance in a probability index (Sud et al). 2004;39:1242–1250
PAR_1 antagonism protects against experimental liver fibrosis. Role of proteinase receptors in stellate cell activation (Fiorucci et al). 2004;39:365–375
Prediction of liver fibrosis in patients with features of the metabolic syndrome regardless of alcohol consumption (Lainé et al). 2004;39:1639–1646
Progressive fibrosis during corticosteroid therapy of autoimmune hepatitis (Czaja and Carpenter). 2004;39:1631–1638

Relative contribution of iron burden, HFE mutations, and insulin resistance to fibrosis in nonalcoholic fatty liver (Bugianesi et al). 2004;39: 179–187
Relative contribution of iron burden, HFE mutations, and insulin resistance to fibrosis in nonalcoholic fatty liver (Loria et al). 2004;39: 1748 (Correspondence)
Risks of a range of alcohol intake on hepatitis C-related fibrosis (Monto et al). 2004;39:826–834
Uric acid levels and liver fibrosis in nonalcoholic fatty liver disease (Bugianesi and Marchesini). 2004; 39:1749 (Correspondence)

Fibrosis probability index
Improved prediction of fibrosis in chronic hepatitis C using measures of insulin resistance in a probability index (Sud et al). 2004;39:1242–1250

Fibrotest
The predictive value of Fibrotest vs. APRI for the diagnosis of fibrosis in chronic hepatitis C (Le Calvez et al). 2004;39:862–863 (Correspondence)
The predictive value of Fibrotest vs. APRI for the diagnosis of fibrosis in chronic hepatitis C (Lok and Wai). 2004;39:863 (Reply)

Fish oil
Dietary n-3 polyunsaturated fatty acids decrease hepatic triglycerides in Fischer 344 rats (Levy et al). 2004; 39:608–616

Fulminant hepatic failure
Optimal management of patients with fulminant hepatic failure: Targeting the brain (Larsen). 2004;39:299–301 (Editorial)
Pediatric fulminant hepatic failure in endemic areas of hepatitis B infection: 15 years after universal hepatitis B vaccination (Chen et al). 2004;39:58–63

Funding
Federally funded research in hepatology (Heathcote). 2004;39:20 (News from Canada)
Liver disease research funding (Hoofnagle JH). 2004;39:279 (This Month From the NIH)

G

α-Galactosylceramide
Electric foot shock stress-induced exacerbation of α-galactosylceramide–triggered apoptosis in mouse liver (Chida et al). 2004;39:1131–1140

The Gambia
The Gambia liver cancer study: Infection with hepatitis B and C and the risk of hepatocellular carcinoma in West Africa (Kirk et al). 2004;39:211–219

Gastroesophageal variceal bleeding
Antibiotic prophylaxis after endoscopic therapy prevents rebleeding in acute variceal hemorrhage: A randomized trial (Hou et al). 2004;39:746–753

Gene expression
Altered gene expression in acute systemic inflammation detected by complete coverage of the human liver transcriptome (Coulouarn et al). 2004;39:353–364
Coordinate expression of regulatory genes differentiates embryonic and perinatal forms of biliary atresia (Zhang et al). 2004;39:954–962
Gene expression pattern in hepatic stem/progenitor cells during rat fetal development using complementary DNA microarrays (Petkov et al). 2004;39:617–627
Stereological measurement of porto–central gradients in gene expression in mouse liver (Ruijter JM et al). 2004;39:343–352

Gene expression profiling
Identification of discriminators of hepatoma by gene expression profiling using a minimal dataset approach (Neo et al). 2004;39:944–953

Genipin
Genipin enhances Mrp2 (Abcc2)-mediated bile formation and organic anion transport in rat liver (Shoda et al). 2004;39:167–178

Genotype
From genotypes to haplotypes in hepatobiliary diseases: One plus one equals (sometimes) more than two (Wasmuth et al). 2004;39:604–607 (Editorial)
HLA class II genotype influences the type of liver injury in drug-induced idiosyncratic liver disease (Andrade et al). 2004;39:1603–1612
Peginterferon alfa-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1 (Jeffers et al). 2004;39:1702–1708
Viral features of lamivudine resistant hepatitis genotypes A and D (Zöllner et al). 2004;39:42–50

Glucose-6-phosphate dehydrogenase deficiency
Low membrane protein sulfhydrils but not glucose-6-phosphate dehydrogenase deficiency predict ribavirin-induced hemolysis in hepatitis C (Grattagliano et al). 2004;39:1251–1258

Glucuronidation
Variation of hepatic glucuronidation: Novel functional polymorphisms of the UDP-glucuronosyltransferase UGT1A4 (Ehmer et al). 2004;39: 970–977

Glutamine
Prognostic value of altered oral glutamine challenge in patients with minimal hepatic encephalopathy (Romero-Gómez et al). 2004;39: 939–943

Glutathione
A role for the 2-oxoglutarate carrier in glutathione transport into hepatocyte mitochondria? (Estrela et al). 2004;39:570–571 (Correspondence)
A role for the 2-oxoglutarate carrier in glutathione transport into hepatocyte mitochondria? (Fernández and Garcia-Ruiz). 2004; 39:571–572 (Reply)

Glutathione ester
Low membrane protein sulfhydrils but not glucose-6-phosphate dehydrogenase deficiency predict ribavirin-induced hemolysis in hepatitis C (Grattagliano et al). 2004;39:1251–1258

Glycogen synthase
Bile acids enhance the activity of the insulin receptor and glycogen synthase in primary rodent hepatocytes (Han et al). 2004;39: 456–463

Granzyme B
Expression of granzyme B in viral hepatitis in patients with ALPS (André et al). 2004;39:864–865 (Correspondence)

Greek mythology
Prometheus and Pandora—Together again (Reuben). 2004;39:1466–1469 (Landmarks in Hepatology)

Gut flora
Gut flora-based therapy in liver disease? The liver cares about the gut (Solga and Diehl). 2004;39:1198–1201 (Editorial)
Synbiotic modulation of gut flora: Effect on minimal hepatic encephalopathy in patients with cirrhosis (Liu et al). 2004;39:1448-1456

H

Haplotype
BSEP and *MDR3* haplotype structure in healthy Caucasians, primary biliary cirrhosis and primary sclerosing cholangitis (Pauli-Magnus et al). 2004;39:779–791
From genotypes to haplotypes in hepatobiliary diseases: One plus one equals (sometimes) more than two (Wasmuth et al). 2004;39:604–607 (Editorial)

Health-related quality of life
Health-related quality of life in active injecting drug users with and

without chronic hepatitis C virus infection (Dalgard et al). 2004;39: 74–80
The patient's perspective in hepatitis C (Fontana and Kronfol). 2004;39: 903–905 (Editorial)

Heme oxygenase-1
Increased vascular heme oxygenase-1 expression contributes to arterial vasodilation in experimental cirrhosis in rats (Chen et al). 2004; 39:1075–1087

Hemochromatosis
Liver transplantation: An "in vivo" model for the pathophysiology of hemochromatosis? (Kowdley). 2004; 39:1495–1498 (Editorial)
Non-*HFE* hemochromatosis (Pietrangelo). 2004;39:21–29 (Perspectives in Clinical Hepatology)
Patient and graft survival after liver transplantation for hereditary hemochromatosis: Implications for pathogenesis (Crawford et al). 2004; 39:1655–1662

Hemodialysis
In vitro comparison of the molecular adsorbent recirculation system (MARS) and single-pass albumin dialysis (SPAD) (Sauer et al). 2004; 39:1415–1421

Hemolysis
Asialoglycoprotein receptor facilitates hemolysis in patients with alcoholic liver cirrhosis (Hilgard et al). 2004; 39:1404–1414
Low membrane protein sulfhydrils but not glucose-6-phosphate dehydrogenase deficiency predict ribavirin-induced hemolysis in hepatitis C (Grattagliano et al). 2004;39:1251–1258

Hepatic encephalopathy
Driving under the influence of minimal hepatic encephalopathy (Córdoba and Lucke). 2004;39:599–601 (Editorial)
Minimal hepatic encephalopathy impairs fitness to drive (Wein et al). 2004; 39:739–745
Prognostic value of altered oral glutamine challenge in patients with minimal hepatic encephalopathy (Romero-Gómez et al). 2004;39: 939–943
Synbiotic modulation of gut flora: Effect on minimal hepatic encephalopathy in patients with cirrhosis (Liu et al). 2004;39:1448–1456
Worsening of cerebral hyperemia by the administration of terlipressin in acute liver failure with severe encephalopathy (Shawcross et al). 2004;39:471–475

Hepatic inflammation
Expression of the CXCR3 ligand I-TAC by hepatocytes in chronic hepatitis C and its correlation with hepatic inflammation (Helbig et al). 2004; 39:1221–1231

Hepatic progenitor cells
Flow cytometric isolation of endodermal progenitors from mouse salivary gland differentiate into hepatic and pancreatic lineages (Hisatomi et al). 2004;39:667–675
Gene expression pattern in hepatic stem/progenitor cells during rat fetal development using complementary DNA microarrays (Petkov et al). 2004;39:617–627
Immortalized p19^{ARF} null hepatocytes restore liver injury and generate hepatic progenitors after transplantation (Mikula et al). 2004; 39:628–634
Liver regeneration and repair: Hepatocytes, progenitor cells, and stem cells (Fausto). 2004;39:1477–1487 (Science Frontier)
Thy1-positive mesenchymal cells promote the maturation of CD49f-positive hepatic progenitor cells in the mouse fetal liver (Hoppo et al). 2004;39:1367–1375

Hepatic steatosis
Do polyunsaturated fatty acids ameliorate hepatic steatosis in obese mice by SREPB-1 suppression or by correcting essential fatty acid deficiency (Alwayn et al). 2004;39: 1176–1177 (Correspondence)
Do polyunsaturated fatty acids ameliorate hepatic steatosis in obese mice by SREPB-1 suppression or by correcting essential fatty acid deficiency (Yahagi et al). 2004;39: 1177–1178 (Reply)
Oval cells compensate for damage and replicative senescence of mature hepatocytes in mice with fatty liver disease (Yang et al). 2004;39:403–411
Steatosis and liver cell apoptosis in chronic hepatitis C: A mechamism for increased liver injury (Walsh et al). 2004;39:1232–1241

Hepatic stellate cells
Differential modulation of rat hepatic stellate phenotype by natural and synthetic retinoids (Hellemans et al). 2004;39:97–108
PAR_1 antagonism protects against experimental liver fibrosis. Role of proteinase receptors in stellate cell activation (Fiorucci et al). 2004;39: 365–375

Hepatic venous pressure gradient
Changing clinical practice with measurements of portal pressure (Boyer). 2004;39:283–285 (Perspectives in Clinical Hepatology)
Monitoring of HVPG during pharmacological therapy: Evidence in favor of the prognostic value of a 20% reduction (Burroughs et al). 2004;39:1747 (Reply)
Monitoring of HVPG during pharmacological therapy: Evidence in favor of the prognostic value of a 20% reduction (Garcia-Pagán and Bosch). 2004;39:1746–1747 (Correspondence)
Targeting portal pressure measurements: A critical reappraisal (Thalheimer et al). 2004;39:286–290 (Perspectives in Clinical Hepatology)
The hepatic venous pressure gradient: Anything worth doing should be done right (Groszmann and Wongcharatrawee). 2004;39:280–282 (Perspectives in Clinical Hepatology)
The hepatic venous pressure gradient: "Remixed and revisited" (Huet and Pomier-Layrargues). 2004;39:295–298 (Editorial)

Hepatitis
Hepatology Highlights (Alter). 2004;39: 877–879
Interleukin 22 (IL-22) plays a protective role in T cell-mediated hepatitis: IL-22 is a survival factor for hepatocytes via STAT3 activation (Radaeva et al). 2004;39:1337–1347

Hepatitis A virus infection
The clinical profile of acute hepatitis A infection: Is it really so severe? (Amoroso et al). 2004;39:572 (Correspondence)
The clinical profile of acute hepatitis A infection: Is it really so severe? (Sjogren MH). 2004;39:572-573 (Reply)

Hepatitis B vaccination
HLA and cytokine gene polymorphisms are independently associated with responses to hepatitis B vaccination (Wang et al). 2004;39:978–988
Pediatric fulminant hepatic failure in endemic areas of hepatitis B infection: 15 years after universal hepatitis B vaccination (Chen et al). 2004;39:58–63

Hepatitis B virus
Identification of HBV DNA sequences that are predictive of responses to lamivudine therapy (Cianco et al). 2004;39:64–73
Viral features of lamivudine resistant hepatitis genotypes A and D (Zöllner et al). 2004;39:42–50

Hepatitis B virus infection
Changing epidemiology of hepatitis B in a U.S. community (Kim et al). 2004;39:811–816
Chronic hepatitis B: Update of recommendations (Lok and

McMahon). 2004;39:857–861 (AASLD Practice Guideline)
DDB treatment of patients with chronic hepatitis (Huber et al). 2004;39: 1732–1733 (Concise Communication)
HBsAg seroclearance in chronic hepatitis B in the Chinese: Virological, histological, and clinical aspects (Yuen et al). 2004;39:1694–1701
Hepatology Highlights (Alter). 2004;39: 877–879
High prevalence of occult hepatitis B in Baltimore injection drug users (Torbenson et al). 2004;39:51–57
Interfering with capsid formation: A practicable antiviral strategy against hepatitis B virus? (Deres et al). 2004;39:838–840 (Hepatology *Elsewhere*)
Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B (van Zonneveld et al). 2004;39:804–810
Pediatric fulminant hepatic failure in endemic areas of hepatitis B infection: 15 years after universal hepatitis B vaccination (Chen et al). 2004;39:58–63
Pre-emptive use of lamivudine in bone marrow transplantation with chronic hepatitis B virus infection (Deschênes and Laneuville). 2004; 39:867 (Correspondence)
Pre-emptive use of lamivudine in bone marrow transplantation with chronic hepatitis B virus infection (Lau et al). 2004;39:867–868 (Reply)
Serum laminin-2 and hyaluronan predict severe liver fibrosis in children with chronic hepatitis B (Lebensztejn et al). 2004;39:868–869 (Correspondence)
The Gambia liver cancer study: Infection with hepatitis B and C and the risk of hepatocellular carcinoma in West Africa (Kirk et al). 2004;39:211–219
Tracking cccDNA in chronic HBV infection (Zhang et al). 2004;39: 1736–1738 (Hepatology *Elsewhere*)

Hepatitis B virus surface antigen

HBsAg and *HBx* knocked into the *p21* locus causes hepatocellular carcinoma in mice (Wang et al). 2004;39:318–324
HBsAg seroclearance in chronic hepatitis B in the Chinese: Virological, histological, and clinical aspects (Yuen et al). 2004;39:1694–1701
Hepatology Highlights (Alter). 2004;39: 2–4

Hepatitis B virus X protein

HBsAg and *HBx* knocked into the *p21* locus causes hepatocellular carcinoma in mice (Wang et al). 2004;39:318–324
Hepatitis B virus X protein is essential for the activation of Wnt/β-catenin signaling in hepatoma cells (Cha et al). 2004;39:1683–1693

Hepatitis C virus

Frequent compartmentalization of hepatitis C virus variants in circulating B cells and monocytes (Ducoulombier et al). 2004;39:817–825
Hepatitis C virus kinetics and host responses associated with disease and outcomes of infection in chimpanzees (Major et al). 2004;39: 1709–1720
Hepatology Highlights (Alter). 2004;39: 2–4, 877–879
Overdependence on its host—an Achilles' heel of HCV? (Ye et al). 2004;39:1734–1735 (Hepatology *Elsewhere*)
Pegylated interferon α therapy in acute hepatitis C: Relation to hepatitis C virus–specific T cell response kinetics (Kamal et al). 2004;39:1721–1731
Reactive oxygen species suppress hepatitis C virus RNA replication in human hepatoma cells (Choi et al). 2004;39:81–89
Structural biology of hepatitis C virus (Penin et al). 2004;39:5–19 (Scientific Frontier)
Unexpected host range of hepatitis C virus replicons (Zhu et al). 2004;39: 835–837 (Hepatology *Elsewhere*)

Hepatitis C virus coinfection

Defining the standard of care: Randomized controlled trials for the treatment of hepatitis C in the HIV-infected person (Sulkowski). 2004; 39:906–908 (Editorial)
Hepatology Highlights (Alter). 2004;39: 877–879
Treatment of chronic hepatitis C in HIV/HCV-coinfection with interferon α-2b+ full-course vs. 16-week delayed ribavirin (Bräu et al). 2004;39:989–998

Hepatitis C virus infection

A critical role for the chimpanzee model in the study of hepatitis C (Bukh). 2004;39:1469–1475 (Concise Review in Mechanisms of Disease)
DDB treatment of patients with chronic hepatitis (Huber et al). 2004;39: 1732–1733 (Concise Communication)
Defining the standard of care: Randomized controlled trials for the treatment of hepatitis C in the HIV-infected person (Sulkowski). 2004; 39:906–908 (Editorial)
Diagnosis, management, and treatment of hepatitis C (Strader et al). 2004; 39:1147–1171 (AASLD Practice Guideline)
Does noninvasive staging of fibrosis challenge liver biopsy as a gold standard in chronic hepatitis C? (Berg et al). 2004;39:1462–1464 (Correspondence)
Effect of peginterferon alfa-2a on liver histology in chronic hepatitis C: A meta-analysis of individual patient data (Cammà et al). 2004;39:333–342
Epidemiology and risk factors for hepatitis C in Alaska Natives (McMahon BJ et al). 2004;39:325–332
Expression of the CXCR3 ligand I-TAC by hepatocytes in chronic hepatitis C and its correlation with hepatic inflammation (Helbig et al). 2004; 39:1221–1231
Factor V Leiden as a risk factor for cirrhosis in chronic hepatitis C (Poujol-Robert et al). 2004;39:1174–1175 (Correspondence)
Health-related quality of life in active injecting drug users with and without chronic hepatitis C virus infection (Dalgard et al). 2004;39: 74–80
Hepatitis C. Development of new drugs and clinical trials. Promises and pitfalls (Pawlotsky and McHutchison). 2004;39:554–567 (Special Article)
Hepatitis C virus kinetics and host responses associated with disease and outcomes of infection in chimpanzees (Major et al). 2004;39: 1709–1720
Hepatitis C virus-infected patients report communication problems with physicians (Zickmund et al). 2004; 39:999–1007
Hepatology Highlights (Alter). 2004;39: 2–4
Host factors and failure of interferon-α treatment in hepatitis C virus (Gao et al). 2004;39:880–890 (Concise Review in Mechanisms of Disease)
Improved prediction of fibrosis in chronic hepatitis C using measures of insulin resistance in a probability index (Sud et al). 2004;39:1242–1250
Long-term outcome (35 years) of hepatitis C after acquisition of infection through mini transfusion of blood given at birth (Casiraghi et al). 2004;39:90–96
Long-term outcome of hepatitis C in children (Bortolotti et al). 2004;39: 1462 (Correspondence)
Low membrane protein sulfhydrils but not glucose-6-phosphate dehydrogenase deficiency predict

ribavirin-induced hemolysis in hepatitis C (Grattagliano et al). 2004;39:1251–1258
Peginterferon alfa-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1 (Jeffers et al). 2004;39:1702–1708
Pegylated interferon α therapy in acute hepatitis C: Relation to hepatitis C virus–specific T cell response kinetics (Kamal et al). 2004;39:1721–1731
Risks of a range of alcohol intake on hepatitis C-related fibrosis (Monto et al). 2004;39:826–834
Short-term interferon-alfa therapy for acute hepatitis C: A randomized controlled trial (Nomura et al). 2004;39:1214–1220
Steatosis and liver cell apoptosis in chronic hepatitis C: A mechamism for increased liver injury (Walsh et al). 2004;39:1232–1241
The Gambia liver cancer study: Infection with hepatitis B and C and the risk of hepatocellular carcinoma in West Africa (Kirk et al). 2004;39:211–219
The patient's perspective in hepatitis C (Fontana and Kronfol). 2004;39:903–905 (Editorial)
Treatment of chronic hepatitis C in HIV/HCV-coinfection with interferon α-2b+ full-course vs. 16-week delayed ribavirin (Bräu et al). 2004;39:989–998
Whom to treat? When to treat? How to treat? Another piece of evidence for early treatment of acute hepatitis C (Wedemeyer et al). 2004;39:1202–1204 (Editorial)

Hepatobiliary disease
From genotypes to haplotypes in hepatobiliary diseases: One plus one equals (sometimes) more than two (Wasmuth et al). 2004;39:604–607 (Editorial)

Hepatobiliary pruritus
Old scratch (Reuben). 2004;39:870–874 (Landmarks in Hepatology)

Hepatocarcinogenesis
Halting the interaction between vascular endothelial growth factor and its receptor attenuates liver carcinogenesis in mice (Yoshiji et al). 2004;39:1517–1524
HBsAg and *HBx* knocked into the *p21* locus causes hepatocellular carcinoma in mice (Wang et al). 2004;39:318–324

Hepatocellular carcinoma
A common staging system for hepatocellular carcinoma (Henderson et al). 2004;39:550–551 (Hepatology *Elsewhere*)
An oncolytic adenoviral vector of Smac increases antitumor activity of TRAIL against HCC in human cells and in mice (Pei et al). 2004;39:1376–1387
Cancer-associated molecular signature in the tissue samples of patients with cirrhosis (Kim et al). 2004;39:518–527
Detection and identification of tumor-associated protein variants in human hepatocellular carcinomas (Zeindl-Eberhart et al). 2004;39:540–549
Hepatology Highlights (Alter). 2004;39:877–879
Impact of cytomorphological detection of circulating tumor cells in patients with liver cancer (Vona et al). 2004;39:792–797
Integration of woodchuck hepatitis and N-myc rearrangement determine size and histologic grade of hepatic tumors (Jacob et al). 2004;39:1008–1016
Is fibrolamellar carcinoma different from hepatocellular carcinoma? A US population-based study (El-Serag and Davila). 2004;39:798–803
Over-expression of the ribosomal protein L36a gene Is associated with cellular proliferation in hepatocellular carcinoma (Kim et al). 2004;39:129–138
Oxidative damage is increased in human liver tissue adjacent to hepatocellular carcinoma (Jüngst et al). 2004;39:1663–1672
Prognostic prediction in HCC: Did anybody expect it to be easy? (Bruix and Llovet). 2004;39:551–552 (Hepatology *Elsewhere*)
Progression of HCC in mice is associated with a downregulation in the expression of hepatocyte nuclear factors (Lazarevich et al). 2004;39:1038–1047
The Gambia liver cancer study: Infection with hepatitis B and C and the risk of hepatocellular carcinoma in West Africa (Kirk et al). 2004;39:211–219
The strategic role of staging in the treatment of HCC: Comments (Colombo and Sangiovanni). 2004;39:552–553 (Hepatology *Elsewhere*)
Vascular interference: A blockade to tumor epithelial growth (Crawford). 2004;39:1491–1494 (Editorial)

Hepatocystin
Abnormal hepatocystin caused by truncating *PRKCSH* mutations leads to autosomal dominant polycystic liver disease (Drenth et al). 2004;39:924–931

Hepatocyte growth factor
Hepatocyte growth factor induces Mcl-1 in primary human hepatocytes and inhibits CD95-mediated apoptosis via Akt (Schulze-Bergkamen et al). 2004;39:645–654

Hepatocyte nuclear factor
Progression of HCC in mice is associated with a downregulation in the expression of hepatocyte nuclear factors (Lazarevich et al). 2004;39:1038–1047

Hepatocytes
A role for the 2-oxoglutarate carrier in glutathione transport into hepatocyte mitochondria? (Estrela et al). 2004;39:570–571 (Correspondence)
A role for the 2-oxoglutarate carrier in glutathione transport into hepatocyte mitochondria? (Fernández and Garcia-Ruiz). 2004;39:571–572 (Reply)
2-Acetylaminofluorene dose-dependent differentiation of oval cells into hepatocytes: Confocal and electron microscopic studies (Paku et al). 2004;39:1358–1366
Bile acids enhance the activity of the insulin receptor and glycogen synthase in primary rodent hepatocytes (Han et al). 2004;39:456–463
CYP2E1 overexpression alters hepatocyte death from menadione and fatty acids by activation of ERK1/2 signaling (Schattenberg et al). 2004;39:444–455
Cytokines increase CRE binding but decrease CRE-mediated reporter activity in hepatocytes by increasing c-Jun (Zhang et al). 2004;39:1348–1357
Expression of the CXCR3 ligand I-TAC by hepatocytes in chronic hepatitis C and its correlation with hepatic inflammation (Helbig et al). 2004;39:1221–1231
Extracellular ATP activates c-jun N-terminal kinase signaling and cell cycle progression in hepatocytes (Thevananther et al). 2004;39:393–402
Hepatocyte growth factor induces Mcl-1 in primary human hepatocytes and inhibits CD95-mediated apoptosis via Akt (Schulze-Bergkamen et al). 2004;39:645–654
Hepatocyte proliferation and tissue remodeling is impaired after liver injury in oncostatin M receptor knockout mice (Nakamura et al). 2004;39:635–644
Immortalized $p19^{ARF}$ null hepatocytes restore liver injury and generate hepatic progenitors after transplantation (Mikula et al). 2004;39:628–634
Improvement of rat liver graft quality by pifithrin-α-mediated inhibition of

hepatocyte necrapoptosis (El-Gibaly et al). 2004;39:1553–1562
Interleukin 22 (IL-22) plays a protective role in T cell-mediated hepatitis: IL-22 is a survival factor for hepatocytes via STAT3 activation (Radaeva et al). 2004;39:1337–1347
Liver regeneration and repair: Hepatocytes, progenitor cells, and stem cells (Fausto). 2004;39:1477–1487 (Science Frontier)
5'-Methylthioadenosine modulates the inflammatory response to endotoxin in mice and in rat hepatocytes (Hevia et al). 2004;39:1088–1098
Murine hepatocyte cell lines promote expansion and differentiation of NK cells from stem cell precursors (Bordoni et al). 2004;39:1508–1516
Nitric oxide protects rat hepatocytes against reperfusion injury mediated by the mitochondrial permeability transition (Kim et al). 2004;39:1533–1543
Oval cells compensate for damage and replicative senescence of mature hepatocytes in mice with fatty liver disease (Yang et al). 2004;39:403–411
Plasticity in the adult rat pancreas: Transdifferentiation of exocrine to hepatocytelike cells in primary culture (Lardon et al). 2004;39:1499–1507
Recently primed CD8+ T cells entering the liver induce hepatocytes to interact with naïve CD8+ T cells in the mouse (Dikopoulos et al). 2004;39:1259–1270
Sinusoidal endothelial cell and hepatocyte death following cold ischemia-warm reperfusion of the rat liver (Huet et al). 2004;39:1110–1119
Susceptibility of murine periportal hepatocytes to hypoxia-reoxygenation: Role for NO and Kupffer cell-derived oxidants (Taniai et al). 2004;39:1544–1552
Tauroursodeoxycholic acid protects rat hepatocytes from bile acid-induced apoptosis via activation of survival pathways (Schoemaker et al). 2004;39:1563–1573
The maintenance and generation of membrane polarity in hepatocytes (Wang and Boyer). 2004;39:892–899 (Science Frontier)
TNF α-induced Ras activation due to ethanol promotes hepatocyte proliferation independently of liver injury in the mouse (Isayama et al). 2004;39:721–731
Topoisomerase inhibitor camptothecin sensitizes mouse hepatocytes *in vitro* and *in vivo* to TNF-mediated apoptosis (Hentze et al). 2004;39:1316–1325
What doesn't kill you makes you stronger: How hepatocytes survive prolonged cholestasis (Schoemaker et al). 2004;39:1141–1143 (Hepatology *Elsewhere*)

Hepatolithiasis

Spontaneous cholecysto- and hepatolithiasis in *Mdr2*$^{-/-}$ mice: A model for low phospholipid-associated cholelithiasis (Lammert et al). 2004;39:117–128

Hepatology

The impact of *Hepatology* (Blei). 2004;39:1 (Editorial)

Hepatoma

Hepatitis B virus X protein is essential for the activation of Wnt/β-catenin signaling in hepatoma cells (Cha et al). 2004;39:1683–1693
Identification of discriminators of hepatoma by gene expression profiling using a minimal dataset approach (Neo et al). 2004;39:944-953
Reactive oxygen species suppress hepatitis C virus RNA replication in human hepatoma cells (Choi et al). 2004;39:81–89

Hepatopulmonary syndrome

The role of endothelin-1 and the endothelin B receptor in the pathogenesis of experimental hepatopulmonary syndrome (Ling et al). 2004;39:1593–1602

Hepatotoxicity

Hepatic adducts, circulating antibodies, and cytokine polymorphisms in patients with diclofenac hepatotoxicity (Aithal et al). 2004;39:1437–1447
Hy's Law (Reuben A). 2004;39:574–578 (Landmarks in Hepatology)
Liver NK cells expressing TRAIL are toxic against self hepatocytes in mice (Ochi et al). 2004;39:1326–1336
Subliminal Fas stimulation increases the hepatotoxicity of acetaminophen and bromobenzene in mice (Tinel et al). 2004;39:655–666

Hereditary tyrosinemia type 1

Chronic liver disease in murine hereditary tyrosinemia type 1 induces resistance to cell death (Vogel et al). 2004;39:433–443

Herpes simplex virus

Effect of murine liver cell proliferation on herpes viral behavior: Implications for oncolytic viral therapy (Delman et al). 2004;39:1525–1532

HFE gene

Relative contribution of iron burden, HFE mutations, and insulin resistance to fibrosis in nonalcoholic fatty liver (Bugianesi et al). 2004;39:179–187
Relative contribution of iron burden, HFE mutations, and insulin resistance to fibrosis in nonalcoholic fatty liver (Loria et al). 2004;39:1748 (Correspondence)

History

Hy's Law (Reuben A). 2004;39:574–578 (Landmarks in Hepatology)
Never say dye (Reuben). 2004;39:259–264 (Landmarks in Hepatology)
Old scratch (Reuben). 2004;39:870–874 (Landmarks in Hepatology)
Prometheus and Pandora—Together again (Reuben). 2004;39:1466–1469 (Landmarks in Hepatology)
The body has a liver (Reuben). 2004;39:1179–1181 (Landmarks in Hepatology)
Try, try, try again . . . and again (Reuben). 2004;39:1750–1753 (Landmarks in Hepatology)

Human immunodeficiency virus infection

Defining the standard of care: Randomized controlled trials for the treatment of hepatitis C in the HIV-infected person (Sulkowski). 2004;39:906–908 (Editorial)
Hepatology Highlights (Alter). 2004;39:877-879
Treatment of chronic hepatitis C in HIV/HCV-coinfection with interferon α-2b+ full-course vs. 16-week delayed ribavirin (Bräu et al). 2004;39:989–998

Human leukocyte antigen

HLA and cytokine gene polymorphisms are independently associated with responses to hepatitis B vaccination (Wang et al). 2004;39:978–988

Human leukocyte antigen class II

HLA class II genotype influences the type of liver injury in drug-induced idiosyncratic liver disease (Andrade et al). 2004;39:1603–1612

Hyaluronan

Serum laminin-2 and hyaluronan predict severe liver fibrosis in children with chronic hepatitis B (Lebensztejn et al). 2004;39:868–869 (Correspondence)

Hyperemia, cerebral

Worsening of cerebral hyperemia by the administration of terlipressin in acute liver failure with severe encephalopathy (Shawcross et al). 2004;39:471–475

Hypernatremia

The effect of hypertonic sodium chloride on intracranial pressure in patients with acute liver failure (Murphy et al). 2004;39:464–470

Hypertension, intracranial

The effect of hypertonic sodium chloride on intracranial pressure in patients with acute liver failure (Murphy et al). 2004;39:464–470

Hyperthyroidism
Severe hyperthyroidism induces mitochondria-mediated apoptosis in rat liver (Upadhyay et al). 2004;39: 1120–1130
Hypertonic saline
Hepatology Highlights (Elias). 2004;39: 579–580
Hyponatremia
Effects of dilutional hyponatremia on brain organic osmolytes and water content in patients with cirrhosis (Restuccia et al). 2004;39:1613–1622
Hepatology Highlights (Elias). 2004;39: 1467–1468
Hypothalamic dysfunction
Nonalcoholic fatty liver disease among patients with hypothalamic and pituitary dysfunction (Adams et al). 2004;39:909–914
Hypoxia/reoxygenation
Susceptibility of murine periportal hepatocytes to hypoxia-reoxygenation: Role for NO and Kupffer cell-derived oxidants (Taniai et al). 2004;39: 1544–1552
Hy's Law
Hy's Law (Reuben A). 2004;39:574–578 (Landmarks in Hepatology)

I

Immune response, cellular
Oxidative stress as a trigger for cellular immune responses in patients with alcoholic liver disease (Stewart et al). 2004;39:197–203
Immune tolerance
Covalent modification as a mechanism for the breakdown of immune tolerance to pyruvate dehydrogenase complex in the mouse (Palmer et al). 2004;39:1583–1592
Immunoglobulin A antimitochondrial antibody
Caspase induction by IgA antimitochondrial antibody: IgA-mediated biliary injury in primary biliary cirrhosis (Matsumura et al). 2004;39:1422–1429
Indian childhood cirrhosis
Immunohistochemical analysis of Mallory bodies in Wilsonian and non-Wilsonian hepatic copper toxicosis (Müller et al). 2004;39:963–969
Indocyanine green
Never say dye (Reuben). 2004;39:259–264 (Landmarks in Hepatology)
Inflammation
Altered gene expression in acute systemic inflammation detected by complete coverage of the human liver transcriptome (Coulouarn et al). 2004;39:353–364
Expression of the CXCR3 ligand I-TAC by hepatocytes in chronic hepatitis C and its correlation with hepatic inflammation (Helbig et al). 2004; 39:1221–1231
Inflammatory liver disease
Angiogenesis in chronic inflammatory liver disease (Medina et al). 2004; 39:1185–1195 (Concise Review in Mechanisms of Disease)
Inflammatory response
5'-Methylthioadenosine modulates the inflammatory response to endotoxin in mice and in rat hepatocytes (Hevia et al). 2004;39:1088–1098
Infliximab
A double-blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis (Naveau et al). 2004;39: 1396–1403
Hepatology Highlights (Elias). 2004;39: 1467–1468
Infliximab and prednisolone: Too much of a good thing? (McClain et al). 2004;39:1488–1490 (Editorial)
Injection drug users
Health-related quality of life in active injecting drug users with and without chronic hepatitis C virus infection (Dalgard et al). 2004;39:74-80
High prevalence of occult hepatitis B in Baltimore injection drug users (Torbenson et al). 2004;39:51–57
Insulin receptor
Bile acids enhance the activity of the insulin receptor and glycogen synthase in primary rodent hepatocytes (Han et al). 2004;39: 456–463
Insulin resistance
Improved prediction of fibrosis in chronic hepatitis C using measures of insulin resistance in a probability index (Sud et al). 2004;39:1242–1250
Relative contribution of iron burden, HFE mutations, and insulin resistance to fibrosis in nonalcoholic fatty liver (Bugianesi et al). 2004;39: 179–187
Relative contribution of iron burden, HFE mutations, and insulin resistance to fibrosis in nonalcoholic fatty liver (Loria et al). 2004;39: 1748 (Correspondence)
Interferon
Hepatology Highlights (Alter). 2004;39: 877–879
Interferon α
Host factors and failure of interferon-α treatment in hepatitis C virus (Gao et al). 2004;39:880–890 (Concise Review in Mechanisms of Disease)
Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B (van Zonneveld et al). 2004;39:804–810
Pegylated interferon α therapy in acute hepatitis C: Relation to hepatitis C virus–specific T cell response kinetics (Kamal et al). 2004;39:1721–1731
Short-term interferon-alfa therapy for acute hepatitis C: A randomized controlled trial (Nomura et al). 2004;39:1214–1220
Interferon α-2a
Effect of peginterferon alfa-2a on liver histology in chronic hepatitis C: A meta-analysis of individual patient data (Cammà et al). 2004;39:333–342
Hepatology Highlights (Alter). 2004;39: 877–879
Peginterferon alfa-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1 (Jeffers et al). 2004;39:1702–1708
Interferon α-2b
Treatment of chronic hepatitis C in HIV/HCV-coinfection with interferon α-2b+ full-course vs. 16-week delayed ribavirin (Bräu et al). 2004;39:989–998
Interferon γ
P-selectin suppresses hepatic inflammation and fibrosis in mice by regulating interferon γ and the IL-13 decoy receptor (Wynn et al). 2004;39:676–687
Interferon regulatory factor 3
Interleukin-1β represses MRP2 gene expression through inactivation of interferon regulatory factor 3 in HepG2 cells (Hisaeda et al). 2004; 39:1574–1582
Interferon-inducible T cell α chemoattractant (I-TAC)
Expression of the CXCR3 ligand I-TAC by hepatocytes in chronic hepatitis C and its correlation with hepatic inflammation (Helbig et al). 2004; 39:1221–1231
Interleukin
Ischemic preconditioning affects interleukin release in fatty livers of rats undergoing ischemia/reperfusion (Serafin et al). 2004;39:688–698
Interleukin 1β
Interleukin-1β represses MRP2 gene expression through inactivation of interferon regulatory factor 3 in HepG2 cells (Hisaeda et al). 2004; 39:1574–1582
Interleukin 13 receptor alpha-2
P-selectin suppresses hepatic inflammation and fibrosis in mice by regulating interferon γ and the IL-13 decoy receptor (Wynn et al). 2004;39:676–687
Interleukin 18
Interleukin 18 causes hepatic ischemia/reperfusion injury by suppressing

anti-inflammatory cytokine expression in mice (Takeuchi et al). 2004;39:699–710

Interleukin 22
Hepatology Highlights (Kaplowitz). 2004;39:1183–1184
Interleukin 22 (IL-22) plays a protective role in T cell-mediated hepatitis: IL-22 is a survival factor for hepatocytes via STAT3 activation (Radaeva et al). 2004;39:1337–1347

Intracranial hypertension
The effect of hypertonic sodium chloride on intracranial pressure in patients with acute liver failure (Murphy et al). 2004;39:464-470

Intracranial pressure
Hepatology Highlights (Elias). 2004;39: 579–580
The effect of hypertonic sodium chloride on intracranial pressure in patients with acute liver failure (Murphy et al). 2004;39:464-470

Intrahepatic cholangiocarcinoma-mass forming type
MUC4 is a novel prognostic factor of intrahepatic cholangiocarcinoma-mass forming type (Shibahara et al). 2004;39:220–229

Intrapulmonary vascular dilatations
Evolution of intrapulmonary vascular dilatations in cirrhosis (França et al). 2004;39:1461 (Correspondence)

Iron burden
Relative contribution of iron burden, HFE mutations, and insulin resistance to fibrosis in nonalcoholic fatty liver (Bugianesi et al). 2004;39: 179–187
Relative contribution of iron burden, HFE mutations, and insulin resistance to fibrosis in nonalcoholic fatty liver (Loria et al). 2004;39: 1748 (Correspondence)

Iron-regulated gene 1
Increased duodenal expression of divalent metal transporter 1 and iron-regulated gene 1 in cirrhosis (Stuart et al). 2004;39:492–499

Ischemia/reperfusion (I/R) injury
Blockade of receptor for advanced glycation end product (RAGE) attenuates ischemia and reperfusion injury to the liver in mice (Zeng et al). 2004;39:422–432
Dual role of tumor necrosis factor-α in hepatic ischemia-reperfusion injury: Studies in tumor necrosis factor-α gene knockout mice (Teoh et al). 2004;39:412–421
Improvement of rat liver graft quality by pifithrin-α-mediated inhibition of hepatocyte necrapoptosis (El-Gibaly et al). 2004;39:1553–1562
Interleukin 18 causes hepatic ischemia/reperfusion injury by suppressing anti-inflammatory cytokine expression in mice (Takeuchi et al). 2004;39:699–710
Ischemic preconditioning affects interleukin release in fatty livers of rats undergoing ischemia/reperfusion (Serafin et al). 2004;39:688–698
Nitric oxide protects rat hepatocytes against reperfusion injury mediated by the mitochondrial permeability transition (Kim et al). 2004;39:1533–1543
Sinusoidal endothelial cell and hepatocyte death following cold ischemia-warm reperfusion of the rat liver (Huet et al). 2004;39:1110–1119

Itching
Old scratch (Reuben). 2004;39:870–874 (Landmarks in Hepatology)

J

Jagged-1
Expression of Notch-1 and its ligand Jagged-1 in rat liver during liver regeneration (Köhler et al). 2004;39: 1056–1065

Jo2
Hepatology Highlights (Kaplowitz). 2004;39:1183–1184

K

Kupffer cells
Kupffer cells alter organic anion transport through multidrug resistance protein 2 in the post-cold ischemic rat liver (Kudo et al). 2004; 39:1099–1109
Kupffer cells required for high affinity peptide-induced deletion, not retention, of activated CD8+ T cells by mouse liver (Kuniyasu et al). 2004;39:1017–1027
Susceptibility of murine periportal hepatocytes to hypoxia-reoxygenation: Role for NO and Kupffer cell-derived oxidants (Taniai et al). 2004;39: 1544–1552

L

Laminin-2
Serum laminin-2 and hyaluronan predict severe liver fibrosis in children with chronic hepatitis B (Lebensztejn et al). 2004;39:868–869 (Correspondence)

Lamivudine
Identification of HBV DNA sequences that are predictive of responses to lamivudine therapy (Cianco et al). 2004;39:64–73
Pre-emptive use of lamivudine in bone marrow transplantation with chronic hepatitis B virus infection (Deschênes and Laneuville). 2004; 39:867 (Correspondence)
Pre-emptive use of lamivudine in bone marrow transplantation with chronic hepatitis B virus infection (Lau et al). 2004;39:867–868 (Reply)
Viral features of lamivudine resistant hepatitis genotypes A and D (Zöllner et al). 2004;39:42–50

Liver abscess
Treatment of pyogenic liver abscess: Prospective randomized comparison of catheter drainage and needle aspiration (Yu et al). 2004;39:932–938

Liver biopsy
Does noninvasive staging of fibrosis challenge liver biopsy as a gold standard in chronic hepatitis C? (Berg et al). 2004;39:1462–1464 (Correspondence)

Liver cancer. ***See also*** **Hepatocellular carcinoma**
Impact of cytomorphological detection of circulating tumor cells in patients with liver cancer (Vona et al). 2004; 39:792–797

Liver disease
Endogenous ursodeoxycholic acid and cholic acid in liver disease due to cystic fibrosis (Smith et al). 2004;39: 1673–1682
Gut flora-based therapy in liver disease? The liver cares about the gut (Solga and Diehl). 2004;39:1198–1201 (Editorial)
Liver disease research funding (Hoofnagle JH). 2004;39:279 (This Month From the NIH)
Old scratch (Reuben). 2004;39:870–874 (Landmarks in Hepatology)
Recombinant activated factor VII (rFVIIa) as a hemostatic agent in liver disease: A break from convention in need of controlled trials (Caldwell et al). 2004; 39:592–598
Screening in liver disease: Report of an AASLD clinical workshop (Adams et al). 2004;39:1205–1213 (Special Article)

Liver enzyme levels
Body fat distribution, relative weight, and liver enzyme levels: A population-based study (Stranges et al). 2004;39:754–763

Liver fibrosis
Does noninvasive staging of fibrosis challenge liver biopsy as a gold standard in chronic hepatitis C? (Berg et al). 2004;39:1462–1464 (Correspondence)
Improved prediction of fibrosis in chronic hepatitis C using measures of insulin resistance in a probability index (Sud et al). 2004;39:1242–1250

PAR_1 antagonism protects against experimental liver fibrosis. Role of proteinase receptors in stellate cell activation (Fiorucci et al). 2004;39: 365–375
Prediction of liver fibrosis in patients with features of the metabolic syndrome regardless of alcohol consumption (Lainé et al). 2004;39: 1639–1646
Progressive fibrosis during corticosteroid therapy of autoimmune hepatitis (Czaja and Carpenter). 2004;39: 1631–1638
Relative contribution of iron burden, HFE mutations, and insulin resistance to fibrosis in nonalcoholic fatty liver (Bugianesi et al). 2004;39: 179–187
Relative contribution of iron burden, HFE mutations, and insulin resistance to fibrosis in nonalcoholic fatty liver (Loria et al). 2004;39: 1748 (Correspondence)
Reversal of liver fibrosis in aryl hydrocarbon receptor *null* mice by dietary vitamin A depletion (Andreola et al). 2004;39:157–166
Risks of a range of alcohol intake on hepatitis C-related fibrosis (Monto et al). 2004;39:826–834
Serum laminin-2 and hyaluronan predict severe liver fibrosis in children with chronic hepatitis B (Lebensztejn et al). 2004;39:868–869 (Correspondence)
The predictive value of Fibrotest vs. APRI for the diagnosis of fibrosis in chronic hepatitis C (Le Calvez et al). 2004;39:862–863 (Correspondence)
The predictive value of Fibrotest vs. APRI for the diagnosis of fibrosis in chronic hepatitis C (Lok and Wai). 2004;39:863 (Reply)
Uric acid levels and liver fibrosis in nonalcoholic fatty liver disease (Bugianesi and Marchesini). 2004; 39:1749 (Correspondence)

Liver grafts
Improvement of rat liver graft quality by pifithrin-α-mediated inhibition of hepatocyte necrapoptosis (El-Gibaly et al). 2004;39:1553–1562
Patient and graft survival after liver transplantation for hereditary hemochromatosis: Implications for pathogenesis (Crawford et al). 2004; 39:1655–1662

Liver regeneration
Activation of NF-κB and STAT3 in rat oval cells during 2-acetylaminofluorene/partial hepatectomy-induced liver regeneration (Sánchez A et al). 2004;39:376–385
Effect of murine liver cell proliferation on herpes viral behavior: Implications for oncolytic viral therapy (Delman et al). 2004;39: 1525–1532
Expression of Notch-1 and its ligand Jagged-1 in rat liver during liver regeneration (Köhler et al). 2004;39: 1056–1065
Extracellular ATP activates c-jun N-terminal kinase signaling and cell cycle progression in hepatocytes (Thevananther et al). 2004;39:393–402
Liver regeneration and repair: Hepatocytes, progenitor cells, and stem cells (Fausto). 2004;39:1477–1487 (Science Frontier)
Prometheus and Pandora—Together again (Reuben). 2004;39:1466–1469 (Landmarks in Hepatology)
Uncoupling protein-2 deficiency promotes oxidant stress and delays liver regeneration in mice (Horimoto M et al). 2004;39:386–392

Liver retransplantation
Hepatology Highlights (Alter). 2004;39: 2-4
Prediction of survival after liver retransplantation for late graft failure based on preoperative prognostic scores (Yao et al). 2004; 39:230–238

Liver transcriptome
Altered gene expression in acute systemic inflammation detected by complete coverage of the human liver transcriptome (Coulouarn et al). 2004;39:353–364

Liver transplantation
Hepatology Highlights (Alter). 2004;39:2–4
Immortalized $p19^{ARF}$ null hepatocytes restore liver injury and generate hepatic progenitors after transplantation (Mikula et al). 2004; 39:628–634
Improvement of rat liver graft quality by pifithrin-α-mediated inhibition of hepatocyte necrapoptosis (El-Gibaly et al). 2004;39:1553–1562
Liver transplantation: An "in vivo" model for the pathophysiology of hemochromatosis? (Kowdley). 2004; 39:1495–1498 (Editorial)
MELD score as a predictor of pretransplant and posttransplant survival in OPTN/UNOS Status 1 patients (Kremers et al). 2004;39: 764–769
Patient and graft survival after liver transplantation for hereditary hemochromatosis: Implications for pathogenesis (Crawford et al). 2004; 39:1655–1662
Prediction of survival after liver retransplantation for late graft failure based on preoperative prognostic scores (Yao et al). 2004; 39:230–238
Prometheus and Pandora—Together again (Reuben). 2004;39:1466–1469 (Landmarks in Hepatology)

***Liverpool* nylon array**
Altered gene expression in acute systemic inflammation detected by complete coverage of the human liver transcriptome (Coulouarn et al). 2004;39:353–364

***LiverTools* database**
Altered gene expression in acute systemic inflammation detected by complete coverage of the human liver transcriptome (Coulouarn et al). 2004;39:353–364

M

Mallory bodies
Hepatology Highlights (Elias). 2004;39: 1467–1468
Immunohistochemical analysis of Mallory bodies in Wilsonian and non-Wilsonian hepatic copper toxicosis (Müller et al). 2004;39: 963–969

Megamitochondria with crystalline inclusions
The zonal distribution of megamitochondria with crystalline inclusions in nonalcoholic steatohepatitis (Le et al). 2004;39: 1430–1436

Membrane polarity
The maintenance and generation of membrane polarity in hepatocytes (Wang and Boyer). 2004;39:892–899 (Science Frontier)

Menadione
CYP2E1 overexpression alters hepatocyte death from menadione and fatty acids by activation of ERK1/2 signaling (Schattenberg et al). 2004; 39:444–455

Metabolic syndrome
Prediction of liver fibrosis in patients with features of the metabolic syndrome regardless of alcohol consumption (Lainé et al). 2004;39: 1639–1646

Metastatic colorectal cancer
Hepatic expression of *ANG2* RNA in metastatic colorectal cancer (Ogawa et al). 2004;39:528–539

Methionine metabolites
Hepatic transmethylation reactions in micropigs with alcoholic liver disease (Villanueva and Halsted). 2004;39:1308–1315

Methotrexate
A randomized controlled trial of colchicine plus ursodiol versus

methotrexate plus ursodiol in primary biliary cirrhosis: Ten-year results (Kaplan et al). 2004;39:915–923

5'-Methylthioadenosine

5'-Methylthioadenosine modulates the inflammatory response to endotoxin in mice and in rat hepatocytes (Hevia et al). 2004;39:1088–1098

Microanatomy

Nomenclature of the finer branches of the biliary tree: Canals, ductules, and ductular reactions in human livers (Roskams et al). 2004;39:1739–1745 (Special Article)

Minimal dataset approach

Identification of discriminators of hepatoma by gene expression profiling using a minimal dataset approach (Neo et al). 2004;39:944–953

Minimal hepatic encephalopathy

Driving under the influence of minimal hepatic encephalopathy (Córdoba and Lucke). 2004;39:599–601 (Editorial)

Minimal hepatic encephalopathy impairs fitness to drive (Wein et al). 2004;39:739–745

Prognostic value of altered oral glutamine challenge in patients with minimal hepatic encephalopathy (Romero-Gómez et al). 2004;39:939–943

Synbiotic modulation of gut flora: Effect on minimal hepatic encephalopathy in patients with cirrhosis (Liu et al). 2004;39:1448–1456

Mitochondria

Nitric oxide protects rat hepatocytes against reperfusion injury mediated by the mitochondrial permeability transition (Kim et al). 2004;39:1533–1543

Severe hyperthyroidism induces mitochondria-mediated apoptosis in rat liver (Upadhyay et al). 2004;39:1120–1130

Mitochondrial DNA (mtDNA)

Depletion of mitochondrial DNA in liver under antiretroviral therapy with didanosine, stavudine, or zalcitabine (Walker et al). 2004;39:311–317

Mitogen-activated protein kinase

CYP2E1 overexpression alters hepatocyte death from menadione and fatty acids by activation of ERK1/2 signaling (Schattenberg et al). 2004;39:444–455

Model for End-Stage Liver Disease (MELD)

MELD score as a predictor of pretransplant and posttransplant survival in OPTN/UNOS Status 1 patients (Kremers et al). 2004;39:764–769

Prediction of survival after liver retransplantation for late graft failure based on preoperative prognostic scores (Yao et al). 2004;39:230–238

Molecular adsorbent recirculation system

In vitro comparison of the molecular adsorbent recirculation system (MARS) and single-pass albumin dialysis (SPAD) (Sauer et al). 2004;39:1415–1421

Monocytes

Frequent compartmentalization of hepatitis C virus variants in circulating B cells and monocytes (Ducoulombier et al). 2004;39:817–825

Mucin (MUC)4

MUC4 is a novel prognostic factor of intrahepatic cholangiocarcinoma-mass forming type (Shibahara et al). 2004;39:220–229

Multidrug resistance gene 2

Hepatology Highlights (Kaplowitz). 2004;39:271–272

Spontaneous cholecysto- and hepatolithiasis in *Mdr2*$^{-/-}$ mice: A model for low phospholipid-associated cholelithiasis (Lammert et al). 2004;39:117–128

Multidrug resistance gene 3

BSEP and *MDR3* haplotype structure in healthy Caucasians, primary biliary cirrhosis and primary sclerosing cholangitis (Pauli-Magnus et al). 2004;39:779–791

Multidrug resistance protein 2

Genipin enhances Mrp2 (Abcc2)-mediated bile formation and organic anion transport in rat liver (Shoda et al). 2004;39:167–178

Interleukin-1β represses MRP2 gene expression through inactivation of interferon regulatory factor 3 in HepG2 cells (Hisaeda et al). 2004;39:1574–1582

Kupffer cells alter organic anion transport through multidrug resistance protein 2 in the post-cold ischemic rat liver (Kudo et al). 2004;39:1099–1109

Myeloid cell leukemia-1

Hepatocyte growth factor induces Mcl-1 in primary human hepatocytes and inhibits CD95-mediated apoptosis via Akt (Schulze-Bergkamen et al). 2004;39:645–654

N

National Institutes of Health (NIH)

Biliary Atresia Research Consortium (BARC) (Hoofnagle). 2004;39:891 (This Month From the NIH)

Hepatobiliary Pathophysiology study section (Hoofnagle). 2004;39:1476 (This Month From the NIH)

Liver disease research funding (Hoofnagle JH). 2004;39:279 (This Month From the NIH)

Natural killer cells

Liver NK cells expressing TRAIL are toxic against self hepatocytes in mice (Ochi et al). 2004;39:1326–1336

Murine hepatocyte cell lines promote expansion and differentiation of NK cells from stem cell precursors (Bordoni et al). 2004;39:1508–1516

Necrapoptosis

Improvement of rat liver graft quality by pifithrin-α-mediated inhibition of hepatocyte necrapoptosis (El-Gibaly et al). 2004;39:1553–1562

Needle aspiration

Treatment of pyogenic liver abscess: Prospective randomized comparison of catheter drainage and needle aspiration (Yu et al). 2004;39:932–938

Nitric oxide

Nitric oxide biology and the liver: Report of an AASLD research workshop (Rockey and Shah). 2004;39:250–257 (Special Article)

Nitric oxide protects rat hepatocytes against reperfusion injury mediated by the mitochondrial permeability transition (Kim et al). 2004;39:1533–1543

Susceptibility of murine periportal hepatocytes to hypoxia-reoxygenation: Role for NO and Kupffer cell-derived oxidants (Taniai et al). 2004;39:1544–1552

N-myc

Integration of woodchuck hepatitis and N-myc rearrangement determine size and histologic grade of hepatic tumors (Jacob et al). 2004;39:1008–1016

Nomenclature

Nomenclature of the finer branches of the biliary tree: Canals, ductules, and ductular reactions in human livers (Roskams et al). 2004;39:1739–1745 (Special Article)

Nonalcoholic fatty liver disease

High sensitivity C-reactive protein values do not reliably predict the severity of histological change in NAFLD (Hui et al). 2004;39:1464 (Correspondence)

High sensitivity C-reactive protein values do not reliably predict the severity of histological change in NAFLD (Wai and Lok). 2004;39:1464–1465 (Reply)

Nonalcoholic fatty liver disease: Improvement in liver histological analysis with weight loss (Dixon et al). 2004;39:1647–1654

Nonalcoholic fatty liver disease among patients with hypothalamic and pituitary dysfunction (Adams et al). 2004;39:909–914
Relative contribution of iron burden, HFE mutations, and insulin resistance to fibrosis in nonalcoholic fatty liver (Bugianesi et al). 2004;39: 179–187
Relative contribution of iron burden, HFE mutations, and insulin resistance to fibrosis in nonalcoholic fatty liver (Loria et al). 2004;39: 1748 (Correspondence)
Uric acid levels and liver fibrosis in nonalcoholic fatty liver disease (Bugianesi and Marchesini). 2004; 39:1749 (Correspondence)

Nonalcoholic steatohepatitis
A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis (Promrat et al). 2004;39:188–196
Administration of the potent PPARα agonist, Wy-14,643, reverses nutritional fibrosis and steatohepatitis in mice (Ip et al). 2004;39:1291–1301
DDB treatment of patients with chronic hepatitis (Huber et al). 2004;39: 1732–1733 (Concise Communication)
Hepatology Highlights (Elias). 2004;39: 579–580, 1467–1468
More on vitamin E therapy (McClain et al). 2004;39:569–570 (Reply)
More on vitamin E therapy (Vajro et al). 2004;39:569 (Correspondence)
Negative trials in nonalcoholic steatohepatitis: Why they happen and what they teach us (Clark and Brancati). 2004;39:602–603 (Editorial)
Pivotal role of superoxide anion and beneficial effect of antioxidant molecules in murine steatohepatitis (Laurent et al). 2004;39:1282–1290
The zonal distribution of megamitochondria with crystalline inclusions in nonalcoholic steatohepatitis (Le et al). 2004;39: 1430–1436
Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: Results of a randomized trial (Lindor et al). 2004;39:770–778
Vitamin E therapy in patients with NASH (Yoneda et al). 2004;39:568 (Correspondence)

Notch-1
Expression of Notch-1 and its ligand Jagged-1 in rat liver during liver regeneration (Köhler et al). 2004;39: 1056–1065

Nuclear factor-erythroid 2-related factors (Nrfs)
Activation of hepatic Nrf2 *in vivo* by acetaminophen in CD-1 mice (Goldring et al). 2004;39:1271–1281
Hepatology Highlights (Kaplowitz). 2004;39:1183–1184

Nuclear factor-kappa B (NF-κB)
Activation of NF-κB and STAT3 in rat oval cells during 2-acetylaminofluorene/partial hepatectomy-induced liver regeneration (Sánchez A et al). 2004;39:376–385

Nucleocapsids
Interfering with capsid formation: A practicable antiviral strategy against hepatitis B virus? (Deres et al). 2004;39:838-840 (Hepatology *Elsewhere*)

Number connection test
Gut flora-based therapy in liver disease? The liver cares about the gut (Solga and Diehl). 2004;39:1198–1201 (Editorial)

Nutritional fibrosis
Administration of the potent PPARα agonist, Wy-14,643, reverses nutritional fibrosis and steatohepatitis in mice (Ip et al). 2004;39:1291–1301

NV1020
Effect of murine liver cell proliferation on herpes viral behavior: Implications for oncolytic viral therapy (Delman et al). 2004;39: 1525–1532

O

Obesity
Do polyunsaturated fatty acids ameliorate hepatic steatosis in obese mice by SREPB-1 suppression or by correcting essential fatty acid deficiency (Alwayn et al). 2004;39: 1176–1177 (Correspondence)
Do polyunsaturated fatty acids ameliorate hepatic steatosis in obese mice by SREPB-1 suppression or by correcting essential fatty acid deficiency (Yahagi et al). 2004;39: 1177–1178 (Reply)

Obstructive cholestasis
Down-regulation of the organic cation transporter 1 of rat liver in obstructive cholestasis (Denk et al). 2004;39:1388–1395

Oncolytic viral therapy
Effect of murine liver cell proliferation on herpes viral behavior: Implications for oncolytic viral therapy (Delman et al). 2004;39: 1525–1532

Oncostatin M receptor
Hepatocyte proliferation and tissue remodeling is impaired after liver injury in oncostatin M receptor knockout mice (Nakamura et al). 2004;39:635–644

Oral contraceptives
Try, try, try again . . . and again (Reuben). 2004;39:1750–1753 (Landmarks in Hepatology)

Oral glutamine challenge
Prognostic value of altered oral glutamine challenge in patients with minimal hepatic encephalopathy (Romero-Gómez et al). 2004;39:939–943

Organ allocation
Prediction of survival after liver retransplantation for late graft failure based on preoperative prognostic scores (Yao et al). 2004; 39:230–238

Organic anion transport
Genipin enhances Mrp2 (Abcc2)-mediated bile formation and organic anion transport in rat liver (Shoda et al). 2004;39:167–178
Kupffer cells alter organic anion transport through multidrug resistance protein 2 in the post-cold ischemic rat liver (Kudo et al). 2004; 39:1099–1109

Organic cation transporter 1
Down-regulation of the organic cation transporter 1 of rat liver in obstructive cholestasis (Denk et al). 2004;39:1388–1395

Orthotopic liver transplantation. *See also* Liver transplantation
Prediction of survival after liver retransplantation for late graft failure based on preoperative prognostic scores (Yao et al). 2004; 39:230–238

Oval cells
2-Acetylaminofluorene dose-dependent differentiation of oval cells into hepatocytes: Confocal and electron microscopic studies (Paku et al). 2004;39:1358–1366
Activation of NF-κB and STAT3 in rat oval cells during 2-acetylaminofluorene/partial hepatectomy-induced liver regeneration (Sánchez A et al). 2004;39:376–385
Oval cells compensate for damage and replicative senescence of mature hepatocytes in mice with fatty liver disease (Yang et al). 2004;39:403–411

Oxidant stress
Uncoupling protein-2 deficiency promotes oxidant stress and delays liver regeneration in mice (Horimoto M et al). 2004;39:386–392

Oxidative damage
Oxidative damage is increased in human liver tissue adjacent to hepatocellular carcinoma (Jüngst et al). 2004;39: 1663–1672

Oxidative stress
Oxidative stress as a trigger for cellular immune responses in patients with

alcoholic liver disease (Stewart et al). 2004;39:197–203

2-Oxoglutarate
A role for the 2-oxoglutarate carrier in glutathione transport into hepatocyte mitochondria? (Estrela et al). 2004;39:570–571 (Correspondence)
A role for the 2-oxoglutarate carrier in glutathione transport into hepatocyte mitochondria? (Fernández and Garcia-Ruiz). 2004;39:571–572 (Reply)

Oxysterols
Oxysterols induce cyclooxygenase-2 expression in cholangiocytes: Implications for biliary tract carcinogenesis (Yoon et al). 2004;39:732–738

P

p19^{ARF}
Immortalized p19^{ARF} null hepatocytes restore liver injury and generate hepatic progenitors after transplantation (Mikula et al). 2004;39:628-634

p21
HBsAg and *HBx* knocked into the *p21* locus causes hepatocellular carcinoma in mice (Wang et al). 2004;39:318–324

Pancreas
Plasticity in the adult rat pancreas: Transdifferentiation of exocrine to hepatocytelike cells in primary culture (Lardon et al). 2004;39:1499–1507

Patient relations
Hepatitis C virus-infected patients report communication problems with physicians (Zickmund et al). 2004;39:999–1007

Paumgartner, Gustav
Never say dye (Reuben). 2004;39:259–264 (Landmarks in Hepatology)

Pediatric fulminant hepatic failure
Pediatric fulminant hepatic failure in endemic areas of hepatitis B infection: 15 years after universal hepatitis B vaccination (Chen et al). 2004;39:58–63

Pediatrics
Long-term outcome of hepatitis C in children (Bortolotti et al). 2004;39:1462 (Correspondence)
Serum laminin-2 and hyaluronan predict severe liver fibrosis in children with chronic hepatitis B (Lebensztejn et al). 2004;39:868–869 (Correspondence)

Periportal hepatocytes
Susceptibility of murine periportal hepatocytes to hypoxia-reoxygenation: Role for NO and Kupffer cell-derived oxidants (Taniai et al). 2004;39:1544–1552

Peroxisome proliferator-activated receptor-α
Administration of the potent PPARα agonist, Wy-14,643, reverses nutritional fibrosis and steatohepatitis in mice (Ip et al). 2004;39:1291–1301

Phospholipids
Spontaneous cholecysto- and hepatolithiasis in *Mdr2*$^{-/-}$ mice: A model for low phospholipid-associated cholelithiasis (Lammert et al). 2004;39:117–128

Physicians
Hepatitis C virus-infected patients report communication problems with physicians (Zickmund et al). 2004;39:999–1007

Pifithrin-α
Improvement of rat liver graft quality by pifithrin-α-mediated inhibition of hepatocyte necrapoptosis (El-Gibaly et al). 2004;39:1553–1562

Pioglitazone
A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis (Promrat et al). 2004;39:188-196

Pituitary dysfunction
Nonalcoholic fatty liver disease among patients with hypothalamic and pituitary dysfunction (Adams et al). 2004;39:909–914

Plasticity
Plasticity in the adult rat pancreas: Transdifferentiation of exocrine to hepatocytelike cells in primary culture (Lardon et al). 2004;39:1499–1507

Polycystic liver disease
Abnormal hepatocystin caused by truncating *PRKCSH* mutations leads to autosomal dominant polycystic liver disease (Drenth et al). 2004;39:924–931

Polyunsaturated fatty acids
Dietary n–3 polyunsaturated fatty acids decrease hepatic triglycerides in Fischer 344 rats (Levy et al). 2004;39:608–616
Do polyunsaturated fatty acids ameliorate hepatic steatosis in obese mice by SREPB-1 suppression or by correcting essential fatty acid deficiency (Alwayn et al). 2004;39:1176–1177 (Correspondence)
Do polyunsaturated fatty acids ameliorate hepatic steatosis in obese mice by SREPB-1 suppression or by correcting essential fatty acid deficiency (Yahagi et al). 2004;39:1177–1178 (Reply)
Hepatology Highlights (Kaplowitz). 2004;39:271–272

Portal pressure
Sustained rise of portal pressure after sclerotherapy, but not band ligation, in acute variceal bleeding in cirrhosis (Avgerinos et al). 2004;39:1623–1630

Portal pressure measurement
Changing clinical practice with measurements of portal pressure (Boyer). 2004;39:283–285 (Perspectives in Clinical Hepatology)
Targeting portal pressure measurements: A critical reappraisal (Thalheimer et al). 2004;39:286–290 (Perspectives in Clinical Hepatology)

Porto-central gradients
Stereological measurement of porto-central gradients in gene expression in mouse liver (Ruijter JM et al). 2004;39:343–352

Portosystemic shunting
Determinants of survival and the effect of portosystemic shunting in patients with Budd-Chiari syndrome (Murad et al). 2004;39:500–508
Hepatology Highlights (Elias). 2004;39:579–580

Practice guidelines
Chronic hepatitis B: Update of recommendations (Lok and McMahon). 2004;39:857–861 (AASLD Practice Guideline)
Diagnosis, management, and treatment of hepatitis C (Strader et al). 2004;39:1147–1171 (AASLD Practice Guideline)
Management of adult patients with ascites due to cirrhosis (Runyon). 2004;39:841–856 (AASLD Practice Guideline)

Prednisolone
A double-blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis (Naveau et al). 2004;39:1396–1403
Infliximab and prednisolone: Too much of a good thing? (McClain et al). 2004;39:1488–1490 (Editorial)

Primary biliary cirrhosis. ***See also*** **Secondary biliary cirrhosis**
A randomized controlled trial of colchicine plus ursodiol versus methotrexate plus ursodiol in primary biliary cirrhosis: Ten-year results (Kaplan et al). 2004;39:915–923
BSEP and *MDR3* haplotype structure in healthy Caucasians, primary biliary cirrhosis and primary sclerosing cholangitis (Pauli-Magnus et al). 2004;39:779–791
Caspase induction by IgA antimitochondrial antibody: IgA-mediated biliary injury in primary biliary cirrhosis (Matsumura et al). 2004;39:1422–1429
Cloning the human betaretrovirus proviral genome from patients with

primary biliary cirrhosis (Xu et al). 2004;39:151–156
Covalent modification as a mechanism for the breakdown of immune tolerance to pyruvate dehydrogenase complex in the mouse (Palmer et al). 2004;39:1583–1592
Hepatology Highlights (Elias). 2004;39: 579–580, 1467–1468
Old scratch (Reuben). 2004;39:870–874 (Landmarks in Hepatology)
Tamoxifen in treatment of primary biliary cirrhosis (Invernizzi et al). 2004;39:1175–1176 (Correspondence)
Trials in primary biliary cirrhosis: Need for the right drugs at the right time (Poupon). 2004;39:900–902 (Editorial)
Unusual suspects in primary biliary cirrhosis (Vergani et al). 2004;39: 38–41 (Editorial)

Primary sclerosing cholangitis
BSEP and *MDR3* haplotype structure in healthy Caucasians, primary biliary cirrhosis and primary sclerosing cholangitis (Pauli-Magnus et al). 2004;39:779–791
Hepatology Highlights (Elias). 2004;39: 579–580
Prevalence and predictors of esophageal varices in patients with primary sclerosing cholangitis (Zein et al). 2004;39:204–210

Programmed cell death
Chronic liver disease in murine hereditary tyrosinemia type 1 induces resistance to cell death (Vogel et al). 2004;39:433–443

Protein kinase C substrate 80K-H *(PRKCSH)*
Abnormal hepatocystin caused by truncating *PRKCSH* mutations leads to autosomal dominant polycystic liver disease (Drenth et al). 2004;39: 924–931

Proteinase receptors
PAR_1 antagonism protects against experimental liver fibrosis. Role of proteinase receptors in stellate cell activation (Fiorucci et al). 2004;39: 365–375

Proteinase-activated receptor 1 (PAR_1)
PAR_1 antagonism protects against experimental liver fibrosis. Role of proteinase receptors in stellate cell activation (Fiorucci et al). 2004;39: 365–375

Proto-oncogenes
Hepatology Highlights (Alter). 2004;39: 877–879

Pruritus
Old scratch (Reuben). 2004;39:870–874 (Landmarks in Hepatology)
Treatment of the pruritus of cholestasis: From unbearable lightness to substance (Terg et al). 2004;39:1457–1460 (Hepatology *Elsewhere*)

P-selectin
P-selectin suppresses hepatic inflammation and fibrosis in mice by regulating interferon γ and the IL-13 decoy receptor (Wynn et al). 2004;39:676–687

Public opinion
The body has a liver (Reuben). 2004;39: 1179–1181 (Landmarks in Hepatology)

Pyogenic liver abscess
Treatment of pyogenic liver abscess: Prospective randomized comparison of catheter drainage and needle aspiration (Yu et al). 2004;39:932–938

Pyruvate dehydrogenase complex
Covalent modification as a mechanism for the breakdown of immune tolerance to pyruvate dehydrogenase complex in the mouse (Palmer et al). 2004;39:1583–1592

Q

Quality of life, health-related
Health-related quality of life in active injecting drug users with and without chronic hepatitis C virus infection (Dalgard et al). 2004;39: 74–80
The patient's perspective in hepatitis C (Fontana and Kronfol). 2004;39: 903-905 (Editorial)

R

Reactive oxygen species
Hepatology Highlights (Alter). 2004;39: 2–4
Pivotal role of superoxide anion and beneficial effect of antioxidant molecules in murine steatohepatitis (Laurent et al). 2004;39:1282–1290
Reactive oxygen species suppress hepatitis C virus RNA replication in human hepatoma cells (Choi et al). 2004;39:81–89
Uncoupling protein-2 deficiency promotes oxidant stress and delays liver regeneration in mice (Horimoto M et al). 2004;39:386–392

Receptor for advanced glycation end product
Blockade of receptor for advanced glycation end product (RAGE) attenuates ischemia and reperfusion injury to the liver in mice (Zeng et al). 2004;39:422–432

Recurrent hepatitis C virus infection
Hepatology Highlights (Alter). 2004;39: 2–4

Research funding
Federally funded research in hepatology (Heathcote). 2004;39:20 (News from Canada)
Liver disease research funding (Hoofnagle JH). 2004;39:279 (This Month From the NIH)

Retinoic acid
Differential modulation of rat hepatic stellate phenotype by natural and synthetic retinoids (Hellemans et al). 2004;39:97–108

Retinoic acid receptor
Differential modulation of rat hepatic stellate phenotype by natural and synthetic retinoids (Hellemans et al). 2004;39:97–108

Retinoid X receptors
Differential modulation of rat hepatic stellate phenotype by natural and synthetic retinoids (Hellemans et al). 2004;39:97-108

Ribavirin
Hepatology Highlights (Alter). 2004;39: 877–879
Low membrane protein sulfhydrils but not glucose-6-phosphate dehydrogenase deficiency predict ribavirin-induced hemolysis in hepatitis C (Grattagliano et al). 2004;39:1251–1258
Peginterferon alfa-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1 (Jeffers et al). 2004;39:1702–1708
Treatment of chronic hepatitis C in HIV/HCV-coinfection with interferon α-2b+ full-course vs. 16-week delayed ribavirin (Bräu et al). 2004;39:989–998

Ribosomal protein L36a gene
Over-expression of the ribosomal protein L36a gene Is associated with cellular proliferation in hepatocellular carcinoma (Kim et al). 2004;39: 129–138

S

Saline, hypertonic
Hepatology Highlights (Elias). 2004;39: 579–580

Salivary gland
Flow cytometric isolation of endodermal progenitors from mouse salivary gland differentiate into hepatic and pancreatic lineages (Hisatomi et al). 2004;39:667–675

Sclerotherapy
Sustained rise of portal pressure after sclerotherapy, but not band ligation, in acute variceal bleeding in cirrhosis (Avgerinos et al). 2004;39:1623–1630

Screening
Screening in liver disease: Report of an AASLD clinical workshop (Adams et al). 2004;39:1205–1213 (Special Article)

Second mitochondria-derived activator of caspases
An oncolytic adenoviral vector of Smac increases antitumor activity of TRAIL against HCC in human cells and in mice (Pei et al). 2004;39:1376–1387
Secondary biliary cirrhosis
Ursodeoxycholic acid protects against secondary biliary cirrhosis in rats by preventing mitochondrial oxidative stress (Serviddio et al). 2004;39:711–720
Serum bacterial DNA
A sequential study of serum bacterial DNA in patients with advanced cirrhosis and ascites (Francés et al). 2004;39:484–491, 1470 (Correction)
Serum carbohydrate-deficient transferrin/transferrin ratio
Prediction of liver fibrosis in patients with features of the metabolic syndrome regardless of alcohol consumption (Lainé et al). 2004;39:1639–1646
Serum hyaluronan
Serum laminin-2 and hyaluronan predict severe liver fibrosis in children with chronic hepatitis B (Lebensztejn et al). 2004;39:868–869 (Correspondence)
Serum hyaluronate
Prediction of liver fibrosis in patients with features of the metabolic syndrome regardless of alcohol consumption (Lainé et al). 2004;39:1639–1646
Serum laminin-2
Serum laminin-2 and hyaluronan predict severe liver fibrosis in children with chronic hepatitis B (Lebensztejn et al). 2004;39:868–869 (Correspondence)
Severe acute respiratory syndrome (SARS)
Hepatology Highlights (Alter). 2004;39:877–879
SARS-associated viral hepatitis caused by a novel coronavirus: Report of three cases (Chau et al). 2004;39:302–310
Severe acute respiratory syndrome and the liver (Humar et al). 2004;39:291–294 (Editorial)
Signal transducer and activator of transcription 3 (STAT3)
Activation of NF-κB and STAT3 in rat oval cells during 2-acetylaminofluorene/partial hepatectomy-induced liver regeneration (Sánchez A et al). 2004;39:376–385
Interleukin 22 (IL-22) plays a protective role in T cell-mediated hepatitis: IL-22 is a survival factor for hepatocytes via STAT3 activation (Radaeva et al). 2004;39:1337–1347
Single-pass albumin dialysis
In vitro comparison of the molecular adsorbent recirculation system (MARS) and single-pass albumin dialysis (SPAD) (Sauer et al). 2004;39:1415–1421
Sinusoidal endothelial cells
Sinusoidal endothelial cell and hepatocyte death following cold ischemia-warm reperfusion of the rat liver (Huet et al). 2004;39:1110–1119
Sister of P-glycoprotein (spgp)
Hepatology Highlights (Kaplowitz). 2004;39:271–272
Sodium chloride
The effect of hypertonic sodium chloride on intracranial pressure in patients with acute liver failure (Murphy et al). 2004;39:464–470
Spain
News from Spain (Rodés). 2004;39:591
Stavudine
Depletion of mitochondrial DNA in liver under antiretroviral therapy with didanosine, stavudine, or zalcitabine (Walker et al). 2004;39:311–317
Steatohepatitis, nonalcoholic
A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis (Promrat et al). 2004;39:188–196
Administration of the potent PPARα agonist, Wy-14,643, reverses nutritional fibrosis and steatohepatitis in mice (Ip et al). 2004;39:1291–1301
DDB treatment of patients with chronic hepatitis (Huber et al). 2004;39:1732–1733 (Concise Communication)
Hepatology Highlights (Elias). 2004;39:579–580, 1467–1468
More on vitamin E therapy (McClain et al). 2004;39:569–570 (Reply)
More on vitamin E therapy (Vajro et al). 2004;39:569 (Correspondence)
Negative trials in nonalcoholic steatohepatitis: Why they happen and what they teach us (Clark and Brancati). 2004;39:602–603 (Editorial)
Pivotal role of superoxide anion and beneficial effect of antioxidant molecules in murine steatohepatitis (Laurent et al). 2004;39:1282–1290
The zonal distribution of megamitochondria with crystalline inclusions in nonalcoholic steatohepatitis (Le et al). 2004;39:1430–1436
Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: Results of a randomized trial (Lindor et al). 2004;39:770–778
Vitamin E therapy in patients with NASH (Yoneda et al). 2004;39:568 (Correspondence)
Steatosis
Do polyunsaturated fatty acids ameliorate hepatic steatosis in obese mice by SREPB-1 suppression or by correcting essential fatty acid deficiency (Alwayn et al). 2004;39:1176–1177 (Correspondence)
Do polyunsaturated fatty acids ameliorate hepatic steatosis in obese mice by SREPB-1 suppression or by correcting essential fatty acid deficiency (Yahagi et al). 2004;39:1177–1178 (Reply)
Oval cells compensate for damage and replicative senescence of mature hepatocytes in mice with fatty liver disease (Yang et al). 2004;39:403-411
Steatosis and liver cell apoptosis in chronic hepatitis C: A mechamism for increased liver injury (Walsh et al). 2004;39:1232–1241
Stem cell culture research
Unexpected artifacts raise new caution in stem cell culture research (Leffert and Sell). 2004;39:258 (Correspondence)
Stem cells
Activation of NF-κB and STAT3 in rat oval cells during 2-acetylaminofluorene/partial hepatectomy-induced liver regeneration (Sánchez A et al). 2004;39:376–385
An uncomfortable silence . . . while we all search for a better reporter gene in adult stem cell biology (Terai et al). 2004;39:1143–1146 (Hepatology *Elsewhere*)
Flow cytometric isolation of endodermal progenitors from mouse salivary gland differentiate into hepatic and pancreatic lineages (Hisatomi et al). 2004;39:667–675
Gene expression pattern in hepatic stem/progenitor cells during rat fetal development using complementary DNA microarrays (Petkov et al). 2004;39:617–627
Liver regeneration and repair: Hepatocytes, progenitor cells, and stem cells (Fausto). 2004;39:1477–1487 (Science Frontier)
Murine hepatocyte cell lines promote expansion and differentiation of NK cells from stem cell precursors (Bordoni et al). 2004;39:1508–1516
Prometheus and Pandora—Together again (Reuben). 2004;39:1466–1469 (Landmarks in Hepatology)
The importance of knowing your identity: Sources of confusion in stem cell biology (Grompe). 2004;39:35–37 (Editorial)

Stereological measurement
Stereological measurement of porto-central gradients in gene expression in mouse liver (Ruijter JM et al). 2004;39:343–352
Steroids
Hepatology Highlights (Elias). 2004;39: 1467–1468
Progressive fibrosis during corticosteroid therapy of autoimmune hepatitis (Czaja and Carpenter). 2004;39: 1631–1638
Sterol regulatory element-binding protein (SREBP)-1
Do polyunsaturated fatty acids ameliorate hepatic steatosis in obese mice by SREPB-1 suppression or by correcting essential fatty acid deficiency (Alwayn et al). 2004;39: 1176–1177 (Correspondence)
Do polyunsaturated fatty acids ameliorate hepatic steatosis in obese mice by SREPB-1 suppression or by correcting essential fatty acid deficiency (Yahagi et al). 2004;39: 1177–1178 (Reply)
Sterol regulatory element-binding proteins (SREBPs)
Hepatology Highlights (Kaplowitz). 2004;39:271–272
Stress, oxidant
Uncoupling protein-2 deficiency promotes oxidant stress and delays liver regeneration in mice (Horimoto M et al). 2004;39:386–392
Stress, oxidative
Oxidative stress as a trigger for cellular immune responses in patients with alcoholic liver disease (Stewart et al). 2004;39:197–203
Sulfhydrils
Low membrane protein sulfhydrils but not glucose-6-phosphate dehydrogenase deficiency predict ribavirin-induced hemolysis in hepatitis C (Grattagliano et al). 2004;39:1251–1258
Superoxide anion
Pivotal role of superoxide anion and beneficial effect of antioxidant molecules in murine steatohepatitis (Laurent et al). 2004;39:1282–1290
Systemic inflammation, acute
Altered gene expression in acute systemic inflammation detected by complete coverage of the human liver transcriptome (Coulouarn et al). 2004;39:353–364

T

T cells
Interleukin 22 (IL-22) plays a protective role in T cell-mediated hepatitis: IL-22 is a survival factor for hepatocytes via STAT3 activation (Radaeva et al). 2004;39:1337–1347
Kupffer cells required for high affinity peptide-induced deletion, not retention, of activated CD8+ T cells by mouse liver (Kuniyasu et al). 2004;39:1017–1027
Pegylated interferon α therapy in acute hepatitis C: Relation to hepatitis C virus–specific T cell response kinetics (Kamal et al). 2004;39:1721–1731
Recently primed CD8+ T cells entering the liver induce hepatocytes to interact with naïve CD8+ T cells in the mouse (Dikopoulos et al). 2004; 39:1259–1270
Taiwan
News from Taiwan (Chen et al). 2004; 39:1196–1197
Tamoxifen
Tamoxifen in treatment of primary biliary cirrhosis (Invernizzi et al). 2004;39:1175–1176 (Correspondence)
Tauroursodeoxycholic acid
Tauroursodeoxycholic acid protects rat hepatocytes from bile acid-induced apoptosis via activation of survival pathways (Schoemaker et al). 2004; 39:1563–1573
Terlipressin
Hepatology Highlights (Elias). 2004;39: 579–580
Worsening of cerebral hyperemia by the administration of terlipressin in acute liver failure with severe encephalopathy (Shawcross et al). 2004;39:471–475
Terminology
Never say dye (Reuben). 2004;39:259–264 (Landmarks in Hepatology)
Nomenclature of the finer branches of the biliary tree: Canals, ductules, and ductular reactions in human livers (Roskams et al). 2004;39:1739–1745 (Special Article)
Thromboxane
Role of thromboxane derived from COX-1 and -2 in hepatic microcirculatory dysfunction during endotoxemia in mice (Katagiri et al). 2004;39:139–150
Thy1 cells
Thy1-positive mesenchymal cells promote the maturation of CD49f-positive hepatic progenitor cells in the mouse fetal liver (Hoppo et al). 2004;39:1367–1375
Tissue remodeling
Hepatocyte proliferation and tissue remodeling is impaired after liver injury in oncostatin M receptor knockout mice (Nakamura et al). 2004;39:635–644
Tolerance
Covalent modification as a mechanism for the breakdown of immune tolerance to pyruvate dehydrogenase complex in the mouse (Palmer et al). 2004;39:1583–1592
Topoisomerase inhibitors
Topoisomerase inhibitor camptothecin sensitizes mouse hepatocytes *in vitro* and *in vivo* to TNF-mediated apoptosis (Hentze et al). 2004;39: 1316–1325
Transmethylation enzymes
Hepatic transmethylation reactions in micropigs with alcoholic liver disease (Villanueva and Halsted). 2004;39:1308–1315
Triglycerides
Dietary n-3 polyunsaturated fatty acids decrease hepatic triglycerides in Fischer 344 rats (Levy et al). 2004; 39:608–616
Tumor growth
Vascular interference: A blockade to tumor epithelial growth (Crawford). 2004;39:1491–1494 (Editorial)
Tumor necrosis factor
Topoisomerase inhibitor camptothecin sensitizes mouse hepatocytes *in vitro* and *in vivo* to TNF-mediated apoptosis (Hentze et al). 2004;39: 1316–1325
Tumor necrosis factor-α
Dual role of tumor necrosis factor-α in hepatic ischemia-reperfusion injury: Studies in tumor necrosis factor-α gene knockout mice (Teoh et al). 2004;39:412–421
TNF α-induced Ras activation due to ethanol promotes hepatocyte proliferation independently of liver injury in the mouse (Isayama et al). 2004;39:721–731
Tumor necrosis factor-related apoptosis-inducing ligand
An oncolytic adenoviral vector of Smac increases antitumor activity of TRAIL against HCC in human cells and in mice (Pei et al). 2004;39: 1376–1387
Liver NK cells expressing TRAIL are toxic against self hepatocytes in mice (Ochi et al). 2004;39:1326–1336
Turner's syndrome
Vascular involvement of the liver in Turner's syndrome (Roulot et al). 2004;39:239–347
Tyrosinemia, hereditary
Chronic liver disease in murine hereditary tyrosinemia type 1 induces resistance to cell death (Vogel et al). 2004;39:433–443

U

UDP-glucuronosyltransferase UGT1A4
Variation of hepatic glucuronidation:

Novel functional polymorphisms of the UDP-glucuronosyltransferase UGT1A4 (Ehmer et al). 2004;39: 970–977

Uncoupling protein-2 deficiency
Hepatology Highlights (Kaplowitz). 2004;39:271–272
Uncoupling protein-2 deficiency promotes oxidant stress and delays liver regeneration in mice (Horimoto et al). 2004;39:386–392

United States
Changing epidemiology of hepatitis B in a U.S. community (Kim et al). 2004;39:811–816
Chronic liver disease mortality in the United States, 1990–1998 (Vong and Bell). 2004;39:476–483

Uric acid
Uric acid levels and liver fibrosis in nonalcoholic fatty liver disease (Bugianesi and Marchesini). 2004; 39:1749 (Correspondence)

Ursodeoxycholic acid
Endogenous ursodeoxycholic acid and cholic acid in liver disease due to cystic fibrosis (Smith et al). 2004;39: 1673–1682
Hepatology Highlights (Kaplowitz). 2004;39:1183–1184
Tauroursodeoxycholic acid protects rat hepatocytes from bile acid-induced apoptosis via activation of survival pathways (Schoemaker et al). 2004; 39:1563–1573
Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: Results of a randomized trial (Lindor et al). 2004;39:770–778
Ursodeoxycholic acid protects against secondary biliary cirrhosis in rats by preventing mitochondrial oxidative stress (Serviddio et al). 2004;39: 711–720

Ursodiol
A randomized controlled trial of colchicine plus ursodiol versus methotrexate plus ursodiol in primary biliary cirrhosis: Ten-year results (Kaplan et al). 2004;39:915–923

V

Variceal bleeding
Antibiotic prophylaxis after endoscopic therapy prevents rebleeding in acute variceal hemorrhage: A randomized trial (Hou et al). 2004;39:746–753
Sustained rise of portal pressure after sclerotherapy, but not band ligation, in acute variceal bleeding in cirrhosis (Avgerinos et al). 2004;39:1623–1630

Vascular dilatations
Evolution of intrapulmonary vascular dilatations in cirrhosis (França et al). 2004;39:1461 (Correspondence)

Vascular disorders
Vascular involvement of the liver in Turner's syndrome (Roulot et al). 2004;39:239–247

Vascular endothelial growth factor
Halting the interaction between vascular endothelial growth factor and its receptor attenuates liver carcinogenesis in mice (Yoshiji et al). 2004;39:1517–1524
Vascular interference: A blockade to tumor epithelial growth (Crawford). 2004;39:1495–1499 (Editorial)

Viral hepatitis
Expression of granzyme B in viral hepatitis in patients with ALPS (André et al). 2004;39:864–865 (Correspondence)

Vitamin A
Reversal of liver fibrosis in aryl hydrocarbon receptor *null* mice by dietary vitamin A depletion (Andreola et al). 2004;39:157–166

Vitamin E therapy
More on vitamin E therapy (McClain et al). 2004;39:569–570 (Reply)
More on vitamin E therapy (Vajro et al). 2004;39:569 (Correspondence)
Vitamin E therapy in patients with NASH (Yoneda et al). 2004;39:568 (Correspondence)

W

Water transport
AQP4 transfected into mouse cholangiocytes promotes water transport in biliary epithelia (Splinter et al). 2004;39:109–116

Wedged hepatic vein pressure
Changing clinical practice with measurements of portal pressure (Boyer). 2004;39:283–285 (Perspectives in Clinical Hepatology)

Weight loss
Hepatology Highlights (Elias). 2004;39: 1467–1468
Nonalcoholic fatty liver disease: Improvement in liver histological analysis with weight loss (Dixon et al). 2004;39:1647–1654

West Africa
The Gambia liver cancer study: Infection with hepatitis B and C and the risk of hepatocellular carcinoma in West Africa (Kirk et al). 2004;39:211–219

Wilson's disease
Immunohistochemical analysis of Mallory bodies in Wilsonian and non-Wilsonian hepatic copper toxicosis (Müller et al). 2004;39: 963–969
Persistence of elevated aminotransferases in Wilson's disease despite adequate therapy (Iorio et al). 2004;39:1173–1174 (Correspondence)

Wnt
Hepatitis B virus X protein is essential for the activation of Wnt/β-catenin signaling in hepatoma cells (Cha et al). 2004;39:1683–1693

Woodchuck hepatitis virus
Hepatology Highlights (Alter). 2004;39: 877–879
Integration of woodchuck hepatitis and N-myc rearrangement determine size and histologic grade of hepatic tumors (Jacob et al). 2004;39:1008–1016

Wy-14,643
Administration of the potent PPARα agonist, Wy-14,643, reverses nutritional fibrosis and steatohepatitis in mice (Ip et al). 2004;39:1291–1301

X

Xenoimmunization
A murine model of type 2 autoimmune hepatitis: Xenoimmunization with human antigens (Lapierre et al). 2004;39:1066–1074

Z

Zalcitabine
Depletion of mitochondrial DNA in liver under antiretroviral therapy with didanosine, stavudine, or zalcitabine (Walker et al). 2004;39: 311–317

Zimmerman, Hyman J.
Hy's Law (Reuben A). 2004;39:574–578 (Landmarks in Hepatology)